<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library</title> <meta content="Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007929.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer" name="citation_title"/> <meta content="Abigail Tattersall&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Kingston Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Neil Ryan&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Alison J Wiggans" name="citation_author"/> <meta content="Cheltenham General Hospital, Glocestershire Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Ewelina Rogozińska" name="citation_author"/> <meta content="The Evidence-Based Medicine Consultancy Ltd" name="citation_author_institution"/> <meta content="Jo Morrison" name="citation_author"/> <meta content="Musgrove Park Hospital, Somerset NHS Foundation Trust" name="citation_author_institution"/> <meta content="jo_morrison@doctors.org.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD007929.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/02/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Carcinoma, Ovarian Epithelial [drug therapy, surgery]; Neoplasm Recurrence, Local [drug therapy]; *Ovarian Neoplasms [drug therapy, genetics]; *Poly(ADP-ribose) Polymerase Inhibitors [adverse effects]; Poly(ADP-ribose) Polymerases [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007929.pub4&amp;doi=10.1002/14651858.CD007929.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007929\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007929\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007929.pub4",title:"Poly(ADP\\u2010ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer",firstPublishedDate:"Feb 16, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007929.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007929.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007929.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007929.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007929.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007929.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007929.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007929.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007929.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007929.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4964 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007929.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/appendices#CD007929-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/supinfo/CD007929StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/supinfo/CD007929StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#CD007929-cr-0004">Abigail Tattersall</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#CD007929-cr-0005">Neil Ryan</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#CD007929-cr-0006">Alison J Wiggans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#CD007929-cr-0007">Ewelina Rogozińska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information#CD007929-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Jo Morrison</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information/en#CD007929-sec-0094">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 February 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007929.pub4">https://doi.org/10.1002/14651858.CD007929.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007929-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007929-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007929-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007929-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007929-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD007929-abs-0004">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007929-abs-0001" lang="en"> <section id="CD007929-sec-0001"> <h3 class="title" id="CD007929-sec-0001">Background</h3> <p>Ovarian cancer is the sixth most common cancer in women world‐wide<i>.</i> Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present when disease has spread outside the pelvis (stage III or IV). Treatment consists of a combination of  surgery and platinum‐based chemotherapy. Although initial responses to chemotherapy are good, most women with advanced disease will relapse. </p> <p>PARP (poly (ADP‐ribose) polymerase) inhibitors (PARPi), are a type of anticancer treatment that works by preventing cancer cells from repairing DNA damage, especially in those with breast cancer susceptibility gene (<i>BRCA</i>) variants. PARPi offer a different mechanism of anticancer treatment from conventional chemotherapy. </p> </section> <section id="CD007929-sec-0002"> <h3 class="title" id="CD007929-sec-0002">Objectives</h3> <p>To determine the benefits and risks of poly (ADP‐ribose) polymerase) inhibitors (PARPi) for the treatment of epithelial ovarian cancer (EOC). </p> </section> <section id="CD007929-sec-0003"> <h3 class="title" id="CD007929-sec-0003">Search methods</h3> <p>We identified randomised controlled trials (RCTs) by searching the Cochrane Central Register of Controlled Trials (Central 2020, Issue 10), Cochrane Gynaecological Cancer Group Trial Register, MEDLINE (1990 to October 2020), Embase (1990 to October 2020), ongoing trials on <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled-trials.com/rct</a>, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>, the National Research Register (NRR), FDA database and pharmaceutical industry biomedical literature. </p> </section> <section id="CD007929-sec-0004"> <h3 class="title" id="CD007929-sec-0004">Selection criteria</h3> <p>We included trials that randomised women with EOC to PARPi with no treatment, or PARPi versus conventional chemotherapy, or PARPi together with conventional chemotherapy versus conventional chemotherapy alone. </p> </section> <section id="CD007929-sec-0005"> <h3 class="title" id="CD007929-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology. Two review authors independently assessed whether studies met the inclusion criteria. We contacted investigators for additional data. Outcomes included overall survival (OS), objective response rate (ORR), quality of life (QoL) and rate of adverse events. </p> </section> <section id="CD007929-sec-0006"> <h3 class="title" id="CD007929-sec-0006">Main results</h3> <p>We included 15 studies (6109 participants); four (3070 participants) with newly‐diagnosed, advanced EOC and 11 (3039 participants) with recurrent EOC. The studies varied in types of comparisons and evaluated PARPi. Eight studies were judged as at low risk of bias in most of the domains. Quality of life data were generally poorly reported. Below we present six key comparisons.  The majority of participants had <i>BRCA</i> mutations, either in their tumour (s<i>BRCA</i> mut) and/or germline (g<i>BRCA</i>mut), or homologous recombination deficiencies (HRD) in their tumours. </p> <p><b>Newly diagnosed EOC</b> </p> <p>Overall, four studies evaluated the effect of PARPi in newly‐diagnosed, advanced EOC. Two compared PARPi with chemotherapy and chemotherapy alone. OS data were not reported. The combination of PARPi with chemotherapy may have little to no difference in progression‐free survival (PFS) (two studies, 1564 participants; hazard ratio (HR) 0.82, 95% confidence interval (CI 0).49 to 1.38; <i>very low‐certainty evidence)</i> (no evidence of disease progression at 12 months' 63% with PARPi versus 69% for placebo).<i> </i> </p> <p>PARPi with chemotherapy likely increases any severe adverse event (SevAE) (grade 3 or higher) slightly (45%) compared with chemotherapy alone (51%) (two studies, 1549 participants, risk ratio (RR) 1.13, 95% CI 1.07 to 1.20; <i>high‐certainty evidence</i> ). PARPi combined with chemotherapy compared with chemotherapy alone likely results in little to no difference in the QoL (one study; 744 participants, MD 1.56 95% CI ‐0.42 to 3.54<i>; moderate‐certainty evidence).</i>  </p> <p>Two studies compared PARPi monotherapy with placebo as maintenance after first‐line chemotherapy in newly diagnosed EOC. PARPi probably results in little to no difference in OS (two studies, 1124 participants; HR 0.81, 95%CI 0.59 to 1.13; <i>moderate‐certainty evidence</i> ) (alive at 12 months 68% with PARPi versus 62% for placebo). However, PARPi may increase PFS (two studies, 1124 participants; HR 0.42, 95% CI 0.19 to 0.92; <i>low‐certainty evidence</i> ) (no evidence of disease progression at 12 months' 55% with PARPi versus 24% for placebo). There may be an increase in the risk of experiencing any SevAE (grade 3 or higher) with PARPi (54%) compared with placebo (19%)(two studies, 1118 participants, RR 2.87, 95% CI 1.65 to 4.99; <i>very low‐certainty evidence</i> ), but the evidence is very uncertain. There is probably a slight reduction in QoL with PARPi, although this may not be clinically significant (one study, 362 participants; MD ‐3.00, 95%CI ‐4.48 to ‐1.52; <i>moderate‐certainty evidence). </i> </p> <p><b>Recurrent, platinum‐sensitive EOC</b> </p> <p>Overall, 10 studies evaluated the effect of PARPi in recurrent platinum‐sensitive EOC. Three studies compared PARPi monotherapy with chemotherapy alone. PARPi may result in little to no difference in OS (two studies, 331 participants; HR 0.95, 95%CI 0.62 to 1.47; <i>low‐certainty evidence</i> ) (percentage alive at 36 months 18% with PARPi versus 17% for placebo). Evidence is very uncertain about the effect of PARPi on PFS (three studies, 739 participants; HR 0.88, 95%CI 0.56 to 1.38; <i>very low‐certainty evidence</i> )(no evidence of disease progression at 12 months 26% with PARPi versus 22% for placebo). There may be little to no difference in rates of any SevAE (grade 3 or higher) with PARPi (50%) than chemotherapy alone (47%) (one study, 254 participants; RR 1.06, 95%CI 0.80 to 1.39; <i>low‐certainty evidence</i>). </p> <p>Four studies compared PARPi monotherapy as maintenance with placebo. PARPi may result in little to no difference in OS (two studies, 560 participants; HR 0.88, 95%CI 0.65 to 1.20; <i>moderate‐certainty evidence</i> )(percentage alive at 36 months 21% with PARPi versus 17% for placebo). However, evidence suggests that PARPi as maintenance therapy results in a large PFS (four studies, 1677 participants; HR 0.34, 95% CI 0.28 to 0.42; <i>high‐certainty evidence</i> )(no evidence of disease progression at 12 months 37% with PARPi versus 5.5% for placebo). PARPi maintenance therapy may result in a large increase in any SevAE (51%) (grade 3 or higher) than placebo (19%)(four studies, 1665 participants, RR 2.62, 95%CI 1.85 to 3.72; <i>low‐certainty evidence</i> ). PARPi compared with chemotherapy may result in little or no change in QoL (one study, 229 participants, MD 1.20, 95%CI ‐1.75 to 4.16; <i>low‐certainty evidence).</i> </p> <p><b>Recurrent, platinum‐resistant EOC</b> </p> <p>Two studies compared PARPi with chemotherapy. The certainty of evidence in both studies was graded as very low. Overall, there was minimal information on the QoL and adverse events. </p> </section> <section id="CD007929-sec-0007"> <h3 class="title" id="CD007929-sec-0007">Authors' conclusions</h3> <p>PARPi maintenance treatment after chemotherapy may improve PFS in women with newly‐diagnosed and recurrent platinum‐sensitive EOC; there may be little to no effect on OS, although OS data are immature. Overall, this is likely at the expense of an increase in SevAE. It is  disappointing that data on quality of life outcomes  are relatively sparse. More research is needed to determine whether PARPi have a role to play in platinum‐resistant disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007929-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007929-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007929-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007929-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007929-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007929-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007929-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007929-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD007929-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007929-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007929-abs-0002" lang="en"> <h3>Do PARP inhibitors improve survival in women with ovarian cancer, and what are the side effects? </h3> <p><b><i>Key messages</i> </b> </p> <p>Compared to an inactive 'dummy' medication (placebo), PARP (poly (ADP‐ribose) polymerase) inhibitors (PARPi) given as daily tablet treatment after chemotherapy (maintenance treatment): </p> <p>‐ may have little to no effect on the amount of time someone with advanced epithelial ovarian cancer (EOC) will live overall (although this outcome may change as more data become available); </p> <p>‐ probably delay disease progression in women with newly‐diagnosed EOC;</p> <p>‐ probably delay disease progression in women with recurrent platinum‐sensitive EOC;</p> <p>‐ probably cause an increase in the risk of severe side effects.</p> <p>We are very uncertain about whether a delay in disease progression has a beneficial effect on quality of life, as data are inconsistently reported, but the limited data suggest that PARPi may improve symptoms  by delaying disease progression. </p> <p><b><i>What is epithelial ovarian cancer?</i> </b> </p> <p>EOC is a cancer that arises from the lining (epithelium) of the ovaries, fallopian tube and the abdominal cavity (peritoneum). Because cells have immediate access to the abdominal cavity, EOC often presents at a late stage. Initial treatment is with a combination of surgery, ideally to remove all visible disease, and chemotherapy. Disease will recur in most people and further treatment is required. Scientists have therefore been looking at new ways to stop cancer cells growing. </p> <p><b><i>What are PARP inhibitors?</i> </b> </p> <p>Being able to repair DNA is vital to cell survival. Normal cells have more than one DNA repair pathway. However, cancer cells often have defects in DNA repair pathways. The <i>BRCA</i> gene is involved in DNA repair and is commonly damaged (mutated) in people with EOC. Blocking another DNA repair pathway with a PARPi stops cancer cells from repairing DNA, causing cells to die. PARPi therefore differ from conventional chemotherapy, and are likely to work better in <i>BRCA‐</i>mutated cells. </p> <p><b><i>What did we want to find out?</i> </b> <br/>We wanted to find out if PARPi treatment, given either with chemotherapy or afterwards as a maintenance treatment: </p> <p>‐  delays death;</p> <p>‐  delays disease progression;</p> <p>‐ improves quality of life;</p> <p>‐ has any unwanted side effects.</p> <p><b><i>What did we do?</i> </b> <br/>We searched for randomised control trials (clinical studies where the treatment or care people receive is chosen at random) from 1990 to Oct 2020.  We searched for studies using PARPi in women with newly‐diagnosed EOC and those whose cancer had returned, either more than six months after stopping platinum‐based chemotherapy (platinum‐sensitive relapse) or within six months of platinum‐based chemotherapy (platinum‐resistant relapse). We collected data, summarised results, and rated our confidence in the evidence, based on factors, such as whether women and their doctors knew what treatment they were having, how studies were conducted, and how many women were included in studies. </p> <p><b><i>What did we find?</i> </b> </p> <p>We found 15 randomised trials of PARP inhibitors (6109 participants) (four studies including 3070 women with newly‐diagnosed EOC (first‐line treatment) and 11 studies including 3039 women with recurrent cancer). We found 17 ongoing studies.  </p> <p><i>First‐line treatment</i> </p> <p>PARPi, in addition to chemotherapy, given<b>during</b> chemotherapy: </p> <p> — made little to no difference in how long ovarian cancer took to return (progress/recur);</p> <p> — probably slightly increased serious side effects experience by women during chemotherapy.  </p> <p>However, continuing PARPi after chemotherapy, compared to placebo as a maintenance treatment, often over many months, probably delayed the cancer recurring/progressing.   </p> <p>PARPi maintenance treatment <b>after</b> chemotherapy: </p> <p>— probably delayed recurrence of ovarian cancer (no disease progression at 12 months: 55% with PARPi versus 24% for placebo); </p> <p>— probably little to no difference in how long women survived overall, despite delay in recurrence, although more information may change this outcome over time; </p> <p>— may be at the expense of an increase in the risk of severe side effects with PARPi, although evidence for this is very uncertain.   </p> <p><i>Treatment of platinum‐sensitive recurrent  EOC</i> </p> <p>Compared to conventional chemotherapy treatment, PARPi:</p> <p>— may have little to no difference in terms of overall survival, delay in progression of disease, quality of life and risk of serious side effects.  </p> <p>All of these studies only included patients with <i>BRCA</i> mutations, so it is not clear whether these results would be similar in non‐<i>BRCA</i> patients.  </p> <p>PARPi as maintenance treatment, after chemotherapy for platinum‐sensitive ovarian cancer: </p> <p>— had a large effect on delaying recurrence of disease (no disease progression at 12 months 37% with PARPi versus 5.5% for placebo); </p> <p>— had little to no difference in the overall survival time after treatment;</p> <p>— may be at the expense of a large increase in the risk of severe side effects.</p> <p><i>Treatment of platinum‐resistant recurrent EOC</i> </p> <p>PARPi compared with chemotherapy:</p> <p>— we are very uncertain about the outcomes, as the quality of the evidence was very low. </p> <p><b><i>What limited our confidence in the evidence?</i> </b> </p> <p>Although half of the studies were at low risk of bias, some studies used methods that risk introducing bias and some studies were small.  Reporting of quality of life data overall was poor or different methods were used, limiting our ability to combine data on these outcomes. </p> <p><b><i>How up to date is this review?</i> </b> </p> <p>The evidence in this review is current to October 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007929-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007929-sec-0082"></div> <h3 class="title" id="CD007929-sec-0083">Implications for practice</h3> <section id="CD007929-sec-0083"> <p>Patients with epithelial ovarian cancer (EOC) of high‐grade serous and endometrial serotypes have a relatively high risk of germline <i>BRCA</i> mutation and national guidelines recommend that these patients should be offered genetic screening (<a href="./references#CD007929-bbs2-0121" title="National Institute for Clinical Excellence (NICE).Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance [CG164]. https://www.nice.org.uk/Guidance/CG1642013. [WEBPAGE: https://www.nice.org.uk/Guidance/CG164]">NICE [CG164] 2019</a>; <a href="./references#CD007929-bbs2-0135" title="RischHA , McLaughlinJR , ColeDE , RosenB , BradleyL , KwanE , et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics2001;68(3):700-10.">Risch 2001</a>). This would be irrespective of whether poly (ADP‐ribose) polymerase) inhibitors (PARPi) are effective, since it has implications for patients and their families. </p> <p>These data suggest that the use of PARPi as a maintenance therapy is of benefit in terms of slowing initial disease progression. Progression‐free survival (PFS) was improved in those who received PARPi, regardless of the type of PARPi used, as maintenance therapy, when compared to those who received a placebo in both the primary and recurrence setting (<a href="./references#CD007929-fig-0016" title="">Analysis 3.3</a>; <a href="./references#CD007929-fig-0028" title="">Analysis 5.2</a>). However, it is less clear if maintenance PARPi treatment, in either setting, leads to an improvement in overall survival (OS). Improvement in PFS comes at the expense of  an increase in adverse events (<a href="./references#CD007929-fig-0020" title="">Analysis 3.7</a>; <a href="./references#CD007929-fig-0038" title="">Analysis 5.12</a>). We did not find that the use of PARPi as a monotherapy alternative to other chemotherapy, or in combination with chemotherapy,  improved PFS or OS in either the primary treatment or recurrence setting. Combination of a PARPi with chemotherapy  increased rates of adverse events (<a href="./references#CD007929-fig-0008" title="">Analysis 1.6</a>; <a href="./references#CD007929-fig-0013" title="">Analysis 2.5</a>; <a href="./references#CD007929-fig-0046" title="">Analysis 7.5</a>). In contrast, the addition of PARPi to chemotherapy that includes bevacizumab did lead to improved PFS; this finding, however, is limited to one study (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>). These findings continue into our subgroup analysis of those with known pathogenic variants in <i>BRCA1/2</i> or homologous recombination DNA repair deficiency (HRD). </p> <p>Due to increasing ability to salvage women with recurrent disease with further treatment options, and a significant risk of cross‐over for those who did not have a PARPi after first‐line treatment, the correlation between PFS and OS in first line treatment of EOC has weakened<a href="./references#CD007929-bbs2-0141" title="SjoquistKM , LordSJ , FriedlanderML , John SimesR , MarschnerIC , LeeCK .Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology2018;10:1758835918788500-1758835918788500.">Sjoquist 2018</a>. In their systematic review of studies comparing PFS and OS for first‐line treatment of advanced EOC, <a href="./references#CD007929-bbs2-0141" title="SjoquistKM , LordSJ , FriedlanderML , John SimesR , MarschnerIC , LeeCK .Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology2018;10:1758835918788500-1758835918788500.">Sjoquist 2018</a> found that there was  was only a moderate correlation (<i>r</i><sup>2</sup> = 0.52) between PFS and OS, which has weakened over time with the introduction of biological agents.They speculated reasons for this, which may include a difference in the definition of progression and increasing cross‐over and other salvage therapies postprogression. They found that fhat few studies detail post‐progression therapies. </p> <p>PARPi can be considered as a maintenance therapy after either primary treatment or treatment of recurrent disease, in those who have not previously received a PARPi, for the improvement of PFS. However, beneficial effects in terms of overall survival (OS) have not been established and therefore PARPi maintenance treatment should be carefully discussed with patients, so they are able to make an informed choice, weighing up the benefits against increased risks of side effects and potential impact on quality of life.  This is echoed in the current National Institute of Health and Care Excellence (NICE) guidance on the use of PARPi in EOC, which currently makes PARPi (or olaparib plus bevacizumab) available via the cancer drug fund, rather than officially endorsing, until further data are available (<a href="./references#CD007929-bbs2-0121" title="National Institute for Clinical Excellence (NICE).Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance [CG164]. https://www.nice.org.uk/Guidance/CG1642013. [WEBPAGE: https://www.nice.org.uk/Guidance/CG164]">NICE [CG164] 2019</a>; <a href="./references#CD007929-bbs2-0122" title="National Institute for Health and Care Excellence (NICE) .Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598). https://www.nice.org.uk/guidance/ta5982019. [WEBPAGE: https://www.nice.org.uk/guidance/ta598/]">NICE [TA598] 2019 </a>; <a href="./references#CD007929-bbs2-0123" title="National Insitute for Health and Care Excellence.Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA611] . https://www.nice.org.uk/guidance/ta611 13 November 2019. [WEBPAGE: https://www.nice.org.uk/guidance/ta611]">NICE [TA611] 2019</a>; <a href="./references#CD007929-bbs2-0124" title="National Insitute for Health and Care Excellence.Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA620] P. https://www.nice.org.uk/guidance/ta620 15 January 2020. [WEBPAGE: https://www.nice.org.uk/guidance/ta620]">NICE [TA620] 2020</a>; <a href="./references#CD007929-bbs2-0125" title="National Institute for Health and Care Excellence (NICE).Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA673]. https://www.nice.org.uk/guidance/ta6732021. [WEBPAGE: https://www.nice.org.uk/guidance/ta673]">NICE [TA673] 2021</a>; <a href="./references#CD007929-bbs2-0126" title="National Institute for Health and Care Excellence (NICE).Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancerTechnology appraisal guidance [TA693] . https://www.nice.org.uk/guidance/ta693 28 April 2021. [WEBPAGE: https://www.nice.org.uk/guidance/ta693]">NICE  [TA693] 2021</a>). </p> <p>Treatment in EOC is becoming highly complex, with an ever‐increasing number of biological agents, used in multiple combinations. Further updates of this review should consider a network meta‐analysis approach, combining different biological agents used alongside chemotherapy and as maintenance treatment, with separate reviews for treatment at diagnosis, and in platinum‐sensitive and platinum resistant/refractory disease settings, in order to further inform patient care. </p> </section> <h3 class="title" id="CD007929-sec-0084">Implications for research</h3> <section id="CD007929-sec-0084"> <p>Our data indicate that the use of PARPi in the maintenance setting  improves PFS survival in women with EOC. Data do not demonstrate a similar improvement in OS, however, although these data are immature. These new data have answered some of the questions that remained from our previous version of this review (<a href="./references#CD007929-bbs2-0157" title="WiggansAJ , CassGK , BryantA , LawrieTA , MorrisonJ .Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub3] [PMID: 25991068]">Wiggans 2015</a>. Despite improvement in PFS, many women will progress on PARPi and will ultimately succumb to their disease. The mechanisms that lead to PARPi resistance within EOC of acute interest. It is evident that EOC has the ability to develop resistance to PARPi and overcome maintenance therapy (<a href="./references#CD007929-bbs2-0116" title="McMullenM , KarakasisK , MadariagaA , OzaAM .Overcoming platinum and PARP-Inhibitor resistance in ovarian cancer. Cancers2020;12(6):1607. [DOI: 10.3390/cancers12061607] [PMID: 32560564]">McMullen 2020</a>). By describing these mechanisms, researchers may have the opportunity to originate novel adjuvant therapies that could prolong the effect of PARPi or prevent resistance. This should be seen as a funding priority.  </p> <p>Our data indicate that the combination of PARPi and bevacizumab may improve PFS.  However, our analysis is based on data from  one study <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>. Therefore, further studies would improve our confidence in this finding. What is more, it is not clear, if bevacizumab should be used in combination with PARPi, or if it would have more utility if used when those on PARPi relapse. In addition, there are limited data about the use of PARPi in combination with novel immune therapies. The <a href="./references#CD007929-bbs2-0071" title="EskanderRN , LedermannJA , BirrerMJ , FujiwaraK , GaillardS , RichardsonGE , et al.JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer. Journal of Clinical Oncology2019;37(8_suppl):no pages. NCT03642132.Avelumab and talazoparib in Untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100). Clinical Trials Gov register2018. Pujade-LauraineE , FujiwaraK , LedermannJA , OzaAM , KristeleitR , Ray-CoquardIL , et al.Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncology2021;22(7):1034-46. [DOI: 10.1016/S1470-2045(21)00216-3] [PMID: 34143970]">JAVELIN</a> study failed to show any benefit from the addition of avelumab. However, there has been some degree of criticism as to the selection criteria for this study (<a href="./references#CD007929-bbs2-0153" title="YonemoriK , MatsumotoT , NagaoS , KatsumataN , OdaK , WatariH , et al.Avelumab in platinum-resistant/refractory ovarian cancer (PRROC): phase 3 results from JAVELIN Ovarian 200. Annals of Oncology2019;30:vi89. [DOI: 10.1093/annonc/mdz339.028]">Yonemori 2019</a>). Therefore, the use of immunotherapy in combination with PARPi remains an area of equipoise.  </p> <p>The impact of the timing of surgery, be it primary or interval debulking, and the use of PARPi is not clear from these data. The current literature has captured little regarding the timing of the surgery and the level of cytoreduction at surgery. Such granularity could help identify subgroups of patients with EOC who may be better suited to PARPi. Moreover, it could help identify  optimal treatment regimens.   </p> <p>In these data, the risk of adverse events (grade three or higher) was increased when PARPi were used as a maintenance therapy. This was to clinically significant levels. This leads to women, not infrequently, choosing to stop a treatment. Future studies should therefore explore ways to mitigate adverse effects in those taking PARPi as a maintenance therapy, or ways to better identify those who are more likely to benefit from PARPi, thereby sparing those who do not side effects that may limit quality of life.  </p> <p>Long‐term harms data is sparse from the use of PARPi as a maintenance therapy in patients with EOC. Given that PARPi impede DNA repair, concerns have been raised as to wether or not they increase the risk of subsequent malignancies, especially haematological malignancies, such as MDS and AML (<a href="./references#CD007929-bbs2-0119" title="MoricePM , Ray-CoquardI , MooreKN , DiérasV ,  AlexandreJ .PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials. Annals of Oncology2021;32(8):1048-50. [DOI: 10.1016/j.annonc.2021.04.023]">Morice 2021</a>). <i>In vivo</i> data would suggest that their long term use is relatively safe (<a href="./references#CD007929-bbs2-0130" title="Póti Á, BertaK , XiaoY , PipekO , KlusGT , RiedT , CsabaiI , WilcoxenK , MikuleK , SzallasiZ , SzütsD .Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. Br J Cancer2018;11:1392-400. [DOI: 10.1038/s41416-018-0312-6.] [PMID: 30425352]">Póti 2018</a>), but this needs to be collaborated with long‐term data from clinical trials and population‐level data from registries and good post‐market surveillance.  </p> <p>Finally, and most importantly, any studies of maintenance treatment in ovarian cancer, which for many is a life‐limiting illness, should assess both OS and the long‐term effects on quality of life, not just a surrogate outcome of PFS, which may have little real benefit to patients. <a href="./references#CD007929-bbs2-0109" title="KovicB , JinX , KennedySA , HylandsM , PedziwiatrM , KuriyamaA , et al.Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Internal Medicine2018;178(12):1586-96.">Kovic 2018</a> performed a systematic review and quantitative analysis examining how PFS correlated with health‐related quality of life (HRQoL) in oncology studies. They noted that PFS was designed as a measurement tool to identify signals of clinical activity on drug development studies and observed that this has now become the primary outcome measure in many cancer studies. They speculated that PFS is an appealing outcome, especially for pharmaceutical companies, as PFS require reduced numbers of participants for statistical power, and further reduce costs as studies with PFS as the primary outcome require shorter follow‐up than studies reporting OS. Arguments for using PFS as the primary outcome include the avoidance of confounders from cross‐over designs and subsequent variation in treatment after progression. They argued that PFS is only a valid surrogate end‐point if: (1) PFS is a valid predictor of OS differences; and (2) if patients who live longer without disease progression have a better overall HRQoL.   </p> <p><a href="./references#CD007929-bbs2-0109" title="KovicB , JinX , KennedySA , HylandsM , PedziwiatrM , KuriyamaA , et al.Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Internal Medicine2018;178(12):1586-96.">Kovic 2018</a> conducted a systematic review of human cancer RCTs published from January 2000, to May 2016 and identified 52 articles reporting on 38 RCTs, of which only 24 reported both PFS and HRQoL data in a single article. Although many studies included HRQoL outcomes, many failed to publish or report these data in formats that allowed quantitative analyses, and so were excluded from their analysis. Of 2351 potentially includable articles, 2303 were excluded, including  for the following reasons: 811 only included PFS data; 490 had insufficient HRQoL data for analysis; 145 had PFS/HRQoL data missing; and 44 only included HRQoL data. Interestingly, 24/38 (60%) of the studies had shorter HRQoL follow‐up than median PFS. Using simple regression analysis, they failed to find an association between PFS and HR QoL outcomes.  They concluded that their findings “...raise questions regarding the assumption that interventions prolonging PFS also improve HRQoL in patients with cancer....clinical trial investigators should measure HRQoL directly and accurately, ensuring adequate duration and follow‐up.” Their findings also demonstrate how poorly HRQol data are reported in cancer studies generally, despite this being one of the most significant outcomes for patients. </p> <p> <a href="./references#CD007929-bbs2-0141" title="SjoquistKM , LordSJ , FriedlanderML , John SimesR , MarschnerIC , LeeCK .Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology2018;10:1758835918788500-1758835918788500.">Sjoquist 2018</a> cautioned the reliance upon PFS as a surrogate outcome, given the weakening correlation with OS in first‐line studies of EOC. They suggested supporting PFS data with additional end points, including patient‐reported outcome measures (including QoL), time to second disease progression (PFS2), and time to first and second subsequent treatments(<a href="./references#CD007929-bbs2-0102" title="HerzogTJ , ArmstrongDK , BradyMF , ColemanRL , EinsteinMH , MonkBJ , et al.Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.  Gynecologic Oncology2014;132(1):8-17. [DOI: 10.1016/j.ygyno.2013.11.008]">Herzog 2014</a>).  Alternative primary outcomes, which may be of greater relevance for patient decision‐making, as well as regulatory approval, include quality‐adjusted PFS (QA‐PFS) (<a href="./references#CD007929-bbs2-0095" title="GlasziouPP , SimesRJ , GelberRD .Quality adjusted survival analysis. Statistics in Medicine1990;9(11):1259-76. [DOI: doi: 10.1002/sim.4780091106] [PMID: 2277877.]">Glasziou 1990</a>) and Q‐TWiST, as these may be a measure of net clinical benefit and, hopefully, lead to an improvement in the recording of patient‐reported outcomes. These outcomes should, however, be pre‐specified in studies to reduce the risk of selective outcome reporting bias and, it should be acknowledged. </p> <p>Without mature OS and good quality of life data, patients are making decisions based on the hope of improvement in survival, which may be at the expense of significant symptoms. This is inappropriate and adequate reporting of outcomes important to patients, including OS, quality of life and other patient‐reported outcomes, should be mandatory in this treatment setting, as for many this may turn out to be palliative chemotherapy. Concerns regarding publishing surrogate end‐point PFS, without adequate HRQoL data, raised by <a href="./references#CD007929-bbs2-0109" title="KovicB , JinX , KennedySA , HylandsM , PedziwiatrM , KuriyamaA , et al.Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Internal Medicine2018;178(12):1586-96.">Kovic 2018</a>, should be addressed by those who lead clinical trials, reviewers and publishers. Consistent and comprehensive reporting of high‐quality HRQoL data, using recognised scoring systems and reporting of data in formats that are openly available and extractable, is highly recommended. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007929-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007929-sec-0008"></div> <div class="table" id="CD007929-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newly‐diagnosed EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi with chemotherapy<br/><b>Comparison:</b> Chemotherapy alone<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy alone<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi with chemotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression<br/>follow‐up: 26 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.82</b><br/>(0.49 to 1.38)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1564<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi with chemotherapy probably results in little to no difference in progression‐free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>685 per 1000</b><br/>(529 to 797)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)<br/>assessed with: European Organization for Research and Treatment of Cancer Questionnaire<br/>Scale from: 0 to 100<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was <b>‐2.89</b><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.56 higher</b><br/>(0.42 lower to 3.55 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>744<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy likely results in little to no difference in the quality of life.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b><br/>(478 to 536)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/>(1.07 to 1.20)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy likely increases any severe adverse event (grade 3 or higher) slightly.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>EOC:</b> epithelial ovarian cancer; <b>HR:</b> hazard Ratio; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426407798344781835" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426407798344781835</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive without evidence of disease progression at 12 months (63%) was taken from the control arm of the VELIA study.<br/><sup>b</sup> Downgraded by two levels for inconsistency (I2&gt;90%)<br/><sup>c</sup> Note: Indirectness one of the trials (PAOLA‐1) included bevacizumab in its chemotherapy regimen.<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: A single study contributed data for this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007929-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Newly diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newly‐diagnosed EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy (maintenance)<br/><b>Comparison:</b> placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy (maintenance)<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive<br/>follow‐up: range 14 months to 41 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b><br/>(0.59 to 1.13)<br/>[survival]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1124<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy likely results in little to no difference in overall survival, although this is based on immature data and more mature data may alter this result. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b><br/>(583 to 754)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression<br/>follow‐up: range 14 months to 41 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.42</b><br/>(0.19 to 0.92)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1124<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e,f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy may increase progression‐free survival.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<sup>d</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>549 per 1000</b><br/>(269 to 763)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life (QoL)<br/>assessed with: The Trial Outcome Index (TOI) score on the Functional Assessment of Cancer Therapy–Ovarian Cancer questionnaire <br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was <b>3.30</b><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3 lower</b><br/>(4.48 lower to 1.52 lower)<sup>g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>h,i,j</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy probably results in a slight reduction in Quality of Life, although this may not be clinically meaningful.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE )<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>537 per 1000</b><br/>(309 to 934)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b><br/>(1.65 to 4.99)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1118<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>i,k</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy may increase/have little to no effect on any severe adverse event (grade 3 or higher) but the evidence is very uncertain.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>EOC:</b> epithelial ovarian cancer;<b>HR:</b> hazard ratio; <b>MD:</b> mean difference;<b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426409458601301064" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426409458601301064</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (62%) was taken from the control arm of the ICON7 study.<br/><sup>b</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>c</sup> Note: Analysis based on immature data<br/><sup>d</sup> The control risk of being alive without evidence of disease progression at 12 months (24%) was taken from the control arm of the PRIMA study.<br/><sup>e</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;90%), which was probably caused by the population recruited in both studies (SOLO1 included only women with BRCA mutation) <br/><sup>f</sup> Note: The evidence was not downgraded for imprecision despite wide confidence intervals around the effect estimate as the pooled effect still indicates the benefit of PARPi use over placebo.<br/><sup>g</sup> adjusted mean change from baseline to 2 years<br/><sup>h</sup> Note: data limited to a population of patients with BRCA mutation<br/><sup>i</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate)<br/><sup>j</sup> Note: A single study contributed data for this outcome<br/><sup>k</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;80%) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007929-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy<br/><b>Comparison:</b> Chemotherapy<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive at 36 months<br/>follow‐up: range 4 months to 14 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.95</b><br/>(0.62 to 1.47)<br/>[survival]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>331<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPimonotherapy may result in little to no difference in overall survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><br/>(71 to 328)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression at 12 months<br/>follow‐up: range 4 months to 29 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.88</b><br/>(0.56 to 1.38)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>739<br/>(3 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d,f,g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of PARPimonotherapy on progression free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<sup>e</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b><br/>(124 to 428)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life (QoL)<br/>assessed with: The Trial Outcome Index (TOI) score on the Functional Assessment of Cancer Therapy–Ovarian Cancer questionnaire<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was <b>‐3.6</b> points<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.2 points higher</b><br/>(1.76 lower to 4.16 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,h,i</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in QoL.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b><br/>(379 to 658)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.80 to 1.39)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>MD:</b> mean difference; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426414839953371161" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426414839953371161</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (16.6%) was taken from the control arm (conventional treatment) of the ICON4 study.<br/><sup>b</sup> Note: both studies were judged at high risk of bias due to study design (open‐label); however, the evidence was not downgraded as OS is a hard, objective outcome.<br/><sup>c</sup> Downgraded by one level due to indirectness (50% of participants in the ICEBERG3 trial were platinum‐resistant).<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> The control risk of being alive without evidence of disease progression at 12 months (22%) was taken from the control arm (chemotherapy) of Oza 2015 study.<br/><sup>f</sup> Downgraded by one level due to risk of bias (open‐label studies)<br/><sup>g</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt; 70%)<br/><sup>h</sup> Note: The evidence is limited only to participants with BRCA mutation<br/><sup>i</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007929-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy (maintenance therapy)<br/><b>Comparison:</b> placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy (maintenance therapy)<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive at 36 months<br/>follow‐up: NR months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.88</b><br/>(0.65 to 1.20)<br/>[alive]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>560<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy (maintenance therapy) probably results in little to no difference in OS.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b><br/>(116 to 311)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS) assessed with: number alive without evidence of disease progression at 12 months follow‐up<br/>follow‐up: median 17 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.34</b><br/>(0.28 to 0.42)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1677<br/>(4 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy (maintenance therapy) results in a large increase in PFS.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(296 to 444) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation (QoL)<br/>assessed with: European Quality of Life–5 Dimensions questionnaires Health Utility Index<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation was <b>0.783</b> points<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.02 points higher</b><br/>(0.01 lower to 0.05 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy (maintenance therapy) probably results in little to no difference in QoL.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>506 per 1000</b><br/>(358 to 719)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.62</b><br/>(1.85 to 3.72)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1665<br/>(4 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy (maintenance therapy) results in a large increase in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>MD:</b> mean difference; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426425278373060041" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426425278373060041</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (16.6%) was taken from the control arm (conventional treatment) of the ICON4 study. <br/><sup>b</sup> Note: One study contributing data to the analysis for this outcome included only participants with BRCA mutation.<br/><sup>c</sup> The control risk of being alive without evidence of disease progression at 12 months (5.5%, an average) was taken from the control arms of ARIEL3 and Study 19 (Ledermann 2012) studies. <br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: Analysis based on immature data<br/><sup>f</sup> Downgraded by one level due to imprecision (only a subset of participants from a single study contributed data to the analysis for this outcome).<br/><sup>g</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;70%) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007929-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi with chemotherapy<br/><b>Comparison:</b> Chemotherapy alone<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy alone<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi with chemotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)<br/>assessed with: not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: e of disease progression at 12 months follow‐up<br/>follow‐up: median 33 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.02</b><br/>(0.69 to 1.51)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of PARPi with chemotherapy on progression‐free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/>(158 to 313)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>573 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b><br/>(510 to 843)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.89 to 1.47)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy may result in little to no difference in any severe adverse event (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial;<b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426427989803404645" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426427989803404645</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive without evidence of disease progression at 12 months (22%) was taken from the control arm (chemotherapy) of Oza 2015 study.<br/><sup>b</sup> Downgraded by one level due to risk of bias (study design: open‐label)<br/><sup>c</sup> Downgraded by one level due to risk of bias (concern over early closure of Kummar 2015)<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: a single, small (&lt;100 participants) study contributed data to the analysis for this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007929-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐resistant recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy<br/><b>Comparison:</b> Chemotherapy<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi<br/>monotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse events (grade 3 or higher) (G3+ SevAE)<br/>assessed with: unclear<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b><br/>(407 to 876)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b><br/>(0.79 to 1.70)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial;<b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426368977301116995" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426368977301116995</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level due to risk of bias (study design: open‐label)<br/><sup>b</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>c</sup> Downgraded by one level due to publication bias (data available only as a conference abstract). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007929-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007929-sec-0009"></div> <p>This is an updated version of a review first published in 2010 in the <i>Cochrane Database of Systematic Reviews</i> (Issue 6). </p> <section id="CD007929-sec-0010"> <h3 class="title" id="CD007929-sec-0010">Description of the condition</h3> <p>In 2018, worldwide, around 300,000 women were diagnosed with epithelial ovarian cancer (EOC), and 184,799  died from the disease, corresponding to an annual incidence of 6.6 cases per 100,000 women, an annual mortality rate of 4.3 deaths per 100,000, and a cumulative lifetime risk of 0.5% (<a href="./references#CD007929-bbs2-0096" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA .Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer Journal for Clinicians2018;68:394-424. [DOI: 10.3322/caac.21492]">GLOBOCAN 2018</a>). In terms of incidence, it is the sixth most common cancer, and it is the seventh most common cause of cancer death in women. EOC poses a diagnostic challenge: the onset is often insidious; the symptoms are vague; and may mimic other, non‐malignant, conditions. This may lead to a delay in diagnosis and currently three‐quarters of women with EOC are diagnosed when the disease has spread throughout the abdomen (stage III or IV) (<a href="./references#CD007929-bbs2-0112" title="LheureuxS , GourleyC , VergoteI , OzaAM .Epithelial ovarian cancer. Lancet2019;23:1240-53. [PMID: 30910306.]">Lheureux 2019</a>), when the five‐year survival is 20% to 30% (<a href="./references#CD007929-bbs2-0106" title="JemalA , SiegelR , WardE , HaoY , XuJ , MurrayT , et al.Cancer statistics. CA: A Cancer Journal for Clinicians2008;58(2):71-96.">Jemal 2008</a>). EOC accounts for 90% of all ovarian cancers and typically presents in post‐menopausal women, with a peak incidence in women  in their early sixties, although it does occur in younger women, often associated with genetic predispositions (<a href="./references#CD007929-bbs2-0131" title="QuinnM , BabbB , BrockA , JonesJ .Cancer Trends in England and Wales. London: The Stationery Office, 2001.">Quinn 2001</a>).  </p> <p>More recent data suggest that the origin of EOC may often be the lining of the fallopian tubes. Intra‐epithelial precursor lesions (so‐called serous tubal intra‐epithelial carcinoma or STIC) are commonly found in the fimbrial ends of fallopian tubes removed from women at high risk of developing EOC due to breast cancer susceptibility gene (<i>BRCA)</i> variants (<i>BRCA‐</i>mut) (<a href="./references#CD007929-bbs2-0093" title="EricksonBK , ConnerMC , LandenCN .The role of the fallopian tube in the origin of ovarian cancer. American Journal of Obstetrics and Gynecology Nov 2013;209(5):409-14.">Erickson 2013</a>). These STIC lesions are microscopic and may explain why EOC is difficult to identify at an early stage, since it has immediate access to the abdominal cavity and often does not typically arise from an ovarian cyst, which could be seen on an ultrasound scan. Sadly, this has prohibited an effective population level screening test for EOC (<a href="./references#CD007929-bbs2-0117" title="MenonU , Gentry-MaharajA , BurnellM , SinghN , RyanA , KarpinskyjC , et al.Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet2021;397(10290):2182-93. [PMID: 33991479]">Menon 2021</a>). </p> <p>The development of rapid sequencing technology has enabled scientists and clinicians an opportunity to better understand the biology of EOC. It is now clear that different histological subtypes of EOC have characteristic somatic landscapes. Endometrioid EOC commonly associates with pathogenic variants in <i>PTEN (p</i> hosphatase and tensin homolog), clear cell EOC often harbours pathogenic variants in <i>ARID1A</i> and the majority of high‐grade serous EOC demonstrate a pathogenic variant in <i>TP53</i> (<a href="./references#CD007929-bbs2-0110" title="LedermannJA , DrewY , KristeleitRS .Homologous recombination deficiency and ovarian cancer. European Journal of Cancer2016;60:49-58. [DOI: 10.1016/j.ejca.2016.03.005] [PMID: 27065456]">Ledermann  2016</a>). The Cancer Genome Atlas was a groundbreaking collaborative study in which numerous cancer types underwent comprehensive molecular characterisation; the first results published were from EOC (<a href="./references#CD007929-bbs2-0147" title="Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma. Nature 2016;58:49-58. [DOI: 10.1016/j.ejca.2016.03.005] [PMID: 27065456]">TCGA 2016</a>). These data demonstrated an overrepresentation of <i>BRCA1/2</i> pathogenic variants and the importance of homologous recombination dysfunction (HRD) in the oncogenesis of EOC. Such insights into EOC biology have enabled the development of novel and targeted therapies, which have shown promise in clinical trials. Herein we will explore the utility of one such molecular targeted therapy: poly (ADP‐ribose) polymerase (PARP) (inhibition.    </p> </section> <section id="CD007929-sec-0011"> <h3 class="title" id="CD007929-sec-0011">Description of the intervention</h3> <p>Management of advanced EOC consists of a combination of debulking surgery and platinum‐based chemotherapy, with or without the addition of a taxane (<a href="./references#CD007929-bbs2-0143" title="StewartL , Advanced Ovarian Cancer Trialists Group.Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews1999, Issue 1. Art. No: CD001418. [DOI: 10.1002/14651858.CD001418]">Stewart 1999</a>). A recently updated Cochrane Review found that there was no difference in survival in women with The International Federation of Gynecology and Obstetrics (FIGO) stage IIC‐IV disease, if surgery were performed before or after the first few cycles of chemotherapy (<a href="./references#CD007929-bbs2-0087" title="ColeridgeSL , BryantA , KehoeS , MorrisonJ .Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD005343. [DOI: 10.1002/14651858.CD005343.pub6]">Coleridge 2021</a>). However, despite good initial responses to platinum agents and taxanes, most women have disease relapse, require further treatment with chemotherapy, and eventually develop resistance to conventional chemotherapeutic agents; only around 30% of women are cured using the current treatment modalities (<a href="./references#CD007929-bbs2-0112" title="LheureuxS , GourleyC , VergoteI , OzaAM .Epithelial ovarian cancer. Lancet2019;23:1240-53. [PMID: 30910306.]">Lheureux 2019</a>). Response to platinum‐based chemotherapy is not uniform across all patients. At diagnosis, EOC that responds to platinum‐based therapy is considered platinum‐sensitive. Platinum‐resistant EOC was originally defined as disease recurrence/progression within six months of completion of first‐line platinum‐based chemotherapy. The term now also applies to include patients progressing within six months after multiple lines of chemotherapy, or to those who do not respond to platinum‐based chemotherapy in a relapsed setting. These classifications are important when assessing new treatments, as they speak to the biology of the cancer and also enable an evaluation in the context of current therapies. It is these conventional therapies against which new interventions are often measured, acting as a control.  </p> <p>Conventional chemotherapeutic agents have activity on all rapidly dividing cells, hence the common side effects such as bone marrow suppression and mucositis (inflammation and ulceration of the mucous membranes lining the digestive tract). Increasing knowledge of the genetic basis for cancer has led to the development of novel 'targeted' agents, which target cancer‐specific pathways. It is hoped that these reagents will preferentially affect cancer cells and spare normal cells, thereby reducing the toxic side effects of chemotherapy, in addition to having an enhanced therapeutic effect. One such class of targeted agent are the PARP inhibitors (PARPi). These can be used as both an adjunct to conventional chemotherapy, or as a maintenance treatment after completion of conventional chemotherapy.  </p> </section> <section id="CD007929-sec-0012"> <h3 class="title" id="CD007929-sec-0012">How the intervention might work</h3> <section id="CD007929-sec-0013"> <h4 class="title">DNA repair inhibition</h4> <p>Cancers arise through a process of sequential mutations that lead to the development of dysfunctional and accelerated cellular growth. Whereby a driver mutation affects the normal molecular mechanisms that ensure DNA fidelity, these sequential mutations happen and are maintained at a faster rate, enabling a cancer to be more adaptive (<a href="./references#CD007929-bbs2-0086" title="ChiangAC , MassaguéJ .Molecular basis of metastasis. New England Journal of Medicine2008;25:2814-23. [DOI: 10.1056/NEJMra0805239] [PMID: 19109576]">Chiang 2008</a>). Therefore, given this survival advantage, many cancer cells harbour mutations that render their ability to repair DNA damage less effectual. Although an evolutionary strength, this reduced ability to repair DNA damage also provides a potential therapeutic target. Indeed, many current therapies for cancer (cytotoxic chemotherapy and radiotherapy) work by damaging DNA. Noncancerous cells are, in the most part, able to utilise their functional DNA repair machinery to rescue themselves. However, due to their dysfunctional DNA repair machinery, cancer cells are unable to correct the damaged caused which, ultimately proves fatal to the cell (<a href="./references#CD007929-bbs2-0127" title="ParkinsonJF , WheelerHT , McDonaldKL .Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma.. Journal of Clinical Neuroscience2008;15(1):1-8. [DOI: 10.1016/j.jocn.2007.06.005] [PMID: 18037296]">Parkinson 2008</a>).       </p> <p>There are numerous mechanisms within a normal cell that ensure the maintained accuracy of newly synthesised DNA (necessary in cell division) and correction of damaged DNA, for example, the mismatch repair system or homologous recombination DNA repair (<a href="./references#CD007929-bbs2-0084" title="ChatterjeeN , WalkerGC .Mechanisms of DNA damage, repair, and mutagenesis. Environmental and Molecular  Mutagenesis2017;58:235-63. [DOI: 10.1002/em.22087] [PMID: 28485537]">Chatterjee 2017</a>). This redundancy means that a healthy cell is not reliant on one particular mechanism for DNA repair and therefore can tolerate impairment of one or more its DNA repair pathways. However, a cancer cell is often overly reliant on one particular means of DNA repair, due to hereditary or acquired mutations.  It is therefore possible to develop therapies that exploit this lack of redundancy and block the predominant DNA repair pathway in the cancer cell, leading to fatal DNA damage. This targeted therapy, should theoretically have minimal effect on healthy cells, as they are able to compensate with their remaining functional DNA repair machinery.  </p> <p>Such targeted therapies are already in clinical use, namely agents against PARP, DNA‐dependent protein kinase (DNA‐PK) and the ataxia‐telangiectasia mutated gene protein kinase (ATM) (<a href="./references#CD007929-bbs2-0083" title="BryantHE , HelledayT .Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Research2006;34(6):1685-91.">Bryant 2006</a>). Of these DNA‐repair inhibitors, PARP inhibitors have been most commonly used as anticancer therapy, so far.  </p> </section> <section id="CD007929-sec-0014"> <h4 class="title">Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi)</h4> <p>PARP  proteins are a family of related enzymes involved in regulating various cellular processes, including DNA repair, cell death and inflammation. PARP inhibitors therefore have a potentially wide range of applications (<a href="./references#CD007929-bbs2-0105" title="JagtapP , SzaboC .Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. National Reviews of Drug Discovery2005;4(5):421-40.">Jagtap 2005</a>). </p> <p>PARP‐1 is the most‐studied of the PARP family. It is a nuclear enzyme, which binds to both single‐stranded and double‐stranded DNA breaks, either facilitating their repair by other enzymes (in the case of mild damage), or triggering cell‐death pathways (in the case of more severe damage) (<a href="./references#CD007929-bbs2-0089" title="CurtinNJ .PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine2005;7(4):1-20.">Curtin 2005</a>; <a href="./references#CD007929-bbs2-0129" title="Peralta-LealA , RodriguezMI , OliverFJ .Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clinical Translations in Oncology2008;10(6):318-23.">Peralta‐Leal 2008</a>; <a href="./references#CD007929-bbs2-0132" title="RatnamK , LowJA .Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research2007;13(5):1383-8.">Ratnam 2007</a>). Through its inhibition, cells lose their ability to effectively repair DNA damage and therefore die, via  apoptosis or necrosis (<a href="./references#CD007929-bbs2-0146" title="TakayaH , NakaiH , TakamatsuS , MandaiM , MatsumuraN .Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports2020;1(10):2757. [DOI: 10.1038/s41598-020-59671-3] [PMID: 32066851]">Takaya 2020</a>). This is of therapeutic benefit in cancers, whereby its targeted inhibition, through PARPi, leads to fatal genomic instability, as cancer cells often lack compensatory DNA repair mechanisms (<a href="./references#CD007929-bbs2-0146" title="TakayaH , NakaiH , TakamatsuS , MandaiM , MatsumuraN .Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports2020;1(10):2757. [DOI: 10.1038/s41598-020-59671-3] [PMID: 32066851]">Takaya 2020</a>). The application of PARPi is of therapeutic interest in EOC as they often display pre‐existing genomic instability (<a href="./references#CD007929-bbs2-0147" title="Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma. Nature 2016;58:49-58. [DOI: 10.1016/j.ejca.2016.03.005] [PMID: 27065456]">TCGA 2016</a>). This is commonly as a result of abnormal BRCA protein expression (<a href="./references#CD007929-bbs2-0146" title="TakayaH , NakaiH , TakamatsuS , MandaiM , MatsumuraN .Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports2020;1(10):2757. [DOI: 10.1038/s41598-020-59671-3] [PMID: 32066851]">Takaya 2020</a>).  </p> <p>The BRC<i>A</i> genes encode for DNA repair enzymes that function independently of the PARP pathway. Cells with <i>BRCA</i> pathogenic variants are very susceptible to PARPi, because both pathways to repair DNA are blocked. This then triggers cell cycle arrest and apoptosis specifically within cells that have the <i>BRCA</i> mutation (<a href="./references#CD007929-bbs2-0082" title="BryantHE , SchultzN , ThomasHD , ParkerKM , FlowerD , LopezE , et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature2005;434(7035):913-7.">Bryant 2005</a>; <a href="./references#CD007929-bbs2-0094" title="FarmerH , McCabeN , LordCJ , TuttAN , JohnsonDA , RichardsonTB , et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature2005;434(7035):917-21.">Farmer 2005</a>). PARP inhibitors have been shown to be effective, when used alone in cell culture or in mouse models, at killing cells with pathogenic variants in the <i>BRCA1</i> and <i>BRCA2</i> genes (<a href="./references#CD007929-bbs2-0082" title="BryantHE , SchultzN , ThomasHD , ParkerKM , FlowerD , LopezE , et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature2005;434(7035):913-7.">Bryant 2005</a>; <a href="./references#CD007929-bbs2-0094" title="FarmerH , McCabeN , LordCJ , TuttAN , JohnsonDA , RichardsonTB , et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature2005;434(7035):917-21.">Farmer 2005</a>), and have been used in clinical trials for breast cancer (<a href="./references#CD007929-bbs2-0029" title="FongPC , BossDS , CardenCP .AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology (Meeting Abstracts)2008;26(15 Suppl):5510. ">Fong 2008</a>). <i>BRCA</i> germline (inherited) mutations pre‐dispose women to develop ovarian cancer. In addition, many ovarian cancers, in women who do not have germline <i>BRCA</i> pathogenic variants, have developed pathogenic variants in the <i>BRCA</i> genes within the tumour — called somatic mutations (<a href="./references#CD007929-bbs2-0101" title="HennessyBT , TimmsKM , CareyMS , GutinA , MeyerLA , Flake DD 2nd, et al.Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Journal of Clinical Oncology2010;28(22):3570-6.">Hennessy 2010</a>) </p> <p>EOC that demonstrates defective homologous recombination DNA repair are also amenable to PARPi (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>). Homologous recombination is a DNA repair mechanism which corrects DNA double‐stranded breaks. The homologous recombination repair pathway is often dysfunctional in EOC due to germline <i>BRCA1/2</i> pathogenic variants, somatic <i>BRCA1/2</i> pathogenic variants and <i>BRCA</i> gene promotor methylation (<a href="./references#CD007929-bbs2-0147" title="Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma. Nature 2016;58:49-58. [DOI: 10.1016/j.ejca.2016.03.005] [PMID: 27065456]">TCGA 2016</a>). However, it is a complex system comprised of multiple proteins and therefore errors in other constituent proteins can lead to a similar molecular profile to those EOC resulting from pathogenic variants in <i>BRCA1/2</i> . This has led to the development of assays that can test for HRD to identify those EOC without <i>BRCA</i> pathogenic variants (either germline or somatic) that do display a homologously recombination deficiency phenotype and therefore could respond to PARPi (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>). Indeed, this subgroup of EOC has been the focus of several recent trials exploring the use of PARPi in EOC (<a href="./references#CD007929-bbs2-0146" title="TakayaH , NakaiH , TakamatsuS , MandaiM , MatsumuraN .Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports2020;1(10):2757. [DOI: 10.1038/s41598-020-59671-3] [PMID: 32066851]">Takaya 2020</a>).  </p> <p>Research into the anticancer applications of PARPi has focused on three main approaches.</p> <p> <ul id="CD007929-list-0001"> <li> <p>First, they can be used in isolation as the primary treatment for EOC either in the first‐line or recurrent settings. (<a href="./references#CD007929-bbs2-0154" title="ZarembaT , CurtinNJ .PARP inhibitor development for systemic cancer targeting. Anti-cancer Agents in Medicinal Chemistry2007;7(5):515-23.">Zaremba 2007</a>). </p> </li> <li> <p>Second, PARPi can be used in combination with conventional anticancer agents that act by damaging DNA, such as cytotoxic chemotherapy and radiotherapy, as PARPi block the DNA‐repair mechanisms that cancer cells use to resist destruction. Again, this can either be in the first‐line or recurrent setting. </p> </li> <li> <p>Finally, they can be used in a maintenance setting, in which they are used after definitive treatment in order to either reduce disease recurrence or delay disease recurrence. </p> </li> </ul> </p> <p>All three modalities will be studied in this systematic review. </p> </section> </section> <section id="CD007929-sec-0015"> <h3 class="title" id="CD007929-sec-0015">Why it is important to do this review</h3> <p>Targeted biological agents that work in different ways to conventional chemotherapy have been developed. It is therefore important to establish whether the addition of these new drugs to conventional chemotherapy regimens, as an alternative to conventional chemotherapy agents is beneficial, in terms of survival and, if so, at what cost and benefit, in terms of additional harmful effects. Furthermore, since these compounds may be less toxic compared to conventional chemotherapy agents, it may be feasible to use these new agents in patients who are not currently taking chemotherapy (so‐called maintenance treatment), to reduce the chance of, or delay, the recurrence of their EOC.  In this maintenance setting, where women would otherwise not be on treatment, there may be a difference balance in terms of harms and benefits of treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007929-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007929-sec-0016"></div> <p>To determine the benefits and risks of poly (ADP‐ribose) polymerase) inhibitors (PARPi) for the treatment of epithelial ovarian cancer (EOC). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007929-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007929-sec-0017"></div> <section id="CD007929-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007929-sec-0019"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD007929-sec-0020"> <h4 class="title">Types of participants</h4> <p>Women ≥ 18 years old with histologically proven epithelial ovarian cancer (EOC) of any stage<i>.</i> We excluded women with other concurrent malignancies. </p> </section> <section id="CD007929-sec-0021"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD007929-list-0002"> <li> <p>DNA‐repair pathway inhibitors versus no treatment</p> </li> <li> <p>DNA‐repair pathway inhibitors + conventional chemotherapy versus conventional chemotherapy</p> </li> <li> <p>DNA‐repair pathway inhibitors versus conventional chemotherapy</p> </li> </ul> </p> </section> <section id="CD007929-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>The primary and secondary outcomes of this review are as follows.</p> <section id="CD007929-sec-0023"> <h5 class="title">Primary outcomes</h5> <p>Overall survival (OS)</p> </section> <section id="CD007929-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p>Progression‐free survival (PFS)</p> <p>Objective response rate (ORR)</p> <p>Quality of life, measured by a validated scale, e.g. QLQ‐C30</p> <p>Severe adverse events (SevAEs); all grades 3+ AEs according to a validated scale such as the Common Terminology Criteria for Adverse Events (CTCAE). Also, severe events according to: </p> <p> <ul id="CD007929-list-0003"> <li> <p>haematological (leucopenia, anaemia, thrombocytopenia, neutropenia, haemorrhage);</p> </li> <li> <p>gastrointestinal (nausea, vomiting, anorexia, diarrhoea, liver, proctitis);</p> </li> <li> <p>genitourinary;</p> </li> <li> <p>skin (stomatitis, mucositis, alopecia, allergy);</p> </li> <li> <p>neurological (peripheral and central);</p> </li> <li> <p>other side effects not categorised above.</p> </li> </ul> </p> </section> </section> </section> <section id="CD007929-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought papers in all languages and carried out translations where necessary.</p> <section id="CD007929-sec-0026"> <h4 class="title">Electronic searches</h4> <p>See: <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/GYNAECA/sect0-meta.html" target="_blank">Cochrane Gynaecological Cancer Group</a> methods used in reviews. </p> <p>We searched the following electronic databases from 1990 to October 2020:</p> <p> <ul id="CD007929-list-0004"> <li> <p>Cochrane Gynaecological Cancer Group Trial Register (to October 2020);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (Central 2020, Issue 10);</p> </li> <li> <p>MEDLINE (1990 up to October week 2, 2020);</p> </li> <li> <p>Enbase (1990 up to week 42, 2020).</p> </li> </ul> </p> <p>The CENTRAL, MEDLINE and Embase search strategies, based on terms related to the review topic, are presented in <a href="./appendices#CD007929-sec-0088">Appendix 1</a>, <a href="./appendices#CD007929-sec-0089">Appendix 2</a> and <a href="./appendices#CD007929-sec-0090">Appendix 3</a>.  </p> </section> <section id="CD007929-sec-0027"> <h4 class="title">Searching other resources</h4> <p>For the original review, we searched Physician Data Query, <a href="http://www.controlled-trials.com/rct" target="_blank">www.controlled-trials.com/rct</a>, <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a> and the National Research Register (NRR) for ongoing trials. We also sought details of ongoing or unpublished trials from the Food and Drug Administration (FDA) (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>) and the European Medicines Agency (EMA) (<a href="http://www.ema.europa.eu" target="_blank">www.ema.europa.eu</a>), and from pharmaceutical company sources. </p> <p>For this latest update, we relied on the electronic search to identify relevant ongoing trials from clinical trial registers. Where possible, we contacted the main investigators of unpublished trials for further information. </p> </section> </section> <section id="CD007929-sec-0028"> <h3 class="title" id="CD007929-sec-0028">Data collection and analysis</h3> <section id="CD007929-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to <a href="./references#CD007929-bbs2-0088" title="Covidence systematic review software.Melbourne, Australia: Veritas Health Innovation, 2019.">Covidence 2019</a> and removed duplicates. At least two review authors (IM, KH in the initial version of the review; a combination of AW, GC, JM and TL for the 2015 updated review; and a combination of JM, NR, AT and AW for the 2021 review) independently examined the remaining references. We excluded those studies that clearly did not meet the inclusion criteria, and obtained copies of the full text of potentially relevant references. At least two review authors (IM, KH for initial review; a combination of AW, GC, JM and TL for the 2015 update; and JM, NR, AT and AW) independently assessed the eligibility of retrieved papers. We documented reasons for exclusion. </p> </section> <section id="CD007929-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we abstracted data as follows.</p> <p> <ul id="CD007929-list-0005"> <li> <p>Author, year of publication and journal citation (including language)</p> </li> <li> <p>Country</p> </li> <li> <p>Setting</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Study design, methodology</p> </li> <li> <p>Study population</p> <ul id="CD007929-list-0006"> <li> <p>Total number enrolled</p> </li> <li> <p>Patient characteristics</p> </li> <li> <p>Age</p> </li> <li> <p>Co‐morbidities</p> </li> <li> <p>Previous treatment</p> </li> </ul> </li> <li> <p>Total study duration</p> </li> <li> <p>Total number of intervention groups</p> </li> <li> <p>Ovarian cancer details at diagnosis</p> <ul id="CD007929-list-0007"> <li> <p>FIGO stage</p> </li> <li> <p>Histological cell type</p> </li> <li> <p>Tumour grade</p> </li> <li> <p>Extent of disease</p> </li> </ul> </li> <li> <p>Intervention details</p> <ul id="CD007929-list-0008"> <li> <p>Type of DNA‐repair pathway inhibitor</p> </li> <li> <p>Dose</p> </li> <li> <p>Duration of treatment</p> </li> <li> <p>Consolidation treatment or treatment of active disease</p> </li> </ul> </li> <li> <p>Comparison details</p> <ul id="CD007929-list-0009"> <li> <p>Type of control: conventional chemotherapy or no treatment</p> </li> <li> <p>Dose (if appropriate)</p> </li> <li> <p>Duration (if appropriate)</p> </li> </ul> </li> <li> <p>Deviations from protocol</p> </li> <li> <p>Risk of bias in a study (see below)</p> </li> <li> <p>Duration of follow‐up</p> </li> <li> <p>Outcomes: overall survival OS), progression‐free survival (PFS), quality of life, toxicity: </p> <ul id="CD007929-list-0010"> <li> <p>for each outcome: outcome definition (with diagnostic criteria if relevant);</p> </li> <li> <p>unit of measurement (if relevant);</p> </li> <li> <p>for scales: upper and lower limits, and whether a high or low score is good;</p> </li> <li> <p>results: number of participants allocated to each intervention group;</p> </li> <li> <p>for each outcome of interest: sample size; missing participants.</p> </li> </ul> </li> </ul> </p> <p>We extracted data on outcomes as below.</p> <p> <ul id="CD007929-list-0011"> <li> <p>For time to event (overall andPFS) data, we extracted the log of the hazard ratio (log(HR)) and its standard error (SE) from trial reports; if these were not reported, we attempted to estimate them from other reported statistics using the methods of <a href="./references#CD007929-bbs2-0128" title="ParmarMK , TorriV , StewartL .Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. toxicity or deaths if it was not possible to use an HR), we extracted the number of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed at an endpoint, in order to estimate a risk ratio (RR). </p> </li> <li> <p>For continuous outcomes (e.g. quality of life measures), we extracted the final value and standard deviation (SD) of the outcome of interest and the number of patients assessed at an endpoint in each treatment arm at the end of follow‐up, in order to estimate the mean difference (MD) (if trials measured outcomes on the same scale) or standardised mean difference (SMD) (if trials measured outcomes on different scales) between treatment arms and its SE. </p> </li> </ul> </p> <p>We extracted both unadjusted and adjusted statistics if reported. When we extracted adjusted results, we recorded the variables for which they were adjusted. </p> <p>Where possible, all data extracted were relevant to an intention‐to‐treat analysis (ITT), in which participants were analysed in the groups to which they were assigned. </p> <p>We noted the time points at which outcomes were collected and reported.</p> <p>At least two review authors (a combination of AT, NR, AW, ER andJM for this review update) independently extracted data onto a data extraction form specially designed for the review update. We resolved differences between review authors by discussion or by appeal to a third review author (TL) if necessary. </p> </section> <section id="CD007929-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included randomised controlled trials (RCTs) using Cochrane's risk of bias tool and the criteria specified in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007929-bbs2-0104" title="HigginsJP , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). This included assessment of: </p> <p> <ul id="CD007929-list-0012"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, healthcare providers and outcome assessors);</p> </li> <li> <p>incomplete outcome data:</p> <ul id="CD007929-list-0013"> <li> <p>we coded the satisfactory level of loss to follow‐up for each outcome as:</p> <ul id="CD007929-list-0014"> <li> <p>yes, if fewer than 20% of patients were lost to follow‐up and reasons for loss to follow‐up were similar in both treatment arms; </p> </li> <li> <p>no, if more than 20% of patients were lost to follow‐up or reasons for loss to follow‐up differed between treatment arms; </p> </li> <li> <p>unclear if the loss to follow‐up was not reported.</p> </li> </ul> </li> </ul> </li> <li> <p>selective reporting of outcomes;</p> </li> <li> <p>other possible sources of bias.</p> </li> </ul> </p> <p>Two review authors (a combination of AT, NR, AW, ER andJM) independently applied the risk of bias tool and resolved differences by discussion or by appeal to a fifth review author (TL). We summarised results in a risk of bias' summary. We interpreted the results of meta‐analyses in the light of the findings with respect to the risk of bias. </p> </section> <section id="CD007929-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment:</p> <p> <ul id="CD007929-list-0015"> <li> <p>For time to event data, we used the HR, if possible.</p> </li> <li> <p>For dichotomous outcomes, we used the RR.</p> </li> <li> <p>For continuous outcomes, we used the MD between treatment arms if all trials measured the outcome on the same scale, otherwise we used SMD. </p> </li> </ul> </p> </section> <section id="CD007929-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD007929-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing outcome data; if only imputed outcome data were reported, we contacted trial authors to request data on the outcomes only among participants who were assessed. </p> </section> <section id="CD007929-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between studies by visual inspection of forest plots, by estimation of the percentage of heterogeneity between trials which cannot be ascribed to sampling variation (<a href="./references#CD007929-bbs2-0103" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD007929-bbs2-0090" title="DeeksJJ , AltmanDG , BradburnMJ .Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London: BMJ Publication Group, 2001.">Deeks 2001</a>). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this. </p> </section> <section id="CD007929-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not produce funnel plots corresponding to meta‐analysis due to the limited number of included studies. In future versions of this review, we will examine funnel plots for meta‐analysis of the primary outcome to assess the potential for small‐study effects. When there is evidence of small‐study effects, we will consider publication bias as only one of a number of possible explanations. If these plots suggest that treatment effects may not be sampled from a symmetric distribution, as assumed by the random‐effects model, we will perform sensitivity analyses using fixed‐effect models. </p> </section> <section id="CD007929-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Where sufficient clinically similar trials were available, we pooled their results in meta‐analyses. </p> <p> <ul id="CD007929-list-0016"> <li> <p>For time‐to‐event data, we pooled HRs using the generic inverse variance facility of RevMan 5.4 (<a href="./references#CD007929-bbs2-0134" title="Review Manager (RevMan).Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </li> <li> <p>For dichotomous outcomes, we calculated the RR for each study and pooled these.</p> </li> <li> <p>No continuous data were synthesised for this review. In future versions of this review, for continuous outcomes (e.g. quality of life) we will pool the mean differences between the treatment arms at the end of follow‐up if all trials measured the outcome on the same scale, otherwise, we will pool standardised mean differences. </p> </li> </ul> </p> <p>We used random‐effects models with inverse variance weighting for all meta‐analyses (<a href="./references#CD007929-bbs2-0091" title="DerSimonianR , LairdN .Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). </p> </section> <section id="CD007929-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered factors such as type of intervention (e.g. use as early‐stage consolidation therapy in chemo‐sensitive cancers or used in late‐stage chemo‐resistant cancers) and stage of disease in the interpretation of any heterogeneity.  </p> <p>As planned <i>a priori</i> for subsequent updates at the time of the 2015 update of the review (<a href="./references#CD007929-bbs2-0157" title="WiggansAJ , CassGK , BryantA , LawrieTA , MorrisonJ .Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub3] [PMID: 25991068]">Wiggans 2015</a>), we analysed the effects of interventions in a number of comparisons, since there are a number of clinical scenarios where it may be appropriate to use PARPi, each of which is a separate clinical question. These comparisons, based on different situations encountered clinically, are separate, clinically relevant, questions. We, therefore, planned subgroup analyses by the line of treatment and by platinum sensitivity of disease at relapse.   </p> <p>Furthermore, increased knowledge about the biology of ovarian cancer, since the original protocol, concerning BRCA somatic and germline mutations and HRD status of the tumour were found to be biological markers of response to PARPi and may enable these drugs to be used more selectively, avoiding treatment of women less likely to respond to treatment. Analysis of results by BRCA and HRD status was therefore planned from the outset for this update. </p> </section> <section id="CD007929-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>There were too few studies to perform sensitivity analysis. In future versions of the review, we will perform sensitivity analysis excluding (i) studies at high risk of bias, and (ii) unadjusted results. </p> </section> <section id="CD007929-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007929-bbs2-0136" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group.Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017a</a>), we prepared a summary of findings table to present the results of the following outcomes. </p> <p> <ul id="CD007929-list-0017"> <li> <p>Overall survival (OS)</p> </li> <li> <p>Progression‐free survival (PFS)</p> </li> <li> <p>Quality of life (QoL)</p> </li> <li> <p>Adverse events (AEs)</p> </li> </ul> </p> <p>For each assumed risk cited in the tables, we provided a rationale and used the GRADE system to rank the quality of the evidence (<a href="./references#CD007929-bbs2-0137" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al, on behalf of the Cochrane Applicability and Recommendations Methods Group.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017b</a>). Evidence was downgraded by ‐1 or ‐2 if the following limitations were present, according to their seriousness: study design limitations, inconsistency, imprecision, indirectness and publication bias. Where the evidence was based on single studies, or where there was no evidence on a specific outcome, we included the outcome in the 'Summary of findings' tables and graded or explained accordingly. We downgraded evidence of a clear effect derived from a single small study and resolved any differences by discussion. We reported and interpreted results based on the Cochrane Effective Practice and Organisation of Care and interactive GRADEpro Summary of Findings table guidance (<a href="./references#CD007929-bbs2-0092" title="Effective Practice and Organisation of Care (EPOC).EPOC Resources for review authors. epoc.cochrane.org/epoc-specific-resources-review-authors (accessed 6 July 2016).">EPOC 2015</a>; <a href="./references#CD007929-bbs2-0138" title="Schunemann HJ , SantessoN , Brozek JL .Interactive summary of findings tables: the way to present and understand results of systematic reviews. JBI Database Systematic Reviews and Implementation Reports2019;17(3):259-60.">Schunemann 2019</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007929-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007929-sec-0041"></div> <section id="CD007929-sec-0042"> <h3 class="title">Description of studies</h3> <p>For details of included, excluded and ongoing studies see <a href="./references#CD007929-sec-0102" title="">Characteristics of included studies</a>; <a href="./references#CD007929-sec-0103" title="">Characteristics of excluded studies</a>; <a href="./references#CD007929-sec-0104" title="">Characteristics of ongoing studies</a>. </p> <section id="CD007929-sec-0043"> <h4 class="title">Results of the search</h4> <p>This review was first published in 2010 (<a href="./references#CD007929-bbs2-0156" title="MartinekI , HaldarK , GaitskellK , BryantA , NicumS , KehoeS , et al.DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews2010, Issue 6. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub2]">Martinek 2010</a>) when two ongoing randomised phase II clinical trials were identified from the clinical trials databases, which met our inclusion criteria, No preliminary data were available from an initial de‐duplicated yield of 473 references. The 2015 update of the review (<a href="./references#CD007929-bbs2-0157" title="WiggansAJ , CassGK , BryantA , LawrieTA , MorrisonJ .Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub3] [PMID: 25991068]">Wiggans 2015</a>) identified four randomised controlled trials (RCTs) (<a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>; <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>), two of which were the ongoing studies identified in the first version of the review.  There were an additional four ongoing studies identified. In total, 14 papers were associated with the four included studies. </p> <p>An updated search conducted on 30th July 2019 yielded the following.</p> <p> <ul id="CD007929-list-0018"> <li> <p>MEDLINE: April 2015 to July week 3 2019 – 519 references</p> </li> <li> <p>Embase: April 2015 to 2019 week 30 – 569 references</p> </li> <li> <p>Central 2019, Issue 7 – 229 references</p> </li> </ul> </p> <p>Following preliminary de‐duplication across the databases, the combined total yield was 1115 references. </p> <p>A further search on the 20th October 2020 yielded the following.</p> <p> <ul id="CD007929-list-0019"> <li> <p>MEDLINE: July 2019 to October week 2 2020 – 244 references</p> </li> <li> <p>Embase: July 2019 to 2020 week 42 – 257 references</p> </li> <li> <p>Central 2020, Issue 10 – 38 references</p> </li> </ul> </p> <p>Following preliminary de‐duplication across the databases, the combined total yield for this search was 487 references, with an additional two published articles  from two included studies found on handsearching after the search date. </p> <p>Following sifting on title and abstract, these two 2019/2020 searches led to the retrieval of 255 full texts for assessment. Of this list, 143 papers related to 15 completed studies (including the four already included studies (<a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>; <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>) (6232 participants in total) and 37 papers related to 17 ongoing studies were included; after exclusion of review articles, commentaries and further duplicates, 48 papers were excluded with reasons (Characteristics of excluded studies) and another 27 were excluded as review articles/commentaries/duplicates after full text review (<a href="#CD007929-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007929-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram from updated searches to 19 October 2020." data-id="CD007929-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram from updated searches to 19 October 2020.</p> </div> </div> </div> <p>In total, we include 15 RCTs in this updated review:</p> <p> <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> (two references); <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> (three references); <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a> (12 references); <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> (six references); <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> (16 references); <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> (one reference); <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> (22 references);  <a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> (13 references); <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> (eight references); <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> (18 references); <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> (26 references); <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> (three references); <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> (five references), <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> (four references) and <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> (two references). </p> <p>The details of 17 ongoing studies can be found in the Characteristics of ongoing studies.</p> </section> <section id="CD007929-sec-0044"> <h4 class="title">Included studies</h4> <p>For the details of the included studies, see the <a href="./references#CD007929-sec-0102" title="">Characteristics of included studies</a> and <a href="#CD007929-tbl-0007">Table 1</a>. </p> <div class="table" id="CD007929-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention/s</b> <br/><b>(name and n)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> <br/><b>(name and n)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomisation ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line treatment or relapsed disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>BRCA</i> status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Somatic</b> </p> <p><b><i>BRCA</i> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Germline</b> </p> <p><b><i>BRCA</i> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRD</b> </p> <p><b>Status</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants with measurable disease (RECIST)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Platinum‐related status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib+Bevacizumab<br/>(537) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo+Bevacizumab<br/>(269) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>806</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum–taxane chemotherapy plus bevacizumab </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib (487) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (246)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>733</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All the patients had received six to nine cycles of first‐line platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(260) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(131) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+<br/>~70% BRCA1+<br/>~30% BRCA2+  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum‐based<br/>chemotherapy without bevacizumab </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐linetreatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veliparib+Chemotherapy followed by placebo<br/>(383)<br/>Veliparib+Chemotherapy followed by veliparib<br/>(382) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo+Chemotherapy followed by placebo<br/>(375)  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1140</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants who undergo primary cytoreductive surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Relapsed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veliparib+Chemotherapy<br/>(37) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(38) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients were required to have received at least one line of standard therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib+Chemotherapy followed by Olaparib<br/>(81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy followed by no treatment<br/>(81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Information available for 107 of 162 pts<br/>38% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of 3 platinum‐based therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (52%) &amp; PPS (48%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib + Bevacizumab<br/>(48) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib<br/>(49) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous platinum‐containing therapy for primary disease but ≤1 prior non‐platinum‐containing regimen for recurrent disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (66%) or PPS (34%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cediranib+Olaparib (189)<br/>Olaparib<br/>(189) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(187) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>565</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.7% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>platinum and non‐platinum based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (details unavailable)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(178) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(88)  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+ ~65% BRCA1+<br/>~31% BRCA2+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 2 prior lines of platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (37%) or PPS (62%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib 200 mg<br/>(32)<br/>Olaparib 400 mg<br/>(32) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+</p> <p>80% BRCA1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>platinum‐based chemotherapy regimen (another<br/>non‐PLD chemotherapy after this was permitted) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (~50%) and PPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rucaparib<br/>(375) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(189) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28%**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 2 previous platinum‐based chemotherapy regimens; prior BEV treatment permitted except BEV maintenance   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS or PPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib<br/>(372) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(181) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49%*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two previous lines of platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (61%) &amp; PPS (39%)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(136) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(129) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two or more platinum‐based regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (60%) &amp; PPS (40%)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(196) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(99) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two previous lines of<br/>platinum‐based chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(67) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 previous line of chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (100%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>PS:</b> Platinum sensitive;<b>PPS:</b> partially‐platinum sensitive; <b>PR:</b> platinum‐resistant; <b>NR:</b> not reported.  </p> <p>** This was defined as in the manscript (or with high dgree loss of hetrogenicity) and is limited to <i>BRCA</i> wild type.  </p> </div> </div> <section id="CD007929-sec-0045"> <h5 class="title">Newly‐diagnosed epithelial ovarian cancer (EOC)</h5> <p>Four included studies evaluated the effect of PARP inhibitors (PARPi) in newly‐diagnosed EOC (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>; <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>). All trials were industry‐funded international, multicentre trials. </p> <section id="CD007929-sec-0046"> <h6 class="title">Participants</h6> <p>All trials included women with newly‐diagnosed advanced (International Federation of Gynecology and Obstetrics stage 3 or 4) EOC with a complete or partial response to first‐line treatment (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>; <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>). In the <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> study, women also had to have a mutation in <i>BRCA1</i> , <i>BRCA2,</i> or both (<i>BRCA1/2</i> ). In other trials, the proportion of women with <i>BRCA</i> mutation was around 30%. The highest proportion of participants with homologous recombination deficiencies (HRD) mutation was in the <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> study (63%), followed by <a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> and <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> studies (approximately 50%). The proportion of participants with HRD mutation in the <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> study is unknown. The median age of participants in the <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> study was also lower (median 53 years) than in the other three studies included in this comparison (median range 60 to 62 years). </p> </section> <section id="CD007929-sec-0047"> <h6 class="title">Interventions</h6> <p>Two studies included in the comparison evaluated the effect of PARPi as maintenance therapy after platinum‐based chemotherapy compared to placebo (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>). One study assessed the effect of PARPi in conjunction with intravenous bevacizumab and platinum–taxane chemotherapy compared to bevacizumab and chemotherapy alone (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>); bevacizumab was given in a dose of 15 mg per kg of body weight every three weeks for a total duration of up to 15 months. The fourth study (<a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>) has a three‐arm design where the PARPi in experimental arms was given as a part of first‐line treatment in conjunction with chemotherapy and extended into the maintenance phase or not (placebo). The control intervention in the <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> study was chemotherapy followed by placebo in the maintenance phase. The chemotherapy consisted of carboplatin (area under the curve of 6 mg per mL per minute, every three weeks) and paclitaxel (175 mg per square metre of body‐surface area, administered every three weeks, or 80 mg per square metre, administered weekly). In two studies, the evaluated PARPi was olaparib 300 mg twice daily (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>). In the other two, niraparib 300 mg (once a day for 28 days) (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>), and veliparib (<a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>) were given at a dose of 150 mg twice a day during the chemotherapy phase. The amount of veliparib was increased to 300 mg (twice a day) for two weeks during a transition phase and then subsequently raised to 400 mg if there were no concerning side effects during the transition phase. </p> </section> <section id="CD007929-sec-0048"> <h6 class="title">Outcomes</h6> <p>The overall survival data were reported as immature in all studies included in this comparison; however, despite data immaturity, authors of <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> and <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> studies reported the effect estimates for the evaluated comparisons. Progression‐free survival (PFS) was a primary outcome in all four studies; however, assessed by a blinded independent review only in one (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>). Overall, the survival data were immature in all studies. The objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 was reported only in the <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> study. The quality of life in the included studies was captured using various tools: the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ‐C30 (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>), the Trial Outcome Index (TOI) score on the Functional Assessment of Cancer Therapy–Ovarian Cancer (FACT‐O) questionnaire (<a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>); the European Quality of Life five‐dimension, five‐level questionnaire (EQ‐5D‐5L) (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>), the Functional Assessment of Cancer Therapy–Ovarian Symptom Index (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>), and the EORTC Quality of Life Questionnaire Ovarian Cancer module (EORTC‐QLQ‐OV28) (<a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>)(<a href="#CD007929-tbl-0008">Table 2</a>). Adverse events were reported as graded by the National Cancer Institute Common Toxicity Criteria (NCI‐CTC) versions 4.0 (<a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>) and 4.03 (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>).  </p> <div class="table" id="CD007929-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health related Quality of Life (HRQoL) measures in the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary HRQoL measures </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="bottom"> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimated between‐group difference was 1.56 points (95% CI, −0.42 to 3.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FOSI, EQ‐5D‐5L, EORTC‐QLQ‐C30, and EORTC‐QLQ‐ OV28.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"analysis of the EORTC‐QLQ‐C30 and EORTC‐QLQ‐OV28 did not indicate a difference in health‐related quality of life scores of patients treated with niraparib vs. placebo" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐O TOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>At baseline, ~20% of patients in both groups reported being somewhat to very much bothered by post‐ chemotherapy side‐effects.  </p> <p>5 weeks after end of chemotherapy, 30% of olaparib patients vs. 11% of placebo patients were still bothered by side‐ effects of maintenance treatment. </p> <p>"Approximately 10% more patients on olaparib than on placebo reported that they were somewhat or quite a bit bothered by side‐effects, predominantly within the first 12 weeks of treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NFOSI‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>"Mean change from baseline in the NFOSI‐18 Disease Related Symptom scores increased over time (indicating improvement), particularly after chemotherapy was completed (cycle 7 and beyond). The differences in the mean change from baseline in scores between treatment groups were small (range, 0.0 to 2.1) and were not considered to be clinically significant." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="bottom"> <p><b>Relapsed/recurrent EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQ‐5D‐5L; *QA‐PFS; *Q‐TWiST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>QA‐PFS months mean difference 6.28 (95% CI 4.85 to 7.47) in favour of PARPi and was 2.1‐fold longer in the PARPi group than in the placebo group in the ITT population (mean months 12.02 vs. 5.74). </p> <p>Q‐TWIST ‐ months mean difference in &gt;= G3+ SevAE 6.88 (95% CI 5.71 to 8.24) in favour of PARPi (mean months 13.32 vs. 6.44). </p> <p>Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FOSI; EQ‐5D‐5L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>baseline mean FOSI values:</p> <p>g<i>BRCA</i>mut cohort = 25∙1 [SD 4∙18] in PARPi group and 25∙6 [3∙84] in placebo group); </p> <p>non‐g<i>BRCA</i>mut cohort = 25∙4 [3∙92] in PARPi group and 25∙0 [4∙07] in placebo group).  </p> <p>Overall QOL scores remained stable during the treatment and pre‐progression period; no significant differences were observed between the PARPi and placebo group. </p> <p>pre‐progression EQ‐5D‐5L scores were similar between the two groups in both cohorts:</p> <p>g<i>BRCA</i>mut cohort = 0·838 [0·0097] in tPARPI group vs. 0·834 [0·0173] in placebo group; </p> <p>non‐gBRCAmut cohort = 0·833 [0·0077] in PARPi group vs 0·815 [0·0122] in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOI FACT‐O (v2016); *Q‐TWiST; *QA‐PFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant detrimental effect HRQOL analysed by change from baseline in TOI score (–3.1 vs –2.9, respectively, difference (PARPi  minus placebo) –0.2; 95% CI –2.4 to 2.1; P=0.88).  </p> <p>Adjusted average mean change from baseline over the first 12 months in TOI was ‐2·90 (95% CI ‐4·13 to ‐1·67) with PARPi and ‐2·87 (‐4·64 to ‐1·10) with placebo (estimated difference ‐0·03; 95% CI ‐2·19 to 2·13; P = 0·98); </p> <p>Q‐TWiST and QA‐PFS improvement for patients on maintenance PARPi (due in part to prolonged PFS and delay in symptoms due to disease): </p> <p>Q‐TWiST (13.5 vs. 7.2 months, difference 6.3; 95% CI 2.9 to 8.6; P&lt;0.001):</p> <p>QA‐PFS (mean 14.0 vs. 7.3 months for PARPi and placebo, respectively, difference 6.7 months; 95% CI 5.0 to  8.5; P&lt;0.0001). Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOI FACT‐O questionnaire Version 4; *Q‐TWiST; *QA‐PFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Mean TOI scores at baseline were 73.2 in PARPi  group and 71.8 in chemotherapy group. </p> <p>Overall least‐squares mean change from baseline in TOI score was 22.3 with PARPi (n = 167) vs. 24.8 with chemotherapy (n = 62), with a between‐group difference of 2.5 (95% CI, 20.5 to 5.5; P = 0.108). Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>EQ‐5D‐5L:</b> European QOL five‐dimension five‐level questionnaire; <b>FACT‐O</b> Functional Assessment of Cancer Therapy‐Ovarian Trial Outcome Index (TOI); <b>FOSI:</b> Functional Assessment of Cancer Therapy–Ovarian Symptoms Index;<b>g<i>BRCA</i>mut:</b> germline breast cancer susceptibility gene (<i>BRCA</i>) mutation; <b>NFOSI‐18:</b> National Comprehensive Cancer Net‐ work Functional Assessment of Cancer Therapy Ovarian Symptom Index–18;  <b>non–g<i>BRCA</i>mut:</b> no germline breast cancer susceptibility gene (<i>BRCA</i>) mutation; <b>PARPi:</b> poly ADP ribose polymerase inhibitor; <b>QA‐PFS:</b> quality‐adjusted progression‐free survival; <b>Q‐TWiST:</b> Quality‐adjusted time without symptoms or toxicity; <b>TOI:</b> Trial outcome index. </p> <p>*QA‐PFS and Q‐TWiST were post hoc analyses.</p> </div> </div> </section> </section> <section id="CD007929-sec-0049"> <h5 class="title">Recurrent, platinum‐sensitive EOC</h5> <p>Three studies compared PARPis with chemotherapy to treat recurrent EOC(<a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>; <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>; <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>). All trials were international, multicentre trials. <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> and <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>  were industry‐funded, and <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> was funded from public resources by the National Cancer Institute. In four studies PARP inhibitor was compared with placebo in the maintenance phase after chemotherapy (<a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>; <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>; <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>; <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>). All of these trials were industry‐funded, international, and multicentre. Three further studies evaluated the effect of PARPi alongside chemotherapy; in two the comparison was made with chemotherapy alone ( <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>), in one with PARPi monotherapy (<a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>). The <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> study was government‐funded, <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> study was industry‐funded, and the <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> study received mixed funding from a non‐profit organisation and a pharmaceutical company. In <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>, participants were recruited only in North America (the USA and Canada); <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> study was an international, multicentre trial; and the <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> study recruited participants in the USA and Scandinavian countries.  </p> <section id="CD007929-sec-0050"> <h6 class="title">Participants</h6> <p>All studies included participants with recurrent, platinum‐sensitive EOC. In <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> and <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> studies included participants who had <i>BRCA</i> mutation and measurable disease according to RECIST. Additionally, approximately 50% of the participants in <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> had relapsed within six months of platinum‐based chemotherapy (platinum‐resistant disease). <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> study enrolled participants with (23.7%) and without <i>BRCA</i> mutation. The proportion of participants with HRD mutation was not declared in all three studies. The age of participants was comparable in <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> and <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> and unknown in <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>. In <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, 40% had the measurable disease by RECIST and around 22% had a <i>BRCA</i> mutation. <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> study included two populations with (203 participants) and without (350 participants) a g<i>BRCA</i> m. The proportion of participants with <i>BRCA</i> mutation in <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> and <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> studies was comparable (37% and 35%, respectively). In <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>, around 37% of participants had a measurable disease (as assessed by the investigator). All participants in the <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> study had a g<i>BRCA</i>m. In <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> and <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> studies majority of participants had a measurable disease according to RECIST criteria version 1.1. The proportion of women with BRCA mutation in <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> and <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> studies was around 40%. In <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> study, approximately 15% of the randomised participants had a <i>BRCA</i> mutation. The proportion of participants with HRD mutation was only reported in the <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> study (60%). The median age of participants in <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> and <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> studies was around 60. In the <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> study, the median age of the participants was 66 years of age. </p> </section> <section id="CD007929-sec-0051"> <h6 class="title">Interventions</h6> <p><a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> has a three‐arm design with both experimental arms containing PARPi (olaparib ) in different dosages. In one arm, the dose was 200 mg, and in another, 400 mg was administered twice a day. The participants in the control arm received chemotherapy (50 mg/m2 of pegylated liposomal doxorubicin). <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> was another three‐arm study in this comparison. One experimental arm received a PARP inhibitor (olaparib) 300 mg twice a day. In the other, a PARP inhibitor (olaparib 200 mg twice a day) was given in combination with cediranib maleate (30 mg daily). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. The control arm received standard of care, i.e. one of three types of chemotherapy: intravenous paclitaxel and carboplatin; intravenous carboplatin with gemcitabine hydrochloride; or intravenous carboplatin with liposomal doxorubicin hydrochloride. In <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, PARP inhibitor was compared with non‐platinum based chemotherapy. The evaluated PARP inhibitor was olaparib in a dose of 300 mg twice a day. The chemotherapy in the control arm was tailored to individual single‐agent chemotherapeutic (pegylated liposomal doxorubicin 50 mg/m2; paclitaxel 80 mg/m2; gemcitabine 1000 mg/m2; or topotecan 4 mg/m2). Out of four studies evaluating PARPi as maintenance therapy, two evaluated olaparib (300 mg twice a day)(<a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>), and two single studies rucaparib (600 mg twice a day) (<a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>) and niraparib (300 mg daily)(<a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>). In <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> study, PARPi combined with platinum‐based chemotherapy followed by PARPi in the maintenance phase was compared with chemotherapy alone (no treatment in the maintenance phase). The experimental arm contained olaparib (200 mg twice a day) combined with chemotherapy (intravenous paclitaxel 175 mg/m<sup>2</sup> with intravenous carboplatin the area under the curve 4 mg/mL per minute according to the Calvert formula). In the maintenance phase, olaparib was continued in a dose of 400 mg twice a day. The chemotherapy in the control arm comprised paclitaxel (175 mg/m<sup>2</sup>) and carboplatin (area under the curve 6 mg/mL per minute). In <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> study, the effect of PARPi (veliparib 60 mg once a day in a 21‐day cycle) in combination with chemotherapy (cyclophosphamide 50 mg once a day) was compared with chemotherapy alone. The <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> study is a proof‐of‐concept trial that aimed to identify a more active regimen for phase 3 evaluation. One of the arms contained niraparib alone (starting dose of 300 mg three times a day) and the other in combination with intravenous bevacizumab (15 mg/kg every three weeks).  </p> </section> <section id="CD007929-sec-0052"> <h6 class="title">Outcomes</h6> <p>The overall survival data were collected and reported in five studies in this population; however, in three studies data were immature at the point of analysis (<a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>, <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>).  In <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>, the conference abstract contains a statement of no difference in overall survival (OS), but without further details. The outcome was not collected in <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> and not reported due to data immaturity in <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>. Progression‐free survival (PFS) was a primary outcome in all nine studies (<a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>, <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>, <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>, <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>, <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>, <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>; <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>). In <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>, <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>) and <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> it is unclear who assessed PFS (investigator or blinded, independent reviewer). In <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>, <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> and <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>, PFS was assessed by the investigator and in the <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> study by blinded central radiological and clinical review. In <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, PFS was assessed by the site investigator and by a blinded independent central review, and in <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> by a blinded independent review. The objective response rate (ORR) assessed according to the RECIST was reported in seven studies (<a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>, <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>, <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>, <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>). The quality of life in the <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> study was evaluated using various tools: Best Quality of Life (QoL) Response for the Trial Outcome Index, Best QoL Response for Total FACT‐O, Best QoL Response for FOSI. In <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, it was assessed using the TOI score on the FACT‐O questionnaire. In the <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> study, the quality of life was evaluated using EQ‐5D‐5L and FOSI with the results of the latter one being reported in insufficient detail. Only the quality of life reported in <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> and <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> could have been incorporated in this review (<a href="#CD007929-tbl-0008">Table 2</a>). Adverse events reported in <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> (NCI‐CTC version 4.0), <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>(NCI‐CTC version 3.0), <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> (NCI‐CTC version 4.0), <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> and (<a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> studies (version 4.02) could be used in the quantitative analysis. The version of the grading system in <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> study was not reported.   </p> </section> </section> <section id="CD007929-sec-0053"> <h5 class="title">Recurrent, platinum‐resistant EOC</h5> <p>A single study (<a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a>) evaluated the effect of PARPi with chemotherapy as a treatment for recurrent platinum‐resistant EOC. <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> is an industry‐funded, single country, multicentre trial. Additionally, around half of the participants in the <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> were platinum‐resistant. However, we decided not to include the <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> study in this comparison. </p> <section id="CD007929-sec-0054"> <h6 class="title">Participants</h6> <p><a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> study included women with recurrent, platinum‐resistant advanced (International Federation of Gynecology and Obstetrics stage 3 or 4) EOC Information about participants’ characteristics is limited as the study is available only as a conference abstract. </p> </section> <section id="CD007929-sec-0055"> <h6 class="title">Interventions</h6> <p> <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> study evaluated the effect of PARPi in comparison to chemotherapy ‐ olaparib 300 mg twice a day for 28 days in 28‐day cycles versus individually‐tailored chemotherapy (carboplatin with gemcitabine, or carboplatin with paclitaxel, or carboplatin with liposomal doxorubicin, or liposomal doxorubicin 4‐weekly, or topotecan, or weekly paclitaxel). </p> </section> <section id="CD007929-sec-0056"> <h6 class="title">Outcomes</h6> <p>Neither overall survival (OS) nor progression‐free survival (PFS) were reported in <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a>. The main trial outcome was the objective response rate (ORR). It is unclear who was assessing ORR and what criteria were used (investigator or blinded, independent reviewer). Quality of life was also not reported in this trial. Adverse events were graded using the National Cancer Institute Common Toxicity Criteria version 4.03.  </p> </section> </section> </section> <section id="CD007929-sec-0057"> <h4 class="title">Excluded studies</h4> <p>After removal of 27 review articles, further duplicates and commentaries, we excluded 48 references after obtaining the full text,  for the following reasons: </p> <p> <ul id="CD007929-list-0020"> <li> <p>wrong study design (27);</p> </li> <li> <p>irrelevant intervention (3);</p> </li> <li> <p>irrelevant comparison (8);</p> </li> <li> <p>systematic review/meta‐analysis (12)</p> </li> </ul> </p> <p>For details of these 47 excluded studies see Characteristics of excluded studies.</p> </section> </section> <section id="CD007929-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Information on potential sources of risk of bias in two unpublished trials (<a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a>; <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>) was limited, resulting in a judgement ‘unclear’ for most of the assessed domains except blinding (performance bias and detection bias). For assessment of the risk of bias items for individual studies see <a href="#CD007929-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007929-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007929-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007929-sec-0059"> <h4 class="title">Allocation</h4> <p>The majority of included studies were randomisation list was computer‐generated and provided by a third party by a web‐based or voice response system. The method of randomisation was insufficiently described in two studies (<a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>). and for <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>, the allocation method was also unclear. </p> </section> <section id="CD007929-sec-0060"> <h4 class="title">Blinding</h4> <p>In seven included studies (<a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>; <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a>; <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>; <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>; <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>), interventions were not concealed (open‐label design); thus, the participants and personnel were aware of the group allocation. The primary outcome in the studies was often progression‐free survival (PFS) (12/15 studies) assessed by an investigator (<a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>, <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>, <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>, <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>, <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>, <a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>) or by a blinded independent reviewer (<a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>). In <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>, the primary outcome was assessed by the investigator and blinded independent reviewer. In <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> and <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> it was not clear who assessed progression‐free survival. The primary outcome in the remaining three studies (<a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>, <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>, <a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a>) was the objective response rate which was clearly described as assessed by a blinded independent reviewer only in <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>. </p> </section> <section id="CD007929-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition was not considered an issue in most studies except <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> where there was insufficient information to judge this domain. </p> </section> <section id="CD007929-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Selective reporting of outcomes was not considered an issue in most studies except <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> where there was insufficient information to judge this domain. </p> </section> <section id="CD007929-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> was judged as at high risk of bias in this domain due to concern over lack of clarity over reasons for earlier termination of the trial. The majority of included studies were industry‐sponsored trials with several authors disclosing a financial conflict of interest hence judged as unclear risk of bias in this domain.  </p> </section> </section> <section id="CD007929-sec-0064"> <h3 class="title" id="CD007929-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD007929-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</a>; <a href="./full#CD007929-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</a>; <a href="./full#CD007929-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</a>; <a href="./full#CD007929-tbl-0004"><b>Summary of findings 4</b> Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</a>; <a href="./full#CD007929-tbl-0005"><b>Summary of findings 5</b> Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</a>; <a href="./full#CD007929-tbl-0006"><b>Summary of findings 6</b> Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</a> </p> <p>The effects of interventions are described in a number of comparisons since there are a number of clinical scenarios where it may be appropriate to use poly (ADP‐ribose) polymerase) inhibitors (PARPi), each of which is a separate clinical question. This review, therefore, represents an umbrella review of different theoretical clinical scenarios. The summary of findings tables are presented for the most clinically relevant comparisons. </p> <section id="CD007929-sec-0065"> <h4 class="title">Newly‐diagnosed epithelial ovarian cancer (EOC)</h4> <p>Four included studies evaluated the effect of PARPi in newly‐diagnosed EOC (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>; <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>). We graded certainty of the evidence of the two most clinically relevant comparisons (see <a href="./full#CD007929-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD007929-tbl-0002">summary of findings Table 2</a>). As bevacizumab is increasingly part of standard care, we classified comparison <a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> trial as chemotherapy with PARPi compared to PARPi. The median OS and PFS times are available in <a href="#CD007929-tbl-0009">Table 3</a> and <a href="#CD007929-tbl-0010">Table 4</a>, respectively. </p> <div class="table" id="CD007929-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Median Overall Survival time (months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PARP inhibitor</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total (N)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total (N)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Medians not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Recurrent, platinum‐sensitive EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.8 (26.9, 38.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6 (27.8, 44.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a><b> </b>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached<br/>(26.9, not reached) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.2<br/>(31.5, not reached) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (29.9, not reached)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (24.2, not reached)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo after chemotherapy (maintenance therapy)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.7 (NR)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.9 (NR)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Recurrent, platinum‐resistant EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Medians not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>EOC:</b> epithelial ovarian cancer; <b>OLA:</b> olaparib; <b>NR:</b> not reported </p> <p>(1) a subgroup with BRCA mutation;</p> </div> </div> <div class="table" id="CD007929-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Median Progression‐Free Survival time (months)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PARP inhibitor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo (maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.5 (19.3 to 26.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3 (15.1 to 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy only</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2 (14.1 to 17.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3 (15.1 to 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants with <i>BRCA</i> mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 1*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (11.1, 18.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.7 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7<br/>(31.8, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0 (17.8, 29.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.1 (17.0, 25.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0 (17.8, 29.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.7 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(2) PARP inhibitor monotherapy compared with chemotherapy in recurrent EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 3<b>* </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4 (10.9, 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.6, 11.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with CED versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICEBERG 3 (Kaye 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA 200 mg) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5 (5.5, 10.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (3.7, 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICEBERG 3 (Kaye 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA 400 mg) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8 (5.4, 9.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(3) PARP inhibitor compared with placebo after chemotherapy in recurrent EOC(maintenance therapy)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.7 (11.0, 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (5.1, 5.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study 19 (Ledermann 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 2<b>^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1 (16.3, 25.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.2, 5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy </p> <p>followed by PARP inhibitor as maintenance </p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (9.7, 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6 (9.1, 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with BRCA mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 3<b>* </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4 (10.9, 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.6, 11.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with CED versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.8<br/>(19.2, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (4.9, 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.3 (16.5, 27.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.0, 5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached <br/>(9.6, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.3, 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9<br/>(16.2, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.1, 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(4) PARP inhibitor in recurrent ovarian cancer (various comparisons)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy </p> <p>followed by PARP inhibitor as maintenance </p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (9.7, 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6 (9.1, 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV </p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9 (8.5, 16.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (3.8, 6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with BRCA mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached <br/>(9.6, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.3, 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV</p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4 (6.2, 22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (3.9, 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV</p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9 (8.5, 22.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (3.9, 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(5) PARP inhibitor compared with chemotherapy in recurrent platinum‐resistant ovarian cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BEV:</b> bevacizumab; <b>CED:</b> cediranib; <b>NIR:,</b> niraparib; <b>NR:</b> not reported; <b>OLA:</b> olaparib; <b>PARP: </b> poly adenosine diphosphate‐ribose polymerase; <b>PLB:</b> placebo;<b>RUC:</b>  rucaparib;<b>VEL:</b> veliparib. </p> <p>*studies that recruited only participants with BRCA mutation;<br/>^97% of participants in the SOLO2 study had a BRCA mutation. </p> </div> </div> <section id="CD007929-sec-0066"> <h5 class="title">1. PARPi with chemotherapy compared with chemotherapy alone </h5> <p>See <a href="./full#CD007929-tbl-0001">summary of findings Table 1</a>. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>OS data were not reported.</p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi with chemotherapy compared with chemotherapy alone may have little or no effect on  PFS (two studies, 1564 participants; hazard ratio (HR) 0.82, 95%confidence interval (CI) 0.49 to 1.38; <i>very low‐certainty evidence;</i> <a href="./references#CD007929-fig-0003" title="">Analysis 1.1</a>). Analysis restricted only to data from <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> trial (chemotherapy without bevacizumab) showed no change in conclusion regarding the effect of PARPi (one study, 758 participants; HR 1.07, 95%CI 0.90 to 1.28). We did not observe a statistically significant difference in the effect according to BRCA (Chi<sup>2</sup> = 0.22, P = 0.64; <a href="./references#CD007929-fig-0004" title="">Analysis 1.2</a>) or homologous recombination deficiencies (HRD) status (Chi<sup>2</sup> = 0.73, P = 0.39; <a href="./references#CD007929-fig-0005" title="">Analysis 1.3</a>). </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>There may be little to no difference in ORR (rate of no evidence of response (i.e. no demonstrable complete response/partial response (CR/PR))) between PARPi with chemotherapy (one study, 192 participants; risk ratio (RR) 0.82, 95%CI 0.49 to 1.37; <a href="./references#CD007929-fig-0006" title="">Analysis 1.4</a>) and chemotherapy alone.  </p> <p><b>Quality of life (QoL)</b> </p> <p>PARPi combined with chemotherapy compared with chemotherapy alone was likely to result in little to no difference in the QoL measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire QLQ‐C30 (one study; 744 participants, mean difference (MD) 1.56 95% CI ‐0.42 to 3.54]<i>; moderate‐certainty evidence; </i><a href="./references#CD007929-fig-0007" title="">Analysis 1.5</a>)<i>.</i> The findings were described as not clinically meaningful.  </p> <p><b>Adverse events</b> </p> <p>There was probably an increased risk of experiencing any severe adverse event (grade 3 or higher) with a combination of PARPi and chemotherapy compared with chemotherapy alone (two studies, 1549 participants, RR 1.13, 95% CI 1.07 to 1.20; <i>high‐certainty evidence;</i> <a href="./references#CD007929-fig-0008" title="">Analysis 1.6</a>). Analysis restricted only to data from <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> trial (chemotherapy without bevacizumab) showed no change in conclusion regarding the effect of PARPi (one study, 747 participants; HR 1.14, 95%CI 1.06 to 1.22).  </p> </section> <section id="CD007929-sec-0067"> <h5 class="title">2. PARPi with chemotherapy and as maintenance therapy compared to chemotherapy alone</h5> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>OS data were not reported.</p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi with chemotherapy followed by PARPi monotherapy as a maintenance therapy resulted in a longer PFS compared to chemotherapy alone (one study, 757 participants; HR 0.68, 95%CI 0.56 to 0.83; <a href="./references#CD007929-fig-0009" title="">Analysis 2.1</a>). We did not observe a statistically significant difference in the effect of PARPi throughout according to <i>BRCA</i> (Chi<sup>2</sup> = 5.57, P = 0.02; <a href="./references#CD007929-fig-0010" title="">Analysis 2.2</a>) but not HRD status (Chi<sup>2</sup> = 2.79, P = 0.10; <a href="./references#CD007929-fig-0011" title="">Analysis 2.3</a>). </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>There may be little to no difference in ORR (rate of no evidence of response (i.e. no demonstrable CR/PR)) between PARPi with chemotherapy and as maintenance therapy (one study, 191 participants; RR 0.63, 95%CI 0.36 to 1.11; <a href="./references#CD007929-fig-0012" title="">Analysis 2.4</a>) compared with chemotherapy alone.  </p> <p><b>Quality of life (QoL)</b> </p> <p>PARPi monotherapy probably results in little to no clinically meaningful difference in the QoL measured using the Functional Assessment of Cancer Therapy Ovarian Symptom Index–18 (one study; 362 participants; MD‐3.00, 95% CI ‐4.48 to ‐1.52; <i>moderate‐certainty evidence; </i><a href="./references#CD007929-fig-0019" title="">Analysis 3.6</a>).<b> </b> </p> <p><b>Adverse events</b> </p> <p>There was probably an increased risk of experiencing any severe adverse event (grade 3 or higher) for the combination of PARPi with chemotherapy and as maintenance therapy (one study, 748 participants, RR 1.15, 95% CI 1.07 to 1.23; <a href="./references#CD007929-fig-0013" title="">Analysis 2.5</a>) compared with chemotherapy alone.   </p> </section> <section id="CD007929-sec-0068"> <h5 class="title">3. PARPi monotherapy compared with placebo (maintenance therapy) </h5> <p>See <a href="./full#CD007929-tbl-0002">summary of findings Table 2</a>. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>PARPi monotherapy as maintenance therapy after chemotherapy probably resulted in little to no difference in OS compared with placebo (two studies, 1124 participants; HR 0.81, 95%CI 0.59 to 1.13; <i>moderate‐certainty evidence;</i> <a href="./references#CD007929-fig-0014" title="">Analysis 3.1</a>).  We did not observe a statistically significant difference in the effect of PARPi monotherapy according to HRD status (Chi<sup>2</sup> = 0.11, P = 0.74; <a href="./references#CD007929-fig-0015" title="">Analysis 3.2</a>). </p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi monotherapy used in the maintenance therapy compared with placebo may improve PFS, irrespective of PARPi type (two studies, 1123 participants; HR 0.42, 95% CI 0.19 to 0.92); <i>low‐certainty evidence; </i><a href="./references#CD007929-fig-0016" title="">Analysis 3.3</a>). We noted some evidence for a subgroup difference in the effect of PARPi monotherapy according to HRD status (Chi<sup>2</sup> = 3.85, P = 0.05; <a href="./references#CD007929-fig-0018" title="">Analysis 3.5</a>), but none according to BRCA status (Chi<sup>2</sup> =1.90, P = 0.17; <a href="./references#CD007929-fig-0017" title="">Analysis 3.4</a>). </p> <p><b>Quality of life (QoL)</b> </p> <p>PARPi monotherapy used in the maintenance therapy compared with placebo probably results in a slight reduction in the QoL measured using the Trial Outcome Index (TOI) score (FACT‐O questionnaire)(one study, 362 participants; MD ‐3.00, 95%CI ‐4.48 to ‐1.52; <i>moderate‐certainty evidence, </i><a href="./references#CD007929-fig-0019" title="">Analysis 3.6</a><i>).</i> The differences were described as not clinically meaningful.  </p> <p><b>Adverse events</b> </p> <p>PARPi monotherapy may increase/have little to no effect on the risk of experiencing any severe adverse event (grade 3 or higher) compared with placebo (two studies, 1118 participants, RR 2.87, 95% CI 1.65 to 4.99; <i>very low‐certainty evidence; </i><a href="./references#CD007929-fig-0020" title="">Analysis 3.7</a>) but the evidence is very uncertain. </p> </section> </section> <section id="CD007929-sec-0069"> <h4 class="title">Recurrent, platinum‐sensitive epithelial ovarian cancer (EOC)</h4> <p>Ten studies evaluated the effect of PARPi in recurrent, platinum‐sensitive EOC (<a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>; <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a>; <a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a>; <a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a>; <a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a>; <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>; <a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a>; <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>; <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>; <a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a>). Out of five comparisons reported in these studies, we report four and graded certainty of the evidence of the three most clinically relevant comparisons (see <a href="./full#CD007929-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD007929-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD007929-tbl-0005">summary of findings Table 5</a>). As the <a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> is a proof‐of‐concept trial having a comparison not relevant to current clinical practice (PARPi with bevacizumab compared with the PARPi alone) we decided not to present its results.  </p> <section id="CD007929-sec-0070"> <h5 class="title">4. PARPi monotherapy compared with chemotherapy alone</h5> <p>The summary of evidence can be seen in the <a href="./full#CD007929-tbl-0003">summary of findings Table 3</a>. The median OS and PFS are available in <a href="#CD007929-tbl-0009">Table 3</a> and <a href="#CD007929-tbl-0010">Table 4</a>, respectively. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>PARPi monotherapy compared with chemotherapy probably resulted in little to no difference in OS (two studies, 331 participants; HR 0.95, 95%CI 0.62 to 1.47; <i>low‐certainty evidence, </i><a href="./references#CD007929-fig-0021" title="">Analysis 4.1</a>) regardless of inhibitor's dose. The evidence comes from the studies involving only participants with <i>BRCA</i> mutation.  </p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi compared with chemotherapy may result in little or no difference in PFS (three studies, 739 participants; HR 0.88, 95%CI 0.56 to 1.38; <i>very low‐certainty evidence,</i> <a href="./references#CD007929-fig-0022" title="">Analysis 4.2</a>), but the evidence is very uncertain.  We did not observe a statistically significant difference in the effect of PARPi monotherapy according to BRCA status (Chi<sup>2</sup> = 0.69, P = 0.41; <a href="./references#CD007929-fig-0023" title="">Analysis 4.3</a>). </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>PARPi compared with chemotherapy may result in little or no reduction in ORR (three studies, 696 participants; RR 0.97, 95%CI 0.56 to 1.67; <a href="./references#CD007929-fig-0024" title="">Analysis 4.4</a>) but the evidence is very uncertain.  </p> <p><b>Quality of life (QoL)</b> </p> <p>PARPi compared with chemotherapy may result in little or no change in the QoL measured using the TOI score (FACT‐O questionnaire) (one study, 229 participants, MD 1.20, 95%CI ‐1.75 to 4.16; <i>low‐certainty evidence,</i> <a href="./references#CD007929-fig-0025" title="">Analysis 4.5</a>).  </p> <p><b>Adverse events</b> </p> <p>PARPi compared with chemotherapy may result in little or no difference in the rate of any severe adverse event (grade 3 or higher) (one study, 254 participants; RR 1.06, 95%CI 0.80 to 1.39; <i>low‐certainty evidence,</i> <a href="./references#CD007929-fig-0026" title="">Analysis 4.6</a>). </p> </section> <section id="CD007929-sec-0071"> <h5 class="title">5. PARPi compared with placebo after chemotherapy (maintenance therapy)</h5> <p>For a summary of evidence for this comparison see <a href="./full#CD007929-tbl-0004">summary of findings Table 4</a>. The median OS and PFS are available in <a href="#CD007929-tbl-0009">Table 3</a> and <a href="#CD007929-tbl-0010">Table 4</a>, respectively. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>There was little to no difference in OS between PARPi and placebo (two studies, 560 participants; HR 0.88, 95% CI 0.65 to 1.20; <i>moderate‐certainty evidence</i>, <a href="./references#CD007929-fig-0027" title="">Analysis 5.1</a>).  </p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi resulted in a large increase in  PFS compared to placebo (four studies, 1677 participants; HR 0.34, 95% CI 0.28 to 0.42; <i>high‐certainty evidence,</i> <a href="./references#CD007929-fig-0028" title="">Analysis 5.2</a>). We observed a statistically significant difference in the effect of PARPi according to <i>BRCA</i> (Chi<sup>2</sup> = 9.82, P = 0.02; <a href="./references#CD007929-fig-0029" title="">Analysis 5.3</a>), but not HRD status (Chi<sup>2</sup> = 3.21, P = 0.07; <a href="./references#CD007929-fig-0030" title="">Analysis 5.4</a> ). </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>PARPi, in comparison to the placebo, probably resulted in an improvement in ORR (two studies, 312 participants; RR 0.90, 95%CI 0.83 to 0.97; <a href="./references#CD007929-fig-0031" title="">Analysis 5.5</a>).  </p> <p><b>Quality of life (QoL)</b> </p> <p>PARPi monotherapy used in the maintenance therapy compared with placebo may result in little to no difference in the QoL measured using the European Quality of Life 5‐dimensions questionnaire Health Utility Index score (first post‐progression measure) (one study, 339 participants, MD 0.02, 95%CI ‐0.01 to 0.05;moderate‐certainty evidence; <a href="./references#CD007929-fig-0032" title="">Analysis 5.6</a>). We did not observe a statistically significant difference in the effect according to BRCA status (Chi<sup>2</sup> = 0.38, P = 0.54; <a href="./references#CD007929-fig-0032" title="">Analysis 5.6</a>). </p> <p>PARPi monotherapy used in the maintenance therapy compared with placebo may result in little to no difference in the QoL measured using the TOI score (FACT‐O questionnaire)(one study, 279 participants, MD‐0.03, 95% CI ‐2.16 to 2.10; <a href="./references#CD007929-fig-0033" title="">Analysis 5.7</a>). </p> <p><b><i>Quality adjusted PFS and Time Without Symptoms of treatment toxicity</i> </b> <br/><br/>The aim of Quality‐Adjusted PFS (QA‐PFS) and Time Without Symptoms of treatment Toxicity (TWiST) is to assess a combination of treatment‐emergent symptoms and disease progression. PARPi monotherapy used in the maintenance therapy compared with placebo showed an improved value of QA‐PFS (two studies, 858 participants, MD 6.41, 95% CI 5.37 to 7.44; <a href="./references#CD007929-fig-0034" title="">Analysis 5.8</a>) and TWiST (two studies, 858 participants, MD 6.52, 95% CI 5.69 to 7.35; <a href="./references#CD007929-fig-0036" title="">Analysis 5.10</a>). For both outcomes, we observed a statistically significant difference in the effect of PARPi according to <i>BRCA</i> status (<a href="./references#CD007929-fig-0035" title="">Analysis 5.9</a>; <a href="./references#CD007929-fig-0037" title="">Analysis 5.11</a>). These were post hoc analyses in both studies contributing to these analyses (see <a href="#CD007929-tbl-0008">Table 2</a>); however, both measures appear to be increasingly used in the context of studies evaluating maintenance treatments. </p> <p><b>Adverse events</b> </p> <p>There may be a large increased risk of experiencing any severe adverse event (grade 3 or higher) with a PARPi compared to placebo (four studies, 1665 participants, RR 2.62, 95%CI 1.85 to 3.72; <i>low‐certainty evidence, </i><a href="./references#CD007929-fig-0038" title="">Analysis 5.12</a>).  </p> </section> <section id="CD007929-sec-0072"> <h5 class="title">6. PARPi with chemotherapy compared with chemotherapy alone</h5> <p>For a summary of evidence for this comparison see  <a href="./full#CD007929-tbl-0005">summary of findings Table 5</a>. The median PFS times are available in <a href="#CD007929-tbl-0010">Table 4</a>. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>OS data were not reported.</p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi with chemotherapy compared with chemotherapy alone may have little or no effect on PFS (one study, 75 participants; HR 1.02, 95%CI 0.69 to 1.51; <i>very low‐certainty evidence</i>, <a href="./references#CD007929-fig-0039" title="">Analysis 6.1</a>), but the evidence is very uncertain.  </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>The combination of PARPi with chemotherapy, compared to chemotherapy alone, may have little to no effect on ORR (one study, 70 participants; RR 1.10, 95%CI 0.89 to 1.34; <a href="./references#CD007929-fig-0040" title="">Analysis 6.2</a>), but the evidence is very uncertain. </p> <p><b>Quality of life (QoL)</b> </p> <p>No QoL data available. </p> <p><b>Adverse events</b> </p> <p>There may be little to no difference in any severe adverse events (grade 3 or higher) with a combination of PARPi and chemotherapy compared to chemotherapy alone (one study, 156 participants; RR 1.14, 95%CI 0.89 to 1.47; <a href="./references#CD007929-fig-0041" title="">Analysis 6.3</a>). </p> </section> <section id="CD007929-sec-0073"> <h5 class="title">7. PARPi with chemotherapy followed by PARPi as maintenance compared with chemotherapy alone </h5> <p>The median OS times are reported in <a href="#CD007929-tbl-0009">Table 3</a>.  </p> <p><b><i>Survival outcomes</i> </b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>PARPi with chemotherapy followed by PARPi as maintenance may result in little to no difference in OS compared to chemotherapy alone (one study, 162 participants; HR 1.17, 95%CI 0.79 to 1.74; <a href="./references#CD007929-fig-0042" title="">Analysis 7.1</a>).  </p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PARPi combined with chemotherapy followed by PARPi as maintenance therapy probably resulted in a  longer PFS compared to chemotherapy alone (one study, 162 participants; HR 0.51, 95%CI 0.34 to 0.77; <a href="./references#CD007929-fig-0043" title="">Analysis 7.2</a>).  We observed a statistically significant difference in the effect of PARPi according to <i>BRCA</i> status (Chi<sup>2</sup> = 4.90, P = 0.03; <a href="./references#CD007929-fig-0044" title="">Analysis 7.3</a>). </p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>PARPi combined with chemotherapy followed by PARPi as maintenance therapy compared with chemotherapy alone may result in little to no difference in ORR (one study, 162 participants; RR 0.85, 95%CI 0.58 to 1.26; <a href="./references#CD007929-fig-0045" title="">Analysis 7.4</a>). </p> <p><b>Quality of life (QoL)</b> </p> <p>No QoL data available. </p> <p><b>Adverse events</b> </p> <p>There may be an increased risk of experiencing any severe adverse events (grade 3 or higher) with PARPi continued into the maintenance phase after combined treatment with PARPi and chemotherapy compared to placebo after chemotherapy alone (one study, 111 participants; RR 2.07, 95%CI 1.03 to 4.18; <a href="./references#CD007929-fig-0046" title="">Analysis 7.5</a>). </p> </section> </section> <section id="CD007929-sec-0074"> <h4 class="title">Recurrent, platinum‐resistant epithelial ovarian cancer (EOC)</h4> <section id="CD007929-sec-0075"> <h5 class="title">8. PARPi monotherapy compared with chemotherapy </h5> <p>For the summary of evidence for this comparison see <a href="./full#CD007929-tbl-0006">summary of findings Table 6</a>. </p> <p><b>Survival outcomes</b> </p> <p><b><i>Overall survival (OS)</i> </b> </p> <p>OS data were not reported.</p> <p><b><i>Progression‐free survival (PFS)</i> </b> </p> <p>PFS data were not reported.</p> <p><b>Objective response rate (ORR) ‐ no response</b> </p> <p>PARPi monotherapy compared to chemotherapy may have little to no effect on ORR  (one study, 100 participants; RR 2.96, 95%CI 0.70 to 12.44<i>;</i> <a href="./references#CD007929-fig-0047" title="">Analysis 8.1</a>), but the evidence is very uncertain.  </p> <p><b>Quality of life (QoL)</b> </p> <p>No QoL data available. </p> <p><b>Adverse events</b> </p> <p>PARPi monotherapy compared with chemotherapy may have little to no effect on the rate of any severe adverse event (grade 3 or higher) (one study, 100 participants; RR 1.16, 95%CI 0.79 to 1.70; <i>very low‐certainty evidence,</i> <a href="./references#CD007929-fig-0048" title="">Analysis 8.2</a>), but the evidence is very uncertain.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007929-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007929-sec-0076"></div> <section id="CD007929-sec-0077"> <h3 class="title" id="CD007929-sec-0077">Summary of main results</h3> <p>In total, 6109 women with epithelial ovarian cancer (EOC) were included from 15 studies (four with primary (3070 participants) and 11 (3039 participants) with recurrent EOC). Eight of these studies were deemed at low risk of bias across most of the assessed domains. Studies included used various poly (ADP‐ribose) polymerase) inhibitors (PARPi) (olaparib n = 9; niraparib n = 3; veliparib n = 2; rucaparib n = 1). In addition, studies either used PARPi in isolation or in combination with a vascular endothelial growth factor agent (bevacizumab n=2 or cediranib n = 1).  Comparisons were performed across six clinically relevant subgroups: </p> <p> <ol id="CD007929-list-0021"> <li> <p>PARPi in newly‐diagnosed EOC versus chemotherapy alone (n = 1);</p> </li> <li> <p>PARPi monotherapy (maintenance) in advanced newly‐diagnosed EOC versus placebo (n = 2); </p> </li> <li> <p>PARPi monotherapy compared with chemotherapy in recurrent platinum‐sensitive EOC (n = 3). </p> </li> <li> <p>PARPi compared with placebo after chemotherapy in EOC (maintenance therapy) (n = 4);</p> </li> <li> <p>PARPi monotherapy in recurrent EOC versus chemotherapy alone (n = 1);</p> </li> <li> <p>PARPi monotherapy compared with chemotherapy in recurrent platinum‐resistant EOC (n = 1). </p> </li> </ol> </p> <p>In addition, one study compared PARPi and chemotherapy with chemotherapy alone. The certainty of the evidence was graded as very low.  </p> <p>Meta‐analysis of these subgroups found that the progression‐free survival (PFS) may be increased (<i>low‐certainty evidence</i> ) with the use of PARPi monotherapy when used as a maintenance treatment after first‐line chemotherapy in newly‐diagnosed EOC. This effect is more pronounced when used as maintenance therapy in recurrent platinum‐sensitive EOC (<i>high‐certainty evidence</i> ).  However, in both instances, little to no difference was seen in overall survival (OS), although these data are immature and may change with further follow‐up. The results for the subgroup of participants with <i>BRCA</i> pathogenic variants were consistent with those reported to have <i>BRCA</i> wild type, although the majority of those recruited, where stated, had either germline or somatic <i>BRCA</i> mutations or HRD, so there are relatively few without some form of HRD for comparison.  </p> <p>Regarding adverse events, the use of PARPi led to an increase in the reported number of any serious adverse events (grade 3 or higher) when used in addition to chemotherapy versus chemotherapy alone in the treatment of advanced primary chemotherapy. This was also the case when PARPi was used as maintenance therapy in either first‐line treatment or recurrent platinum‐sensitive EOC. However, there may be little to no difference (<i>low‐certainty evidence</i>) in the rate of serious adverse events seen in PARPi monotherapy compared with chemotherapy when used to treat recurrent platinum‐sensitive EOC.   </p> <p>The quality of life data were generally not well‐reported, compared to efficacy data, and heterogenous so not all available for meta‐analysis (see <a href="#CD007929-tbl-0008">Table 2</a> for details). Quality of life (QoL) outcomes in trials exploring the use of PARPi in women with newly‐diagnosed EOC is based on the secondary outcome reporting of four studies (<a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a>; <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a>; <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a>; <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>). Analyses were limited and there are no separate published reports detailing QoL outcomes. Heterogenous QoL measures were used, making data synthesis challenging. All of these studies reported no significant difference in their respective QoL measures between their PARPi arm and placebo arm. <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a>also found no difference in QoL measure in their intention‐to‐treat, BRCA or homologous recombination deficient (HRD) populations. </p> <p>The evidence base for QoL outcomes for PARPi use in the recurrence setting is more robust. Four studies reported QOL data as secondary outcomes (<a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a>; <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a>; <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>; <a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a>). Meta‐analysis was challenging due to the use of different measures and conditions between studies. Three studies have separately published comprehensive QoL data. <a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a>utilised the Quality Time Without Significant Symptoms of Toxity (Q‐TWIST) score and Quality Adjusted Progression Free Survival (QA‐PFS).  These are post‐hoc analyses, which measure time without symptoms from  a combination of treatment and disease progression, and so are affected  by PFS, as well as adverse effects from treatment. The authors concluded there were clinically meaningful patient‐centred benefits in both Q‐TWiST and QA‐PFS, despite the adverse effects associated with olaparib. <a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> have also published separate QoL data which was derived from the Functional Assessment of Cancer Therapy – Ovarian Symptoms Index (FOSI) score. Their results suggest that women who receive niraparib as maintenance treatment for recurrent ovarian cancer after responding to platinum treatment can maintain QoL during their treatment when compared with placebo. Finally, <a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> conducted and published a specific QoL analysis. The authors measured QoL outcomes with the European QoL Five‐dimension five level questionnaire (EQ‐5D‐5L) and did a post‐hoc analysis of Q‐TWiST and QA‐PFS. Their data supported the use of rucaparib; those treated with it, including those without g<i>BRCA</i> or s<i>BRCA</i>, had longer periods without clinically‐relevant symptoms. </p> </section> <section id="CD007929-sec-0078"> <h3 class="title" id="CD007929-sec-0078">Overall completeness and applicability of evidence</h3> <p>We are confident that we have captured studies assessing PARPi in ovarian cancer, having identified ongoing studies in a previous review update and compared included studies to subsequent systematic reviews. </p> <p>Evidence is most robust for olaparib, with less complete data for veliparib, niraparib and rucaparib. Data are also heavily skewed to the germline <i>BRCA</i>m populations, which makes up 16% of patients with high‐grade serous EOC (depending on population) (<a href="./references#CD007929-bbs2-0135" title="RischHA , McLaughlinJR , ColeDE , RosenB , BradleyL , KwanE , et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics2001;68(3):700-10.">Risch 2001</a>).  However, subgroup data suggest that PARPi responses are also seen in those with somatic (tumour) <i>BRCA</i>m and HRD.  Since the last update of the review (<a href="./references#CD007929-bbs2-0157" title="WiggansAJ , CassGK , BryantA , LawrieTA , MorrisonJ .Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub3] [PMID: 25991068]">Wiggans 2015</a>), tumour testing for <i>BRCA</i> m and access to germline testing for <i>BRCA</i> m in those with <i>BRCA</i>m tumours is routine in the UK. This was driven initially by pharmaceutical company testing, but supported by updated National Institute for Clinical Excellence<b>(</b>NICE) guidance, which recommends <i>BRCA</i> testing for breast cancer (<a href="./references#CD007929-bbs2-0121" title="National Institute for Clinical Excellence (NICE).Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance [CG164]. https://www.nice.org.uk/Guidance/CG1642013. [WEBPAGE: https://www.nice.org.uk/Guidance/CG164]">NICE [CG164] 2019</a>). </p> <p>In terms of applicability, patients in studies tend to be younger and fitter than the general cohort of patients with ovarian cancer. The increased risk of severe adverse events and effects on the quality of life of long‐term maintenance treatment may therefore be different in the wider population of patients with ovarian cancer. </p> <p>From the available data, it is still not clear whether PARPi only delays the onset of recurrent disease, or whether there is an OS benefit for certain subgroups of women. Overall survival endpoints are harder to obtain since they require longer for the data to mature. Furthermore, OS was a secondary outcome in many of the studies, so studies were not powered for OS effects. In addition, the effects of individual therapeutic agents can be obscured due to the effects of other treatments, especially in EOC where women often have multiple rounds (or lines) of treatment over what can be several years. We hope a more complete picture will emerge with longer‐term follow‐up data from randomised controlled trials (RCTs), but have concerns that there is an over‐emphasis on PFS outcomes (see <a href="#CD007929-sec-0082">Authors' conclusions</a> for further discussion). </p> <p>Serious adverse events, which were more common in women receiving PARPi maintenance treatment, which may have a significant impact on quality of life. We were unable to adequately evaluate the quality of life due to insufficient data and more evidence on this is needed. </p> </section> <section id="CD007929-sec-0079"> <h3 class="title" id="CD007929-sec-0079">Quality of the evidence</h3> <p>Many studies appear to be well conducted with pre‐defined outcome criteria and robust randomisation systems. Eight of the 15 studies were at low risk of bias for the majority of assessment criteria, whereas eight studies were open‐label studies and therefore at risk of bias of many outcome measures, although OS is unlikely to have been affected (<a href="#CD007929-fig-0002">Figure 2</a>). The evidence is of moderate certainty for studies looking at the affects of olaparib and estimates of effect may change with further research. There was low‐certainty evidence for veliparib, and we are very uncertain about the effects of the treatment.  </p> </section> <section id="CD007929-sec-0080"> <h3 class="title" id="CD007929-sec-0080">Potential biases in the review process</h3> <p>We are not aware of any biases in the review process. We conducted this review using standard Cochrane methodology, which aims to reduce bias through double sifting, double data extraction and transparent grading of evidence. None of the authors have any links to drug companies, a financial interest in the prescription of chemotherapeutic agents, nor were they involved in the conduct of the included studies. </p> </section> <section id="CD007929-sec-0081"> <h3 class="title" id="CD007929-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>In the previous update of the review, we found one review article of PARPi in gynaecological cancers, including epithelial ovarian cancer, that did not identify any additional studies (<a href="./references#CD007929-bbs2-0133" title="ReinboltRE , HaysJL .The role of PARP inhibitors in the treatment of gynecologic malignancies. Frontiers in Oncology2013;3(237):1-11.">Reinbolt 2013</a>) and did not include a meta‐analysis of the results. However, a PubMed search in July 2021 (using the broad terms “PARP” “ovarian” and “systematic review”) revealed 26 systematic reviews, subsequent to the last version of this Cochrane Review, reflecting the importance and growth of this topic since the last update of the review in 2015 (<a href="./references#CD007929-bbs2-0016" title="Al HadidiS , AburahmaA , BadamiS , UpadhayaS .PARP (Poly(ADP-Ribose) Polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials. Oncology Research Treatments2018;41(4):226-35. ">Al Hadidi 2018</a>; <a href="./references#CD007929-bbs2-0081" title="BartolettiM , PelizzariG , GerratanaL , BortotL , LombardiD , NicolosoM , et al.Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis. International Journal of Molecular Science2020;21(11):3805. [DOI: 10.3390/ijms21113805]">Bartoletti 2020</a>; <a href="./references#CD007929-bbs2-0085" title="ChengH , YangJ , LiuH , XiangY .Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Archives of  Gynecology and Obstetrics2021;304(2):285-96. [DOI: 10.1007/s00404-021-06070-2]">Cheng 2021</a>; <a href="./references#CD007929-bbs2-0097" title="GongH , NieD , HuangY , LiZ .Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. International Journal of Gynecological Cancer2020;30(10):1576-82.">Gong 2020</a>; <a href="./references#CD007929-bbs2-0099" title="GuL , DuN , JinQ , LiS , XieL , MoJ , et al.Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: a meta-analysis. Critical Reviews in Oncology/Hematology2020;147:102888.">Gu 2020</a>; <a href="./references#CD007929-bbs2-0100" title="HaoJ , LiuY , ZhangT , HeJ , ZhaoH , AnR , et al.Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology2021;157:103145.">Hao 2021</a>; <a href="./references#CD007929-bbs2-0107" title="JiangY , ZhaoJ , ZhangL , TianS , YangT , WangL , et al.Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Frontiers in Oncology2020;10:954.">Jiang 2020</a>; <a href="./references#CD007929-bbs2-0108" title="KanekoM .Effect of PARP inhibitors as maintenance treatment on restricted mean survival time in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis. Annals of Pharmacotherapy2021;Epub ahead of print:Apr 29:10600280211013489. [DOI: 10.1177/10600280211013489]">Kaneko 2021</a>; <a href="./references#CD007929-bbs2-0111" title="Lee CK , Friedlander ML , TjokrowidjajaA , LedermannJA , ColemanRL , MirzaMR , et al, Gynecologic Cancer Intergroup Meta-Analysis Committee.Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer2021;127(14):2432-41.">Lee 2021</a>; <a href="./references#CD007929-bbs2-0113" title="LiJ , ZhangZ .Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. Journal of Chemotherapy2021;E pub ahead of print:1-10. [DOI: 10.1080/1120009X.2021.1884797]">Li 2021</a>; <a href="./references#CD007929-bbs2-0114" title="LinQ , LiuW , XuS , ShangH , LiJ , GuoY , et al.PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. BJOG2021;128(3):485-93.">Lin 2021</a>; <a href="./references#CD007929-bbs2-0115" title="LiuY , MengJ , WangG .Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Design, Development and Therapy2018;12:3013-9.">Liu 2018</a>; <a href="./references#CD007929-bbs2-0118" title="MohyuddinGR , AzizM , BrittA , WadeL , SunW , BarandaJ , et al.Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer2020;20(1):507. [DOI: 10.1186/s12885-020-06948-5] [PMID: 32493233]">Mohyuddin 2020</a>; <a href="./references#CD007929-bbs2-0119" title="MoricePM , Ray-CoquardI , MooreKN , DiérasV ,  AlexandreJ .PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials. Annals of Oncology2021;32(8):1048-50. [DOI: 10.1016/j.annonc.2021.04.023]">Morice 2021</a>; <a href="./references#CD007929-bbs2-0120" title="MoricePM , LearyA , DolladilleC , ChretienB , PoulainL , Gonzalez-MartinA , et al.Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematology2021;8(2):e122-e134.">Morice 2021a</a>; <a href="./references#CD007929-bbs2-0060" title="RuscitoI , BellatiF , Ray-CoquardI , MirzaMR , du BoisA , GasparriML , et al.Incorporating Parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews2020;87:102040. ">Ruscito 2020</a>; <a href="./references#CD007929-bbs2-0139" title="ShaoF , LiuJ , DuanY , LiL , LiuL , ZhangC , et al.Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Bioscience Reports2020;40(3):BSR20192226.">Shao 2020</a>; <a href="./references#CD007929-bbs2-0140" title="ShaoF , DuanY , ZhaoY , LiY , LiuJ , ZhangC , et al.PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. Aging (Albany NY)2021;13(6):8975-88.">Shao 2021</a>; <a href="./references#CD007929-bbs2-0142" title='StaropoliN , CilibertoD , Del GiudiceT , IulianoE , CuceM , GrilloneF , et al.The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. CriticalReviews in Oncology/ Hematology2018;131:83-9.'>Staropoli 2018</a>; <a href="./references#CD007929-bbs2-0144" title="StodtmannS , NuthalapatiS , EckertD , KasichayanulaS , JoshiR , BachBA , et al.A population pharmacokinetic meta-analysis of veliparib, a PARP inhibitor, across phase 1/2/3 trials in cancer patients. Journal of Clinical Pharmacology2021;61(9):1195-205. [DOI: 10.1002/jcph.1875]">Stodtmann 2021</a>; <a href="./references#CD007929-bbs2-0145" title="SunW , LiJ , ZhangZ , SuX .Gastrointestinal events with PARP inhibitors in cancer patients: a meta-analysis of phase II/III randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics2021;46(2):241-55.">Sun 2021</a>; <a href="./references#CD007929-bbs2-0148" title="TomaoF , BardhiE , Di PintoA , Sassu CM , BiagioliE , PetrellaMC , et al.Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treatment Reviews2019;80:101909.">Tomao 2019</a>; <a href="./references#CD007929-bbs2-0149" title="WangY , RenF , SongZ , WangX , ZhangC , OuyangL .PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials. Frontiers in Oncology2020;10:1204.">Wang 2020</a>; <a href="./references#CD007929-bbs2-0150" title="XuY , DingL , TianY , BiM , HanN , WangL .Comparative efficacy and safety of parp inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis. Frontiers in Oncology2020;10:573801.">Xu 2020</a>; <a href="./references#CD007929-bbs2-0151" title="YangY , DuN , XieL , JiangJ , MoJ , HongJ , et al.The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology2020;18(1):151.">Yang 2020</a>; <a href="./references#CD007929-bbs2-0152" title="YiT , FengY , SundaramR , TieY , ZhengH , QianY , et al.Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer2019;145(5):1209-20.">Yi 2019</a>).   </p> <p><a href="./references#CD007929-bbs2-0016" title="Al HadidiS , AburahmaA , BadamiS , UpadhayaS .PARP (Poly(ADP-Ribose) Polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials. Oncology Research Treatments2018;41(4):226-35. ">Al Hadidi 2018</a>  assessed studies of maintenance treatment in platinum‐sensitive relapsed EOC. They included four studies with a total of 1264 patients (PARP n = 780). They determined that PFS was better in the PARPi group in both  BRCA‐positive patients (hazard ratio (HR) 0.24, 95% confidence interval (CI) 0.19 to 0.30; P &lt; 0.00001) and BRCA‐negative patients (HR 0.52, 95% CI 0.36 to 0.75; P &lt; 0.00001). They also found a difference in overall survival (OS) between the two groups in BRCA‐positive patients (HR 0.72, 95% CI 0.53 to 0.97, P= 0.03). This study is one of the excluded studies in this review (<a href="#CD007929-sec-0057">Excluded studies</a>). </p> <p><a href="./references#CD007929-bbs2-0081" title="BartolettiM , PelizzariG , GerratanaL , BortotL , LombardiD , NicolosoM , et al.Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis. International Journal of Molecular Science2020;21(11):3805. [DOI: 10.3390/ijms21113805]">Bartoletti 2020</a> conducted a network meta‐analysis comparing PARPi with bevacizumab in EOC platinum‐sensitive recurrent EOC. They concluded that PARPi improved PFS compared with bevacizumab, especially in <i>BRCA</i> m patients who had not previously received PARPi.  They calculated PFS for participants with <i>BRCA</i> m was HR = 0.46 (95% CI 0.36 to 0.59), whereas those with wild type <i>BRCA h</i>ad an HR = 0.87 (95% CI 0.63 to 1.20);. They performed a Surface Under the Cumulative RAnking curve analysis<b>(</b>SUCRA) analysis and estimated that  PARPi "had the highest probability of being ranked as the most effective therapy (90% and 60%, for [sic] PARP inhibition and bevacizumab, respectively)". It should be noted that authors declared fees from pharmaceutical companies, including Amgen, Eli Lilly, Eisai, Ipsen, MSD, Novartis, Pfizer, Roche and Takeda. </p> <p><a href="./references#CD007929-bbs2-0085" title="ChengH , YangJ , LiuH , XiangY .Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Archives of  Gynecology and Obstetrics2021;304(2):285-96. [DOI: 10.1007/s00404-021-06070-2]">Cheng 2021</a> looked at maintenance therapy in women with newly‐diagnosed ovarian cancer, comparing PARPi with placebo. They identified four RCTs with a total of 3070 participants. In the HRD population they found that PFS was improved with PARPi (HR 0.39; 95% CI, 0.29 to 0.53), but 'no clear difference' in the homologous recombination proficient population (HR 0.83, 95% CI 0.67 to 1.03) and agreed 'no clear difference' between the groups in terms of other outcomes of OS, health‐related quality of life and adverse events. They also concluded that results were probably not affected by stage, response to first‐line chemotherapy and residual disease after debulking surgery. </p> <p><a href="./references#CD007929-bbs2-0097" title="GongH , NieD , HuangY , LiZ .Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. International Journal of Gynecological Cancer2020;30(10):1576-82.">Gong 2020</a> compared different PARPi regimens in <i>BRCA</i>m EOC in the first‐line treatment of EOC (bevacizumab and olaparib versus veliparib and chemotherapy versus olaparib) and in a platinum‐sensitive relapsed setting (olaparib, rucaparib, niraparib) in a network meta‐analysis, and did not find a difference between different PARPi in terms of PFS.  Toxicity of PARPi regimens was less in the first‐line setting than at relapse. In an analysis of cost‐effectiveness, they determined that adding bevacizumab to olaparib (US $353.72) increased the cost per unit net health benefit for patients compared with olaparib monotherapy (US $260.57).  </p> <p><a href="./references#CD007929-bbs2-0099" title="GuL , DuN , JinQ , LiS , XieL , MoJ , et al.Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: a meta-analysis. Critical Reviews in Oncology/Hematology2020;147:102888.">Gu 2020</a> performed a meta‐analysis of PARPi in solid tumours, not just EOC. They demonstrated an improvement in PFS and OS in participants with <i>BRCA</i>1/2 mutations (PFS = HR 0.32 (P &lt; 0.001) and OS = HR 0.74 (P &lt; 0.001) and concluded that quote: “PARP inhibitors may prolong survival" and that “PARP inhibitors were more [sic] favourable for BRCA1/2 mutations in ovarian cancer patients". </p> <p><a href="./references#CD007929-bbs2-0100" title="HaoJ , LiuY , ZhangT , HeJ , ZhaoH , AnR , et al.Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology2021;157:103145.">Hao 2021</a> looked at PARPi in patients with advanced EOC and, with a search date of January 2020, they found 10 phase II and III studies for inclusion, with a total of 4,21 participants included in survival analyses.  The pooled HR (PARPi versus control group) for PFS was 0.41 (95 % CI, 0.35 to 0.50) in all included patients.  The PFS had an HR of 0.51 (95 % CI, 0.40 to 0.64) in studies that included participants with both <i>BRCA</i> m and wild type; the HR for PFS was 0.32 (95 % CI, 0.26 to 0.39) in participants with a <i>BRCA</i> m, and 0.57 (95 % CI, 0.41 to 0.78) in patients with <i>BRCA</i> wild‐type. They agreed that PARPi use conferred increased risks of all‐grade and high‐grade haematological toxicities (P &lt; 0.05) and all‐grade gastrointestinal side effects and high‐grade nausea and vomiting (P &lt; 0.05). </p> <p><a href="./references#CD007929-bbs2-0107" title="JiangY , ZhaoJ , ZhangL , TianS , YangT , WangL , et al.Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Frontiers in Oncology2020;10:954.">Jiang 2020</a>, with a search date to April 2020, included a total of 12 studies with 5,347 participants with advanced EOC. Compared with the control group, PARPi  improved PFS (HR 0.51; 95% CI, 0.40 to 0.65; P &lt; 0.00001) and ORR (RR, 1.26; 95% CI, 1.11‐1.43; P = 0.0003) this was regardless of <i>BRCA</i> and HRD status. They also found no difference in OS, in the seven studies which reported this outcome, with a pooled HR of 0.86 (95% CI, 0.73‐1.01; P = 0.06). PARP inhibitors use was associated with a higher risk of haematologic events and different PARPi had differing toxicity profiles. This outcome held regardless of <i>BRCA</i> mutation status and first‐line/relapsed settings. Despite the lack of OS effect, they concluded that "PARP inhibitors are an effective and well‐tolerated treatment for patients with advanced‐stage epithelial ovarian cancer".  The authors declared that they had no commercial conflict of interest. </p> <p><a href="./references#CD007929-bbs2-0108" title="KanekoM .Effect of PARP inhibitors as maintenance treatment on restricted mean survival time in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis. Annals of Pharmacotherapy2021;Epub ahead of print:Apr 29:10600280211013489. [DOI: 10.1177/10600280211013489]">Kaneko 2021</a> was a single‐author meta‐analysis of maintenance PARPi treatment in relapse platinum‐sensitive EOC. With a search date of the end of July 2020, they included four studies with a total of  1079 participants and evaluated differences in restricted mean survival times (RMST). The RMST difference for up to 360 days for PARP inhibitors versus placebo for all participants was 87 days (95% CI 71 to 102 days). For those with <i>BRCA</i> mutations, the RMST was 112 days (95% CI 96 to 129 days), for those with HRD tumours the RMST was 99 days (95% CI 80 to 119), and for those with BRCA wild‐type cancers, the RMST was 69 days (95% CI = 47, 92), respectively. </p> <p><a href="./references#CD007929-bbs2-0111" title="Lee CK , Friedlander ML , TjokrowidjajaA , LedermannJA , ColemanRL , MirzaMR , et al, Gynecologic Cancer Intergroup Meta-Analysis Committee.Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer2021;127(14):2432-41.">Lee 2021</a> performed a meta‐analysis of PARPi in patients with EOC and a platinum‐sensitive relapse. They analysed results by the following subgroups: germline <i>BRCA</i> mutation (g<i>BRCA</i> m), somatic <i>BRCA</i> mutation (s<i>BRCA</i> m), wild‐type <i>BRCA</i> but HRD; and those with homologous recombinant‐proficient (HRP) tumours.  They included four studies with 972 participants who received a PARPi and 530 who received placebo. PFS results were as follows: g<i>BRCA1</i> m (n = 471 participants) HR = 0.29 (95% CI 0.23 to 0.37); g<i>BRCA2</i> m (n = 236 participants) HR = 0.26 (95% CI 0.17 to 0.39); sBRCAm (n = 123 participants) HR = 0.22 (95% CI 0.12 to 0.41); wild‐type <i>BRCA</i> HRD tumours (n = 309 participants)  HR = 0.41 (95% CI 0.31 to 0.56); wild‐type <i>BRCA</i> HRP tumours (n = 346 participants) HR = 0.64 (95% CI 0.49 to 0.83).  Most authors had declared a financial conflict of interest (Amgen, Arcagy Research, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline/Tesaro, Novartis, Pfizer, Roche, Takeda, and Yuhan), including three authors who were employees of AstraZeneca, Clovis Oncology, and GlaxoSmithKline; the meta‐analysis included unpublished subgroup data from AstraZeneca, Clovis Oncology, and GlaxoSmithKline. </p> <p><a href="./references#CD007929-bbs2-0113" title="LiJ , ZhangZ .Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. Journal of Chemotherapy2021;E pub ahead of print:1-10. [DOI: 10.1080/1120009X.2021.1884797]">Li 2021</a> was a meta‐analysis specifically looking at fatigue in cancer patients caused by PARPi. They included 29 RCTs with a total of 9479 participants. PARPi  increased the risk of developing all‐grade (RR 1.25, 95%CI 1.20 to 1.31; P &lt; 0.00001; I<sup>2</sup> = 48%) and high‐grade  (G3+) fatigue (RR 1.92, 95%CI 1.51 to 2.45; P &lt; 0.00001; I<sup>2</sup>  = 11%). Veliparib had a lower risk of fatigue and participants with ovarian cancer may have a higher risk of fatigue than those with non‐ovarian cancer. No potential conflict of interest was reported by the authors. </p> <p><a href="./references#CD007929-bbs2-0114" title="LinQ , LiuW , XuS , ShangH , LiJ , GuoY , et al.PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. BJOG2021;128(3):485-93.">Lin 2021</a> assessed PARPi maintenance treatment in patients with newly‐diagnosed advanced EOC. Four RCTs met the inclusion criteria, including 2,687 participants. PARPi were associated with improved PFS  (HR = 0.53, 95% CI 0.40‐0.71; P &lt; 0.0001). The subgroup analysis for PFS by <i>BRCA</i> status were: <i>BRCA</i> m (HR = 0.35, 95% CI 0.29 to 0.42; P &lt; 0.00001) and HRD (HR = 0.43, 95% CI 0.32 to 0.60; P &lt; 0.00001); <i>BRCA</i>wt tumours (HR = 0.72, 95% CI 0.63‐0.82; P &lt; 0.00001) ; and HRP tumours (HR = 0.83, 95% CI 0.70‐0.99; P = 0.04). OS data were not presented. The authors reported no conflicts of interest. </p> <p><a href="./references#CD007929-bbs2-0115" title="LiuY , MengJ , WangG .Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Design, Development and Therapy2018;12:3013-9.">Liu 2018</a> looked specifically at gastrointestinal (GI) adverse effects  of PARPi. They included 2286 participants with EOC patients from 12 studies. All‐grade GI adverse events were common: nausea 68.8% (95% CI 63.5 to 73.6%); vomiting 36.2% (95% CI 30.9 to 41.8%); diarrhoea 25.3% (95% CI 21.2 to 29.8%); and constipation 25.3% (95% CI 17.9 to 34.5%). However, G3+ adverse events were uncommon; nausea 3.4% (95% CI 2.6 to 4.5%); vomiting 2.0% (95% CI 1.4 to 3.0%); diarrhoea 1.7% (95% CI 1.0 to 3.0%), and constipation 1.4% (95% CI 0.9 to 2.3%). The relative risks (RR) of all‐grade adverse events were: nausea = RR 2.00 (95% CI: 1.79 to 2.24; P&lt;0.001); vomiting = RR 2.12 (95% CI: 1.75 to 2.58; P&lt;0.001); diarrhoea = RR 1.20 (95% CI 1.01 to 1.44; P=0.044); and constipation = RR 1.20 (95% CI: 0.88‐1.80; P=0.21). The RR of G3+ adverse events were: nausea = 3.74 (95% CI: 1.50‐9.36; P=0.005); vomiting = 2.81 (95% CI: 1.17‐6.74; P=0.02); diarrhoea = 0.56 (95% CI: 0.22‐1.43; P=0.23); and constipation = 0.92 (95% CI: 0.34‐2.49, P=0.87). The authors reported no conflicts of interest. </p> <p><a href="./references#CD007929-bbs2-0118" title="MohyuddinGR , AzizM , BrittA , WadeL , SunW , BarandaJ , et al.Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer2020;20(1):507. [DOI: 10.1186/s12885-020-06948-5] [PMID: 32493233]">Mohyuddin 2020</a> was a systematic review comparing responses to PARPi in patients with genetic and somatic <i>BRCA</i> m, not limited to ovarian cancer. They found 18 studies for inclusion, although only eight detailed response rates separately for participants with germline and somatic <i>BRCA</i> m, which were found to be similar (55.8% response versus 43.9% response for somatic and germline <i>BRCAm</i>, respectively; P= 0.003) </p> <p><a href="./references#CD007929-bbs2-0120" title="MoricePM , LearyA , DolladilleC , ChretienB , PoulainL , Gonzalez-MartinA , et al.Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematology2021;8(2):e122-e134.">Morice 2021a</a> conducted a meta‐analysis specifically to look at the risk of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) associated with PARPi, not restricted to patients with EOC.  They extracted data from ClinicalTrials.gov and went next to published manuscripts, or subsequently contacted corresponding authors or sponsors to provide data, if not available.  They also conducted an observational, retrospective, cross‐sectional pharmacovigilance study of VigiBase. They included 28 RCTs (18 placebo and ten non‐placebo RCTs), with 5693 participants in PARPi groups and 3406 participants in control groups. Data from the 18 placebo RCTs (n=7307 participants) demonstrated that PARPi increased the risk of MDS and AML compared with placebo treatment (OR 2.63, 95% CI 1.13 to 6.14, P = 0.026; I<sup>2</sup> = 0).  The incidence of MDS and AML in PARPi groups was 0.73% (95% CI 0.50 to 1.07; I<sup>2</sup> = 0%; 21 events in 4533 participants) compared with an incidence of 0.47% (95% CI 0.26 to 0.85; I<sup>2</sup> = 0%; three events in 2774 participants) in the placebo groups. These findings were supported by the pharmacovigilance study where 99 cases of MDS and 79 cases of AMD related to PARPi therapy were extracted. In 58 patients, where data were available, the median latency period from first exposure to a PARPi to developing MDS or AML was 17.8 months (8.4 to 29.2 months; n = 58) and in the 104 cases with reported outcomes, there were 47 deaths. </p> <p><a href="./references#CD007929-bbs2-0119" title="MoricePM , Ray-CoquardI , MooreKN , DiérasV ,  AlexandreJ .PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials. Annals of Oncology2021;32(8):1048-50. [DOI: 10.1016/j.annonc.2021.04.023]">Morice 2021</a> has only been published online, ahead of print, no abstract is available and we have not yet been able to access the full text. </p> <p><a href="./references#CD007929-bbs2-0060" title="RuscitoI , BellatiF , Ray-CoquardI , MirzaMR , du BoisA , GasparriML , et al.Incorporating Parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews2020;87:102040. ">Ruscito 2020</a> performed a systematic review with a search date of December 2019. They included 12 RCTs, including 5171 participants. They concluded that PARPi maintenance inhibitors improved PFS in both recurrent and first‐line treatment for EOC, which was independent of <i>BRCA</i> mutational status.  For the recurrent platinum‐sensitive cohort, pooled data for PFS for PARPi versus placebo demonstrated benefit (HR 0.37, 95% CI 0.32 to 0.42) with pooled data for the first‐line cohort showing similar results (HR 0.62, 95% CI 0.50 to 0.76). Interestingly, no data were presented in the abstract, nor were any OS data reported, with what appears to be reporting bias in the systematic review. They reported that severe adverse events, including haematological and fatigue, were more common with PARPi treatment.  There was no conflict of interest statement that we have been able to discern in the published version, although one author is a lead author on a PARPi study. This study is one of the excluded studies in this review (<a href="#CD007929-sec-0057">Excluded studies</a>). </p> <p><a href="./references#CD007929-bbs2-0139" title="ShaoF , LiuJ , DuanY , LiL , LiuL , ZhangC , et al.Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Bioscience Reports2020;40(3):BSR20192226.">Shao 2020</a> was a systematic review of PARPi maintenance treatment in participants with ovarian cancer, both in newly‐diagnosed and in platinum‐sensitive and platinum‐resistant relapse and compared PARPi treatment with placebo or other chemotherapy drugs. They included nine studies in the meta‐analysis, five in newly‐diagnosed participants and four in recurrent disease.  In total there were 4526 participants. The pooled OS data across all the studies, despite different treatment settings, and found an OS of HR = 0.78 (95%CI  0.61 to 1.01; <i>P</i> = 0.06). Similarly, they pooled PFS data across both newly diagnoses and recurrent settings and found an improvement in PFS for PARPi (HR = 0.53, 95%CI 0.43 to 0.68, <i>P</i> &lt; 0.00001). They found an incidence of G3+ adverse events of 55.19% and "serious adverse events" of 26.29%. What constitutes “serious” was not defined.  They concluded that “[PARPi] therapy can significantly improve PFS in ovarian cancer patients, but it has no benefit in OS. However, the therapy is associated with a significant increase in the risk of AEs of grade &gt;/= 3 and serious AEs”. The authors declared that they had no competing interests and the work was funded by a national grant. </p> <p><a href="./references#CD007929-bbs2-0140" title="ShaoF , DuanY , ZhaoY , LiY , LiuJ , ZhangC , et al.PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. Aging (Albany NY)2021;13(6):8975-88.">Shao 2021</a> was another systematic review of PARPi from the same team as  <a href="./references#CD007929-bbs2-0139" title="ShaoF , LiuJ , DuanY , LiL , LiuL , ZhangC , et al.Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Bioscience Reports2020;40(3):BSR20192226.">Shao 2020</a>, but focused on the treatment of participants with breast and ovarian cancer who had a <i>BRCA</i> m. They found that PFS improved for participants with both <i>BRCA</i> m breast (HR 0.64, 95% CI 0.55 to 0.75, P&lt;0.001) and ovarian cancer (HR 0.33, 95% CI 0.27 to 0.42, P &lt; 0.001). They agreed with our findings that  OS of patients was not significantly increased (breast cancer: HR 0.87, 95% CI 0.76 to 1.01, P = 0.065; ovarian cancer: HR 0.78, 95% CI 0.61 to 1.01, P = 0.058). They concluded that [PARPi were "most beneficial to the ovarian cancer subset when administered early after diagnosis, rather than after recurrence”.  Details about the number of studies and number of participants included were not stated in the abstract, but the results state that 15 RCTs were included for <i>BRCA</i> m‐positive participants with breast and ovarian cancer (11 RCTs in ovarian cancer), with a total of 3,756 <i>BRCA</i>m positive patients  (40% breast cancer participants and 60% ovarian cancer patients).  </p> <p> <a href="./references#CD007929-bbs2-0142" title='StaropoliN , CilibertoD , Del GiudiceT , IulianoE , CuceM , GrilloneF , et al.The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. CriticalReviews in Oncology/ Hematology2018;131:83-9.'>Staropoli 2018</a> included search dates of January 2008  to April 2018.  PFS and adverse events were primary and secondary end‐points, OS data were not presented. They included five RCTs with 1839 participants. PFS in the <i>BRCA</i> m cohort was HR 0.25 (95%CI 0.21 to 0.31; 871 participants) and for the <i>BRCA</i>wt cohort was HR 0.41 (95%CI 0.31 to 0.55; 836 participants). More severe (G3+) GI toxicities were noted with rucaparib and G3+ haematological toxicities with niraparib. Despite the lack of OS data, they concluded that “We confirm a significant benefit in survival outcome of [sic] PARPis for EOC patients”.  The disclosures section (after acknowledgements) was not completed and the work was performed as part of a PhD programme and funded by an academic institution. </p> <p> <a href="./references#CD007929-bbs2-0144" title="StodtmannS , NuthalapatiS , EckertD , KasichayanulaS , JoshiR , BachBA , et al.A population pharmacokinetic meta-analysis of veliparib, a PARP inhibitor, across phase 1/2/3 trials in cancer patients. Journal of Clinical Pharmacology2021;61(9):1195-205. [DOI: 10.1002/jcph.1875]">Stodtmann 2021</a> was a meta‐analysis of pharmacokinetic outcomes for veliparib from phase I to III trials in patients with a range of cancers, so outcomes were not relevant to this review. </p> <p> <a href="./references#CD007929-bbs2-0145" title="SunW , LiJ , ZhangZ , SuX .Gastrointestinal events with PARP inhibitors in cancer patients: a meta-analysis of phase II/III randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics2021;46(2):241-55.">Sun 2021</a> was a meta‐analysis of GI toxicities with PARPi in a range of cancers. They found that  PARPi increased the risk of “high‐grade” (presumed G3+) nausea (RR 1.99, 95% CI 1.44 to 2.74), vomiting (RR 1.54, 95% CI, 1.11 to 2.14) and decreased appetite (RR 2.03, 95% CI 1.22 to 3.40).  Pooled incidence rates of severe adverse events were: nausea 2.3%; vomiting 2.0%; diarrhoea 1.7%; reduced appetite 1.0%; and constipation 0.5%. Incidence of less severe GI adverse events were not given and natural frequency data relatively were difficult to find compared to RR. The authors declared that they had no conflict of interests.  </p> <p><a href="./references#CD007929-bbs2-0148" title="TomaoF , BardhiE , Di PintoA , Sassu CM , BiagioliE , PetrellaMC , et al.Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treatment Reviews2019;80:101909.">Tomao 2019</a> was an update of a systematic review of PARPi for platinum‐sensitive recurrent EOC. The number of included studies and participants was not included in the abstract, but was stated as four in the full text version (five articles), including 1677 participants (1079 PARPi and 598 placebo). Outcomes focused on PFS data, which were improved for both patients with germline <i>BRCA</i> m (0.26, 95% CI 0.21 to 0.31) and somatic <i>BRCA</i> m (HR 0.24, 95% CI 0.12 to 0.48), as well as the overall population (HR 0.49, 95% CI 0.41 to 0.59), although <i>BRCA</i>m rates and HRD across the studies may be higher than in the general EOC population. The authors declared that they had no conflict of interest. </p> <p> <a href="./references#CD007929-bbs2-0149" title="WangY , RenF , SongZ , WangX , ZhangC , OuyangL .PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials. Frontiers in Oncology2020;10:1204.">Wang 2020</a> performed a systematic review of PARPi as maintenance treatment in patients following first‐line treatment of EOC. They included three RCTs (all included in this review), with 1881 participants. The authors declared that there was “absence of any commercial or financial relationships that could be construed as a potential conflict of interest”. Overall PFS was improved with PARPi (HR, 0.51; 95% CI, 0.33–0.80).  OS data were not presented.  These findings were robust for subgroup analyses by age group, stage, timing of surgery (upfront versus interval debulking). Improvement in PFS was not significant for those without a <i>BRCA</i>m (HR 0.67, 95% CI 0.43 to 1.04), but was for the subset of participants where data were reported by HRD status (HRD cohort (HR 0.5, 95% CI 0.38 to 0.66) and for those with HRP (0.75, 95% CI 0.60 to 0.93). They reported some adverse events in a narrative review by study/individual PARPi.  The link to the meta‐analysis data in figures is limited to PFS data, not SAE or QoL data. </p> <p> <ul id="CD007929-list-0022"> <li> <p>In <a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> (olaparib) anaemia was the most common G3+ adverse event (22% in PARPi group versus 2% in control); </p> </li> <li> <p>In <a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> (veliparib) G3+ thrombocytopaenia was most common (28% in PARPi group versus 8% in control); </p> </li> <li> <p>In <a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> (niraparib) any G3+ adverse events were common in the study arm (70% in PARPi group versus 18.9% in control), with haematological toxicities being the most common. </p> </li> </ul> </p> <p> <a href="./references#CD007929-bbs2-0150" title="XuY , DingL , TianY , BiM , HanN , WangL .Comparative efficacy and safety of parp inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis. Frontiers in Oncology2020;10:573801.">Xu 2020</a> was a network meta‐analysis of PARPi treatment, in patients with platinum‐sensitive EOC, with a primary end‐point of PFS, with analysis by <i>BRCA</i> m  and HRD status. PFS was improved with PARPi maintenance treatment in participants and was similar in participants with <i>BRCA</i>m and HRD.  They presented data by treatment: chemotherapy plus olaparib followed by olaparib maintenance (olaparib‐throughout) (HR 0.51,  95% CI 0.34 to 0.76); rucaparib maintenance (HR 0.37, 95% CI 0.30 to 0.45); olaparib maintenance only (HR 0.35, 95% CI 0.25 to 0.49); and niraparib maintenance (HR 0.38, 95% CI 0.30 to 0.4). The rank probability (SUCRAs) of PFS in  participants was: olaparib (79.1%) &gt; rucaparib (72.5%) &gt; niraparib (66.7%) &gt; olaparib‐throughout (31.6%) &gt; Placebo (0.016%), which were similar in BRCAm and HRD participant subgroups.  Discontinuation of treatment due to adverse events was commoner in the PARPi groups in the whole population. All had an increase in G3+ adverse events compared to placebo in maintenance treatment  (rucaparib (RR  3.8, 95% CI 2.8 to 5.6); olaparib (RR 2, 95% CI 1.5 to 2.6);  and niraparib (RR 3.3, 95% CI 2.5 to 4.4)). G3+ adverse events were commoner in the rucaparib and niraparib groups than for olaparib (SUCRAs = placebo (100.0%) &gt; olaparib (66.4%) &gt; niraparib (25.7%) &gt; rucaparib (7.8%). They concluded that "clinicians should consider adverse events” but that these were “generally manageable”.  The authors stated that there was an “absence of any commercial or financial relationships that could be construed as a potential conflict of interest”. </p> <p> <a href="./references#CD007929-bbs2-0151" title="YangY , DuN , XieL , JiangJ , MoJ , HongJ , et al.The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology2020;18(1):151.">Yang 2020</a> was a systematic review of PARPi in EOC with a search date to February 2020. They excluded treatments that included neoadjuvant chemotherapy.  They included three phase II RCTs and seven phase III RCTs with 5006 participants in total. They included both PFS and OS outcomes and concluded that both PFS and OS were improved across all cohorts (PFS = HR 0.44 95% CI, 0.34 to 0.53; and OS = HR 0.79, 95% CI 0.65 to 0.94), and were similar by <i>BRCA</i>m and HRD status. However, the forest plots are difficult to interpret, with more than one data point from each study in each forest plot with no explanation as to the difference between the data points. There were no conflicts of interests declared.  </p> <p> <a href="./references#CD007929-bbs2-0152" title="YiT , FengY , SundaramR , TieY , ZhengH , QianY , et al.Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer2019;145(5):1209-20.">Yi 2019</a> was a systematic review of PARPi in a variety of cancers cancer comparing outcomes in participants with HRD and HRP tumours.  They included 13 studies. Eight were studies of participants with ovarian cancer and six were studies including other cancers: breast cancer (1 study);  gastric cancer (2 studies); colorectal cancer (2 studies); and prostate cancer (1 study). One study included participants with breast and ovarian cancer.  Outcomes included PFS and OS. Participant cohorts were as follows: <i>BRCA</i> m HRD, n = 697; <i>BRCA</i> wt HRD, n = 478; and HRP (n = 1417).  They reported PFS at 6‐ and 12‐months and found that the BRCAm/HRD population had an increased PFS at 6 months (OR 2.29, 95% CI 1.03 to 5.08) and 12 months (OR 1.95, 95% CI 1.26 to 3.01) compared with <i>BRCA</i>wt/HRD participants. BRCAwt/HRD participants had a higher PFS at 6 (OR 1.72, 95% CI 1.27 to 2.43) and 12 months (OR 1.85, 95% CI 1.31 to 2.62) than HRP patients. There were no conflicts of interests declared. </p> <p>It should be noted that some of these systematic reviews were at risk of bias since authors had stated (or sometimes not) conflicts of interest, for others conflict of interest statements, were not apparent. Few, if any, of the studies reported an assessment of the quality of the included studies, and certainty of the results, with a GRADE assessment or similar. Data presented in abstracts were often incomplete and did not all meet reporting guidance (PRISMA and EQUATOR). Some studies included questionable comparisons of different groups and the conclusions, in some cases, overly promoted the benefits of PARPi treatment, especially those that only included PFS data.  It is of concern that some systematic reviews make strong recommendations supporting PARPi use, despite the lack of reporting of OS data. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007929-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram from updated searches to 19 October 2020." data-id="CD007929-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram from updated searches to 19 October 2020.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007929-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 1: Progression‐free survival" data-id="CD007929-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 2: Progression‐free survival by BRCA status" data-id="CD007929-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 2: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by HRD status" data-id="CD007929-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by HRD status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response)" data-id="CD007929-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 5: Quality of Life ‐ European Organization for Research and Treatment of Cancer Questionnaire QLQ‐C30" data-id="CD007929-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 5: Quality of Life ‐ European Organization for Research and Treatment of Cancer Questionnaire QLQ‐C30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 6: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 6: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 1: Progression‐free survival" data-id="CD007929-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 2: Progression‐free survival by BRCA status" data-id="CD007929-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 2: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by HRD status" data-id="CD007929-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by HRD status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response)" data-id="CD007929-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 5: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 5: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 1: Overall survival" data-id="CD007929-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 2: Overall survival by HRD status " data-id="CD007929-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 2: Overall survival by HRD status  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 3: Progression‐free survival" data-id="CD007929-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 3: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 4: Progression‐free survival by BRCA status" data-id="CD007929-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 4: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 5: Progression‐free survival by HRD status" data-id="CD007929-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 5: Progression‐free survival by HRD status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire" data-id="CD007929-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 7: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 7: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 1: Overall survival" data-id="CD007929-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 2: Progression‐free survival" data-id="CD007929-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 3: Progression‐free survival by BRCA status" data-id="CD007929-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 3: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 4: Objective response rate (no response)" data-id="CD007929-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 4: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 5: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire" data-id="CD007929-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 5: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 6: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 6: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 1: Overall survival" data-id="CD007929-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 2: Progression‐free survival" data-id="CD007929-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 3: Progression‐free survival by BRCA status" data-id="CD007929-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 3: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 4: Progression‐free survival by HRD status" data-id="CD007929-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 4: Progression‐free survival by HRD status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 5: Objective response rate (no response)" data-id="CD007929-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 5: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ European Quality of Life 5‐dimensions questionnaire" data-id="CD007929-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 6: Quality of Life ‐ European Quality of Life 5‐dimensions questionnaire </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 7: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire" data-id="CD007929-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 7: Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 8: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS)" data-id="CD007929-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 8: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 9: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS) by BRCA status" data-id="CD007929-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 9: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS) by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 10: Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST)" data-id="CD007929-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 10: Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 11: Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST) by BRCA status" data-id="CD007929-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 11: Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST) by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 12: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 12: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 1: Progression‐free survival" data-id="CD007929-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 2: Objective response rate (no response)" data-id="CD007929-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 2: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 3: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome 3: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 1: Overall survival" data-id="CD007929-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 2: Progression‐free survival" data-id="CD007929-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by BRCA status" data-id="CD007929-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 3: Progression‐free survival by BRCA status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response)" data-id="CD007929-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 4: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 5: Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone, Outcome 5: Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 1: Objective response rate (no response)" data-id="CD007929-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 1: Objective response rate (no response) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007929-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/urn:x-wiley:14651858:media:CD007929:CD007929-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 2:  Any severe adverse event (grade 3 or higher)" data-id="CD007929-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_t/tCD007929-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy, Outcome 2:  Any severe adverse event (grade 3 or higher) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/media/CDSR/CD007929/image_n/nCD007929-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newly‐diagnosed EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi with chemotherapy<br/><b>Comparison:</b> Chemotherapy alone<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy alone<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi with chemotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression<br/>follow‐up: 26 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.82</b><br/>(0.49 to 1.38)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1564<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi with chemotherapy probably results in little to no difference in progression‐free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>685 per 1000</b><br/>(529 to 797)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)<br/>assessed with: European Organization for Research and Treatment of Cancer Questionnaire<br/>Scale from: 0 to 100<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was <b>‐2.89</b><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.56 higher</b><br/>(0.42 lower to 3.55 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>744<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy likely results in little to no difference in the quality of life.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b><br/>(478 to 536)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/>(1.07 to 1.20)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy likely increases any severe adverse event (grade 3 or higher) slightly.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>EOC:</b> epithelial ovarian cancer; <b>HR:</b> hazard Ratio; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426407798344781835" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426407798344781835</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive without evidence of disease progression at 12 months (63%) was taken from the control arm of the VELIA study.<br/><sup>b</sup> Downgraded by two levels for inconsistency (I2&gt;90%)<br/><sup>c</sup> Note: Indirectness one of the trials (PAOLA‐1) included bevacizumab in its chemotherapy regimen.<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: A single study contributed data for this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Newly diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newly‐diagnosed EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy (maintenance)<br/><b>Comparison:</b> placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy (maintenance)<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive<br/>follow‐up: range 14 months to 41 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.81</b><br/>(0.59 to 1.13)<br/>[survival]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1124<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy likely results in little to no difference in overall survival, although this is based on immature data and more mature data may alter this result. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b><br/>(583 to 754)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression<br/>follow‐up: range 14 months to 41 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.42</b><br/>(0.19 to 0.92)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1124<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e,f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy may increase progression‐free survival.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000<sup>d</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>549 per 1000</b><br/>(269 to 763)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life (QoL)<br/>assessed with: The Trial Outcome Index (TOI) score on the Functional Assessment of Cancer Therapy–Ovarian Cancer questionnaire <br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was <b>3.30</b><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3 lower</b><br/>(4.48 lower to 1.52 lower)<sup>g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>h,i,j</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy probably results in a slight reduction in Quality of Life, although this may not be clinically meaningful.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE )<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>537 per 1000</b><br/>(309 to 934)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b><br/>(1.65 to 4.99)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1118<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>i,k</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy may increase/have little to no effect on any severe adverse event (grade 3 or higher) but the evidence is very uncertain.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>EOC:</b> epithelial ovarian cancer;<b>HR:</b> hazard ratio; <b>MD:</b> mean difference;<b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426409458601301064" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426409458601301064</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (62%) was taken from the control arm of the ICON7 study.<br/><sup>b</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>c</sup> Note: Analysis based on immature data<br/><sup>d</sup> The control risk of being alive without evidence of disease progression at 12 months (24%) was taken from the control arm of the PRIMA study.<br/><sup>e</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;90%), which was probably caused by the population recruited in both studies (SOLO1 included only women with BRCA mutation) <br/><sup>f</sup> Note: The evidence was not downgraded for imprecision despite wide confidence intervals around the effect estimate as the pooled effect still indicates the benefit of PARPi use over placebo.<br/><sup>g</sup> adjusted mean change from baseline to 2 years<br/><sup>h</sup> Note: data limited to a population of patients with BRCA mutation<br/><sup>i</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate)<br/><sup>j</sup> Note: A single study contributed data for this outcome<br/><sup>k</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;80%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy compared with placebo (maintenance therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy<br/><b>Comparison:</b> Chemotherapy<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive at 36 months<br/>follow‐up: range 4 months to 14 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.95</b><br/>(0.62 to 1.47)<br/>[survival]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>331<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPimonotherapy may result in little to no difference in overall survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<sup>a</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><br/>(71 to 328)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: alive without evidence of disease progression at 12 months<br/>follow‐up: range 4 months to 29 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.88</b><br/>(0.56 to 1.38)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>739<br/>(3 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,d,f,g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of PARPimonotherapy on progression free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<sup>e</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b><br/>(124 to 428)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life (QoL)<br/>assessed with: The Trial Outcome Index (TOI) score on the Functional Assessment of Cancer Therapy–Ovarian Cancer questionnaire<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was <b>‐3.6</b> points<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1.2 points higher</b><br/>(1.76 lower to 4.16 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,h,i</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in QoL.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b><br/>(379 to 658)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.80 to 1.39)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>MD:</b> mean difference; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426414839953371161" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426414839953371161</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (16.6%) was taken from the control arm (conventional treatment) of the ICON4 study.<br/><sup>b</sup> Note: both studies were judged at high risk of bias due to study design (open‐label); however, the evidence was not downgraded as OS is a hard, objective outcome.<br/><sup>c</sup> Downgraded by one level due to indirectness (50% of participants in the ICEBERG3 trial were platinum‐resistant).<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> The control risk of being alive without evidence of disease progression at 12 months (22%) was taken from the control arm (chemotherapy) of Oza 2015 study.<br/><sup>f</sup> Downgraded by one level due to risk of bias (open‐label studies)<br/><sup>g</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt; 70%)<br/><sup>h</sup> Note: The evidence is limited only to participants with BRCA mutation<br/><sup>i</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy (maintenance therapy)<br/><b>Comparison:</b> placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi monotherapy (maintenance therapy)<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>assessed with: number alive at 36 months<br/>follow‐up: NR months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.88</b><br/>(0.65 to 1.20)<br/>[alive]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>560<br/>(2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy (maintenance therapy) probably results in little to no difference in OS.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b><br/>(116 to 311)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS) assessed with: number alive without evidence of disease progression at 12 months follow‐up<br/>follow‐up: median 17 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.34</b><br/>(0.28 to 0.42)<br/>[survival without evidence of disease progression]<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1677<br/>(4 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PARPi monotherapy (maintenance therapy) results in a large increase in PFS.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(296 to 444) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation (QoL)<br/>assessed with: European Quality of Life–5 Dimensions questionnaires Health Utility Index<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation was <b>0.783</b> points<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.02 points higher</b><br/>(0.01 lower to 0.05 higher)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>f</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi monotherapy (maintenance therapy) probably results in little to no difference in QoL.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: NCI‐CTCAE<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>506 per 1000</b><br/>(358 to 719)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.62</b><br/>(1.85 to 3.72)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1665<br/>(4 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,g</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy (maintenance therapy) results in a large increase in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>MD:</b> mean difference; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426425278373060041" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426425278373060041</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive at 36 months (16.6%) was taken from the control arm (conventional treatment) of the ICON4 study. <br/><sup>b</sup> Note: One study contributing data to the analysis for this outcome included only participants with BRCA mutation.<br/><sup>c</sup> The control risk of being alive without evidence of disease progression at 12 months (5.5%, an average) was taken from the control arms of ARIEL3 and Study 19 (Ledermann 2012) studies. <br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: Analysis based on immature data<br/><sup>f</sup> Downgraded by one level due to imprecision (only a subset of participants from a single study contributed data to the analysis for this outcome).<br/><sup>g</sup> Downgraded by two levels due to inconsistency (indicator of statistical heterogeneity I2 &gt;70%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐sensitive recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi with chemotherapy<br/><b>Comparison:</b> Chemotherapy alone<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy alone<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi with chemotherapy<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival (OS)<br/>assessed with: not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>assessed with: e of disease progression at 12 months follow‐up<br/>follow‐up: median 33 months<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.02</b><br/>(0.69 to 1.51)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c,d,e</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence is very uncertain about the effect of PARPi with chemotherapy on progression‐free survival. <br/>  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/>(158 to 313)<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse event (grade 3 or higher) (G3+ SevAE)<br/>assessed with: not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>573 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b><br/>(510 to 843)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.89 to 1.47)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PARPi with chemotherapy may result in little to no difference in any severe adverse event (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial;<b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426427989803404645" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426427989803404645</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The control risk of being alive without evidence of disease progression at 12 months (22%) was taken from the control arm (chemotherapy) of Oza 2015 study.<br/><sup>b</sup> Downgraded by one level due to risk of bias (study design: open‐label)<br/><sup>c</sup> Downgraded by one level due to risk of bias (concern over early closure of Kummar 2015)<br/><sup>d</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>e</sup> Note: a single, small (&lt;100 participants) study contributed data to the analysis for this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007929-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</b><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> platinum‐resistant recurrent EOC<br/><b>Setting:</b> specialist hospital<br/><b>Intervention:</b> PARPi monotherapy<br/><b>Comparison:</b> Chemotherapy<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments<br/> </b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Chemotherapy<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PARPi<br/>monotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progression‐free survival ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any severe adverse events (grade 3 or higher) (G3+ SevAE)<br/>assessed with: unclear<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>598 per 1000</b><br/>(407 to 876)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b><br/>(0.79 to 1.70)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence suggests that PARPi monotherapy results in little to no difference in any SevAE (grade 3 or higher).<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of Life ‐ not reported<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>PARPi:</b> poly (ADP‐ribose) polymerase) inhibitors; <b>RCT:</b> randomised controlled trial;<b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426368977301116995" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_426368977301116995</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by one level due to risk of bias (study design: open‐label)<br/><sup>b</sup> Downgraded by one level due to imprecision (wide confidence interval around the effect estimate crossing a line of no effect)<br/><sup>c</sup> Downgraded by one level due to publication bias (data available only as a conference abstract). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007929-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention/s</b> <br/><b>(name and n)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> <br/><b>(name and n)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomisation ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line treatment or relapsed disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>BRCA</i> status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Somatic</b> </p> <p><b><i>BRCA</i> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Germline</b> </p> <p><b><i>BRCA</i> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HRD</b> </p> <p><b>Status</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants with measurable disease (RECIST)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prior treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Platinum‐related status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib+Bevacizumab<br/>(537) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo+Bevacizumab<br/>(269) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>806</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum–taxane chemotherapy plus bevacizumab </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib (487) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (246)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>733</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All the patients had received six to nine cycles of first‐line platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(260) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(131) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+<br/>~70% BRCA1+<br/>~30% BRCA2+  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platinum‐based<br/>chemotherapy without bevacizumab </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐linetreatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veliparib+Chemotherapy followed by placebo<br/>(383)<br/>Veliparib+Chemotherapy followed by veliparib<br/>(382) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo+Chemotherapy followed by placebo<br/>(375)  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1140</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants who undergo primary cytoreductive surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS / first‐line treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Relapsed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0005" title="KummarS , FlemingGF , OzaAM , SullivanDM , GandaraDR , NaughtonM , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]KummarS , OzaA , FlemingG , SullivanD , GandaraD , ErlichmanC , et al.Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology2012;30(15 Suppl):5020. [http://meetinglibrary.asco.org/content/98169-114]KummarS , OzaAM , FlemingGF , SullivanDM , GandaraDR , NaughtonMJ , et al.Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-Mutant ovarian cancer. Clinical Cancer Research2015;21(7):1574-82. ">Kummar 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veliparib+Chemotherapy<br/>(37) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(38) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients were required to have received at least one line of standard therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib+Chemotherapy followed by Olaparib<br/>(81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy followed by no treatment<br/>(81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Information available for 107 of 162 pts<br/>38% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of 3 platinum‐based therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (52%) &amp; PPS (48%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0002" title="MirzaMR , Åvall LundqvistE , BirrerMJ , dePont ChristensenR , NyvangGB , MalanderS , et al, for the AVANOVA investigators.Niraparib plus bevacizumab versus niraparib alone forplatinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2,superiority trial. Lancet Oncololgy2019;20(10):1409–19. [DOI: 10.1016/ S1470-2045(19)30515-7]">AVANOVA2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib + Bevacizumab<br/>(48) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib<br/>(49) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Previous platinum‐containing therapy for primary disease but ≤1 prior non‐platinum‐containing regimen for recurrent disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (66%) or PPS (34%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0006" title="Liu JF , BradyMF , MatulonisUA , MillerA , KohnEC , SwisherEM , et al.A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinumbased chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology2020;15_suppl:6003. [DOI: 10.1200/JCO.2020.38.15_suppl.6003]NCT02446600.Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinicl Trial. gov register2015. ">NCT02446600</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cediranib+Olaparib (189)<br/>Olaparib<br/>(189) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(187) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>565</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.7% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>platinum and non‐platinum based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (details unavailable)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(178) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(88)  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+ ~65% BRCA1+<br/>~31% BRCA2+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 2 prior lines of platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (37%) or PPS (62%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0004" title="KayeSB , LubinskiJ , MatulonisU , Ang JE , GourleyC , KarlanBY , et al.Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology2012;30(4):372-9. KayeSB .ICEBERG3. http://clinicaltrials.gov/show/NCT00628251 26 February 2008. ">ICEBERG 3 (Kaye 2012)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib 200 mg<br/>(32)<br/>Olaparib 400 mg<br/>(32) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All BRCA+</p> <p>80% BRCA1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>platinum‐based chemotherapy regimen (another<br/>non‐PLD chemotherapy after this was permitted) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (~50%) and PPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rucaparib<br/>(375) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(189) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% BRCA+ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28%**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 2 previous platinum‐based chemotherapy regimens; prior BEV treatment permitted except BEV maintenance   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS or PPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niraparib<br/>(372) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(181) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49%*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two previous lines of platinum‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (61%) &amp; PPS (39%)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(136) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(129) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two or more platinum‐based regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS (60%) &amp; PPS (40%)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(196) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo<br/>(99) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% BRCA+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two previous lines of<br/>platinum‐based chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0003" title="CallewaertT , VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , et al.Quality-of-life analysis in the randomized phase ii CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. International Journal of Gynecological Cancer2019;29:A129-30. NCT02822157.Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. Clinical Trials. gov Register2016. VandersticheleA , LoverixL , De VogelaereC , HeyrmanL , Van GorpT , Van NieuwenhuysenE , et al.Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial. Annals of Oncology2020;31(Supplement 4):S617-S618. VandersticheleA , Van NieuwenhuysenE , HanS , ConcinN , Van GorpT , BertelootP , et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology2019;37(15_supp):5507. ">CLIO</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olaparib<br/>(67) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy<br/>(33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 previous line of chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR (100%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p><b>PS:</b> Platinum sensitive;<b>PPS:</b> partially‐platinum sensitive; <b>PR:</b> platinum‐resistant; <b>NR:</b> not reported.  </p> <p>** This was defined as in the manscript (or with high dgree loss of hetrogenicity) and is limited to <i>BRCA</i> wild type.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007929-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health related Quality of Life (HRQoL) measures in the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary HRQoL measures </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="bottom"> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0009" title="ColomboN , GantzerJ , AtasevenB , CropetC , ScambiaG , HerreroA , et al.Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol.2020;31(Supplement 4):S614. [DOI: 10.1016/j.annonc.2020.08.951]De GregorioN , HarterP , SehouliJ , CanzlerU , MarmeF , BuderathP , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab (BEV) as maintenance therapy in patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCH) plus BEV. Oncology Resarch and Treatment2020;43(Supplement 1):93. EUCTR2014-004027-52-FI.Randomized, double-blind, phase iii trial of olaparib vs. placebo added to bevacizumab in maintenance in patients with advanced ovarian, fallopian tube, or peritoneal cancer after treatment with standard first-line treatment, combining platinum-taxane chemotherapy and concurrent bevacizumab. EU Clinical Trials register2016. FujiwaraK , HarterP , LearyA , PerolD , PignataS , Gonzalez-MartinA , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(Supplement 9):IX191-2. HarterP , Mouret-ReynierMA , PignataS , CropetC , Gonzalez-MartinA , BognerG , et al.Phase III PAOLA-1/ENGOT-OV25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. International Journal of Gynecological Cancer 2019;29(Supplement 4):A10-A11. LorussoD , Lotz J-P, HarterP , CropetC , PerezMJ , SchauerC , et al.Maintenance olaparib plus bevacizumab (bev) after platinumbased chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. Journal of Clinical Oncology2020;38(15_suppl):6039. MartinAG , TaziY , HeitzF , MontaneL , GargiuloP , BergerR , et al.Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Annals of Oncology2020;31(suppl_4):S1163-4. [DOI: 10.1016/annonc/annonc325]Ray-CoquardI , PautierP , PignataS , PerolD , Gonzalez-MartinA , BergerR , et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England ournal of Medicine2019;381(25):2416-28. [DOI: 10.1056/NEJMoa1911361]Ray-CoquardI , SelleF , HarterP , CropetC , MarthC , VergoteI , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2016;34(15_suppl):no pagination. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5607]Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al .PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;34(15_suppl):no pagination. Ray-CoquardIL , HarterP , MartinAG , CropetC , PignataS , FujiwaraK , et al.PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Journal of Clinical Oncology2017;35(15):no pagination. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS5605]Ray-CoquardIL , PautierP , PignataS , PerolD , Gonzalez-MartinA , SeveldaP , et al.Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology2019;30(suppl_5):v851-v934. [DOI: 10.1093/annonc/mdz394]UMIN000019560.Randomized, double-blind, phase iii trial of olaparib vs. placebo in patients with advanced FIGO Stage IIIB-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance. UMIN Clinical Trials Registry2015. ">PAOLA‐1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estimated between‐group difference was 1.56 points (95% CI, −0.42 to 3.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0010" title="GonzalezA , MirzaMR , VergoteI , LiY , HazardS , ClarkR , et al.A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim safety data from the PRIMA Study. In: Annals of Oncology. Vol. 29. 2018:viii335-viii336. GonzalezA , MooreKN , MirzaMR , VergoteIB , PothuriB , OzaAM , et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Gynecologic Oncology. Vol. 145. 2017:98 . Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. In: International Journal of Gynecological Cancer. Vol. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria. 27. 2017:1510. Gonzalez MartinA , RojasLA , BralyP , BarterJ , O'MalleyDM , OzaA , et al.The engot-ov26/prima phase 3 trial: niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy. International Journal of Gynecolical Cancer2017;27:1510. Gonzalez MartinA , RojasLA , BralyPS , BarterJ , O'MalleyDM , OzaAM , et al.A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. In: Annals of Oncology. Vol. 28. 2017:V351. Gonzalez-Martin A Backes FJ Baumann KH Chase DM Fehr MK Coleman RL et al.A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. In: Journal of Clinical Oncology. Vol. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34. 2016:TPS5606-TPS5606. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS5606]PothuriB , HanS , ChaseD , HeitzF , BurgerR , GabaL , et al.Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S612-3. ">PRIMA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FOSI, EQ‐5D‐5L, EORTC‐QLQ‐C30, and EORTC‐QLQ‐ OV28.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"analysis of the EORTC‐QLQ‐C30 and EORTC‐QLQ‐OV28 did not indicate a difference in health‐related quality of life scores of patients treated with niraparib vs. placebo" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0011" title="BanerjeeS , MooreKN , ColomboN ,  ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. In: Annals of oncology; Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. 2020. BanerjeeS , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):S613. ColomboN , MooreKN , ScambiaG , OakninA , FriedlanderM , LisyanskayaAS , et al.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5539. DiSilvestroP , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial. Journal of Clinical Oncology2020;38(30):3528-37. DiSilvestroP , MooreK .A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT018449862013. FriedlanderM , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;29(Supplement 8):VIII727. FriedlanderM , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Journal of Clinical Oncology2019;37(Supplement 15):5551. FriedlanderML ,  HettleR ,  ParkhomenkoE .Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy. Annals of Oncology2019;30:ix77-8. FriedlanderML , MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 5):V405-6. FriedlanderML , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). Annals of Oncology2019;30(Supplement 9):ix77-90. MathewsCA , MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , et al.Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial. J Clin Oncol.2019;Conference: 2019 Annual Meeting of the American Society of Clinical Oncology, ASCO 2019. United States. 37(Supplement 15):5541. MooreK ,  ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , , et al.Maintenance olaparib in patients with newly diagnosed aAdvanced ovarian cancer. New England Journal of Medicine2018;379:2495-505. [DOI: 10.1056/NEJMoa1810858]MooreK , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the ph. In: Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. 29. 2019:A14-5. MooreKN , ColomboN , ScambiaG , Kim B-G, OakninA , FriedlanderM , et al.Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (PTS) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): phase III SOLO1 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii727. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15-suppl). May 2014:TPS5616. OakninA , MooreK , ColomboN , ScambiaG , Kim B-G, FriedlanderM , et al.Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Annals of Oncology2019;30(Supplement 5):v405. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology2019;30(Supplement 9):ix79.. WuL , ZhuJ , YinR , WuX , LouG , WangJ , et al.Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Journal of Clinical Oncology2019;37(Supplement 15):5554. ">SOLO 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FACT‐O TOI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>At baseline, ~20% of patients in both groups reported being somewhat to very much bothered by post‐ chemotherapy side‐effects.  </p> <p>5 weeks after end of chemotherapy, 30% of olaparib patients vs. 11% of placebo patients were still bothered by side‐ effects of maintenance treatment. </p> <p>"Approximately 10% more patients on olaparib than on placebo reported that they were somewhat or quite a bit bothered by side‐effects, predominantly within the first 12 weeks of treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0015" title="CellaD , BookmanM , SteffensenKD , ColemanRL , DinhM , KhandelwalN , et al.Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint). Annals of Oncology2020;31(Supplement 4):S612. ColemanRL , FlemingGF , BradyMF , SwisherEM , SteffensenKD , FriedlanderM , et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine2019;381(25):2403-15. [DOI: 10.1056/NEJMoa1909707]EUCTR2014-005070-11-PL.Veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy in subjects with newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. EU Clinical Trials register2015. NCT02470585.Veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage iii or iv, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer (VELIA). Clinical Trial Gov register2015. NCT02477644.Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Clinical Trials Gov register2015. ">VELIA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NFOSI‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>"Mean change from baseline in the NFOSI‐18 Disease Related Symptom scores increased over time (indicating improvement), particularly after chemotherapy was completed (cycle 7 and beyond). The differences in the mean change from baseline in scores between treatment groups were small (range, 0.0 to 2.1) and were not considered to be clinically significant." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="bottom"> <p><b>Relapsed/recurrent EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0001" title="A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&amp;rank=1]ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research2018;24(15):625. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:PR06. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet2017;390(10106):1949-61. ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , DeanA , ColomboN , et aa, ARIEL3 investigators CNO - CN-01643386.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226]. Lancet (london, England)2017;390(10106):1949-61. [DOI: 10.1016/S0140-6736(17)32440-6]Coleman Rl, OzaAM , LorussoD , AghajanianC , OakninA , DeanA , et al, CNO - CN-01646796.ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). In: Clinical Cancer Research. Vol. Conference: AACR Special Conference &quot;Addressing Critical Questions in Ovarian Cancer Research and Treatment&quot;. United States. 24. 2018:625. [DOI: 10.1158/1557-3265.OVCA17-PR06]ColomboN , OzaA , LorussoD , AghajanianetC , OakninA , alDeanA , et al.Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. In: International Journal of Gynecologic Cancer. Vol. 29. 2019:A28-A29. DeanA , OzaAM , LorussoD , AghajanianC , OakninA , ColomboN , et al.Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology2020;Conference: ESMO Virtual Congress 2020. 31(Supplement 4):Abstract 821P. KhanA , O'MalleyDM , CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. In: Journal of Oncology Pharmacy Practice. Vol. Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24. 2018:9-10. [DOI: 10.1177/1078155217751308]KhanA , O'Malley DM CNO - CN-01571651.Ariel3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Journal of Oncology Pharmacy Practice2018;Conference: 14th Annual Meeting for the Hematology/Oncology Pharmacy Association. United States. 24(2 Supplement 1):9-10. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):2. KonecnyGE , OzaAM , TinkerAV , ColemanRL , O'MalleyDM , MaloneyL , et al.Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. In: Gynecologic Oncology. Vol. Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145. 2017:2. [DOI: 10.1016/j.ygyno.2017.03.028]LearyA , LedermannJA , OakninA , OzaAM , LorussoD , ColomboN , et al.Use of the Poly (ADP-Ribose) polymerase inhibitor rucaparib in women with recurrent ovarian carcinoma with endometrioid and other nonserous histopathologic subtypes. In: International Journal of Gynecological Cancer. Vol. 28. 2018:200-201. [DOI: 10.1097/01.IGC.0000547510.84464.ba]Ledermann JA , Oza AM , LorussoD , AghajanianC , OakninA , DeanA , et al.Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology2020;21(5):710-22. O'MalleyDM , ColemanRL , OzaAM , LorussoD , AghajanianC , OakninA , et al.Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive highgrade ovarian carcinoma. In: MolecularCancerTtherapeutics. . Vol. 17. 2018:no pagination. [DOI: 10.1158/1535-7163.TARG-17-LB-A12]SwisherEM , McNeishIA , ColemanRL , BrentonJ , KaufmannSH , AllenAR , et al.ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. In: Journal of Clinical Oncology (Meeting Abstracts). Vol. 32 (15_Suppl). May 2014:TPS5619. ">ARIEL3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EQ‐5D‐5L; *QA‐PFS; *Q‐TWiST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>QA‐PFS months mean difference 6.28 (95% CI 4.85 to 7.47) in favour of PARPi and was 2.1‐fold longer in the PARPi group than in the placebo group in the ITT population (mean months 12.02 vs. 5.74). </p> <p>Q‐TWIST ‐ months mean difference in &gt;= G3+ SevAE 6.88 (95% CI 5.71 to 8.24) in favour of PARPi (mean months 13.32 vs. 6.44). </p> <p>Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0007" title="Del CampoJM , MatulonisUA , MalanderS , ProvencherD , MahnerS , FollanaP , et al.Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology2019;37(32):2968-73. [DOI: 10.1200/JCO.18.02238]Del CampoJM , MirzaMR , BerekJS , ProvencherDM , EmonsG , FabbroM , et al.The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl):5560. [DOI: 10.1200/JCO.2017.35.15_suppl.5560]FabbroM , MooreKN , DørumA , TinkerAV , MahnerS , BoverI , et al.Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology2019;152(3):560-7. FabbroM , MooreKN , DorumA , TinkerAV , MahnerS , BoverI , et al.Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC). Annals of Oncology2017;28(Supplement 5 [42nd ESMO Congress]):V332. LordR , MirzaMR , WoelberL , LesoinA , PinedaMJ , PeenU , et al.Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology2018;149(Supplement 1 [49th Annual Meeting of the Society of Gynecologic Oncology] ):11. [DOI: 10.1016/j.ygyno.2018.04.031]MatulonisU , HerrstedtJ , OzaA , MahnerS , RedondoA , FabbroM , et al.Engot-ov16/nova: a maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecological Cancer2016;26([16th Biennial Meeting of the International Gynecologic Cancer Society]  ):19-20. MatulonisU , MahnerS , WenhamRM , LedermannJA , MonkBJ , Del CampoJM , et al.A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). J Clinical Oncology2014;32(15_suppl  [ASCO Annual Meeting]):no pagination. [DOI: 10.1200/jco.2014.32.15_suppl.tps5625]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). J Clinical Oncology2017;35(15_suppl):5534. [DOI: 10.1200/JCO.2017.35.15_suppl.5534]MatulonisUA , HerrstedtJ , TinkerA , MarmeF , RedondoA , KalbacherE , et al.Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Journal of Clinical Oncology2017;35(15_suppl (Annual Meeting of the American Society of Clinical Oncology, ASCO) ):no pagination . MatulonisUA , WalderL , NottrupTJ , BessetteP , MahnerS , Gil-MartinM , et al.Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinicsl Oncology2019;37(34):3183-91. [DOI: 10.1200/JCO.19.00917.]MatulonisUA , WalderL , NottrupTJ , TinkerAV , MahnerS , Gil-MartinM , et al.Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: a TWIST analysis of the ENGOT24-OV16/NOVA trial. Gynecol Oncol2019;154(Supplement 1 [50th Annual Meeting of the Society of Gynecologic Oncology] ):2. [DOI: 10.1016/j.ygyno.2019.04.016]Mirza MR,  Benigno B,  Dørum A,  Mahner S,  Bessette P,  Bover BarcelóI , et al.Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16/NOVA trial. Gynecolic Oncology2020;159(2):442-8. [DOI: 10.1016/j.ygyno.2020.09.006]MirzaM , BerekJS , VergoteI , WenhamRM , Del CampoJM , OzaAM , et al.Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International Journal of Gynecolical Cancer2014;[15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia]:33-4. MirzaMR , BenignoB , DorumA , MahnerS , BessetteP , Gil-MartinM , et al.Long-term safety of niraparib in patients with recurrent ovarian cancer (ROC): results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2018;28(Supplement 2 [17th Biennial Meeting of the International Gynecologic Cancer Society]):21-2. MirzaMR , DorumA , BenignoB , MahnerS , BessetteP , Bover BarceloIM , et al.Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. International Journal of Gynecological Cancer2019;29(Supplement 4):A15-A16. [DOI: 10.1136/ijgc-2019-ESGO.18]MirzaMR , MatulonisU .A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT018472742013. MirzaMR , MonkBJ , Gil-MartinM , GilbertL , CanzlerU , FollanaP , et al.Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. Journal of Clinical Oncology2017;35(15_suppl [Annual Meeting of the American Society of Clinical Oncology, ASCO]):5517. MirzaMR , MonkBJ , HerrstedtJ , OzaAM , MahnerS , RedondoA , et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine2016;375(22):2154-64. [DOI: 10.1056/NEJMoa1611310]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of. Oncology2016;27:no pagination. [DOI: 10.1093/annonc/mdw435.26]MirzaMR , MonkBJ , OzaA , MahnerS , RedondoA , FabbroM , et al.PR A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology2016;27(6):1-36. [DOI: 10.1093/annonc/mdw435]NCT03709316.A Study of ZL-2306 (niraparib) as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer. Clinical Trials Gov register2018. OzaAM , MatulonisUA , MalanderS , SehouliJ , Del CampoJM , Berthon-RigaudD , et al.Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16/NOVA Trial. Ann Oncol.2017;28(Supplement 5 [42nd ESMO Congress] ):v330. ">NOVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FOSI; EQ‐5D‐5L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>baseline mean FOSI values:</p> <p>g<i>BRCA</i>mut cohort = 25∙1 [SD 4∙18] in PARPi group and 25∙6 [3∙84] in placebo group); </p> <p>non‐g<i>BRCA</i>mut cohort = 25∙4 [3∙92] in PARPi group and 25∙0 [4∙07] in placebo group).  </p> <p>Overall QOL scores remained stable during the treatment and pre‐progression period; no significant differences were observed between the PARPi and placebo group. </p> <p>pre‐progression EQ‐5D‐5L scores were similar between the two groups in both cohorts:</p> <p>g<i>BRCA</i>mut cohort = 0·838 [0·0097] in tPARPI group vs. 0·834 [0·0173] in placebo group; </p> <p>non‐gBRCAmut cohort = 0·833 [0·0077] in PARPi group vs 0·815 [0·0122] in placebo group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0012" title="Frenel J-S, Kim J-W, BertonD , AsherR , VidalL , PautierP , et al.Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):suppl, 6070. Frenel J-S, Kim J-W, Berton-RigaudD , AsherR , VidalL , PautierP , et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial. In: Annals of Oncology. Vol. Conference: ESMO Virtual Congress 2020. 31. 2020:S615. FriedlanderM , GebskiV , GibbsE , BloomfieldR , HilpertF , WenzelLB , et al.Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27 (Supplement 4):1941. FriedlanderM , GebskiV , GibbsE , DaviesL , BloomfieldR , HilpertF , et al.Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology2018;19(8):1126-34. FriedlanderM , GourleyC , MatulonisU , ShirinkinV , SelleF , ScottC , et al.Clinically significant long-term maintenance treatment with olaparib in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International Journal of Gynecological Cancer.2017;[Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria] 27(Supplement 4):13. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology. 2017;13([Conference: annual scientific meeting of the medical oncology group of australia incorporated, MOGA 2017. Australia 2017]):51. FriedlanderM , Pujade-LauraineE , LedermannJA , PensonRT , MOzaA , KorachJ , et al.Treatment with maintenance olaparib significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results of SOLO2 study. Asia-Pacific Journal of Clinical Oncology2017;[Conference: Annual Scientific Meeting of the Medical Oncology Group of Australia Incorporated, MOGA 2017. Australia] 13:51. GourleyC , FriedlanderM , MatulonisUA , ShirinkinV , SelleF , ScottCL , et al.Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2017;[Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States]  35(15 Supplement 1):13. HankerC , HeitzF , Park-Simon TW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al AGO Study Group &amp; GINECOL.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe und frauenheilkunde2018;78(10):93. HankerLC , HeitzF , Park-SimonTW , Gropp-MeierM , AtasevenB , Pujade-LauraineE , et al.Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2/AGO-OVAR2.23 trial, AGO Study Group &amp; GINECO. In: Geburtshilfe und Frauenheilkunde. Vol. 78 [62. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe - DGGG 2018]. 2018. [DOI: 10.1055/s-0038-1671027]HasenburgA , HarterP , Park-Simon T-W, Gropp-MeierM , HeitzF , SoergelP , et al.Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCAmutated platinum-sensitive relapsed serous ovarian cancer: sOLO2 Phase III. Oncology Research and Treatment2018;[Conference: 33. Deutscher Krebskongress, DKK. Germany] 41(Supplement 1):88-89. KorachJ , FreyerG , BanerjeeS , AsherR , CosinJ , OzaAM , et al.Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii340-1. LedermannJA , LortholaryA , PensonRT , GibbsE , ProvencherDM , BruchimI , et al.Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): phase III SOLO2 trial. Journal of Clinical Oncology2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. 35(15 Supplement 1):5518. LiuJ , YinR , WuL , ZhuJ , LouG , WuX , et al.Olaparib maintenance monotherapy improves progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC): solo2 study-China cohort. International Journal of Gynecological2018;Conference: 17th Biennial Meeting of the International Gynecologic Cancer Society. Japan. 28(Supplement 2):49-50. MatulonisU , FriedlanderM , Du BoisA , GourleyC , VergoteI , RustinGJS , et al.Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinumsensitive relapsed serous ovarian cancer (PSR SOC). Journal of Clinical Oncology2015;Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: 33(15 Suppl. 1):5505. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer2016;122(12):1844-52. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJS , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy. Gynecologic Oncology2015;137:8. MooreKN , DiSilvestroP , LoweES , Garnett S Pujade-LauraineE .SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).. In: Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014. OzaAM , CombeP , LedermannJ , MarschnerS , AmitA , HuzarskiT , et al.Evaluation of tumour responses and olaparib efficacy in platinum sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v344. PensonR , Kaminsky-Forrett M-C, LedermannJ , BrownC , PlanteM , KorachJ , et al.Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology2017;Conference: 42nd ESMO Congress, ESMO 2017. Spain. 28(Supplement 5):v331. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6002. PovedaA , FloquetA , LedermannJA , AsherR , PensonRT , OzaAM , et al.SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2021;22(5):620-31. [DOI: 10.1016/S1470-2045(21)00073-5] [PMID: 33743851]Pujade-LauraineE , LedermannJA , PensonRT , OzaAM , KorachJ , HuzarskiT , et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Gynecologic Oncology2017;Conference: 48th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2017. United States. 145(Supplement 1):219-20. Pujade-LauraineE , LedermannJA , SelleF , GebskiV , PensonRT , OzaAM , et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017;18(9):1274-84. [DOI: 10.1016/ S1470-2045(17)30469-2]Pujade-LauraineE .Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT018743532013. TrillschF , MahnerS , AtasevenB , AsherR , DubotC , ClampAR , et al.Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOTOv21) study. Journal of Clinical Oncology2020;Conference: 2020 Annual Meeting of the American Society of Clinical Oncology, ASCO 2020. United States. 38(15):6068. ">SOLO 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOI FACT‐O (v2016); *Q‐TWiST; *QA‐PFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant detrimental effect HRQOL analysed by change from baseline in TOI score (–3.1 vs –2.9, respectively, difference (PARPi  minus placebo) –0.2; 95% CI –2.4 to 2.1; P=0.88).  </p> <p>Adjusted average mean change from baseline over the first 12 months in TOI was ‐2·90 (95% CI ‐4·13 to ‐1·67) with PARPi and ‐2·87 (‐4·64 to ‐1·10) with placebo (estimated difference ‐0·03; 95% CI ‐2·19 to 2·13; P = 0·98); </p> <p>Q‐TWiST and QA‐PFS improvement for patients on maintenance PARPi (due in part to prolonged PFS and delay in symptoms due to disease): </p> <p>Q‐TWiST (13.5 vs. 7.2 months, difference 6.3; 95% CI 2.9 to 8.6; P&lt;0.001):</p> <p>QA‐PFS (mean 14.0 vs. 7.3 months for PARPi and placebo, respectively, difference 6.7 months; 95% CI 5.0 to  8.5; P&lt;0.0001). Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOI FACT‐O questionnaire Version 4; *Q‐TWiST; *QA‐PFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Mean TOI scores at baseline were 73.2 in PARPi  group and 71.8 in chemotherapy group. </p> <p>Overall least‐squares mean change from baseline in TOI score was 22.3 with PARPi (n = 167) vs. 24.8 with chemotherapy (n = 62), with a between‐group difference of 2.5 (95% CI, 20.5 to 5.5; P = 0.108). Neither Q‐TWiST nor QA‐PFS were pre‐specified outcomes in the ClinicalTrials.gov record. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>EQ‐5D‐5L:</b> European QOL five‐dimension five‐level questionnaire; <b>FACT‐O</b> Functional Assessment of Cancer Therapy‐Ovarian Trial Outcome Index (TOI); <b>FOSI:</b> Functional Assessment of Cancer Therapy–Ovarian Symptoms Index;<b>g<i>BRCA</i>mut:</b> germline breast cancer susceptibility gene (<i>BRCA</i>) mutation; <b>NFOSI‐18:</b> National Comprehensive Cancer Net‐ work Functional Assessment of Cancer Therapy Ovarian Symptom Index–18;  <b>non–g<i>BRCA</i>mut:</b> no germline breast cancer susceptibility gene (<i>BRCA</i>) mutation; <b>PARPi:</b> poly ADP ribose polymerase inhibitor; <b>QA‐PFS:</b> quality‐adjusted progression‐free survival; <b>Q‐TWiST:</b> Quality‐adjusted time without symptoms or toxicity; <b>TOI:</b> Trial outcome index. </p> <p>*QA‐PFS and Q‐TWiST were post hoc analyses.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Health related Quality of Life (HRQoL) measures in the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007929-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Median Overall Survival time (months)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PARP inhibitor</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total (N)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Median (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total (N)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Medians not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Recurrent, platinum‐sensitive EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.8 (26.9, 38.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6 (27.8, 44.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0008" title="Oza AM,  Cibula D,  Benzaquen AO,  Poole C,  Mathijssen RHJ,  Sonke GS et al.Correction to olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncology2015;16(2):e55-erratum to original e-pub paper. [DOI: 10.1016/S1470-2045(15)70044-6]OzaA , CibulaD , BenzaquenOA , PooleC , MathijssenRH , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology2015;16(1):87-97  (Epub 2014 Dec 4). [DOI: 10.1016/S1470-2045(14)71135-0]OzaAM , CibulaD , BenzaquenAO , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncolgy2015;16(1): E6-erratum. [DOI: 10.1016/S1470-2045(14)71216-1]OzaAM , CibulaD , OakninA , PooleC , MathijssenRHJ , SonkeGS , et al.Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology2018;29(Supplement 8):viii340. OzaAM , CibulaD , OakninA , PooleCJ , Mathijssen RHJ SonkeGS , et al.Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. Journal of Clinical Oncology2012;30(15 Suppl):5001. [http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]OzaAM , CibulaD , Oaknin BenzaquenA , PooleCJ , MathijssenRHJ , et al.Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer2013;49 Suppl 2:S712-S3. ">Oza 2015</a><b> </b>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached<br/>(26.9, not reached) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.2<br/>(31.5, not reached) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0013" title="LoweES , JayawardeneD , PensonRT .SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCAI/2 mutation (gBRCAm). Journal of Clinical Oncology2016; 34(15_supp):no pages. Penson RT,  ValenciaRV , CibulaD ,  ColomboN , Leath IIICA , BidzinskiM , KimJW ,  NamJH , MadryR , HernandezC , MoraPAR , RyuSY ,  MilenkovaT , LoweES , BarkerL , Scambia G.Olaparib Versus Nonplatinum Chemotherapy inPatients With Platinum-Sensitive RelapsedOvarian Cancer and a Germline BRCA1/2Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol2020;38:1164-1174. [DOI: 10.1200/JCO.19. 02745]PensonRT , ValenciaRV , CibulaD , ColomboN , LeathCA , BidzihskiM , et al.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. Journal of Clinical Oncology2019;37(15_supp):5506. ">SOLO 3</a><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (29.9, not reached)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (24.2, not reached)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007929-bbs2-0014" title="FriedlanderM , MatulonisU , GourleyC , du BoisA , VergoteI , RustinG , et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer.2018;119(9):1075-85. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology2014;15(8):852-61. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69((10)):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical &amp; Gynecological Survey2015;69(10):594-6. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine2012;366(15):1382-92. LedermannJ , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: International Journal of Gynecological Cancer. Vol. 21 (S13). 2011. LedermannJ .Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol.2016;17(11):1579-89. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinG , et al.Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer2016;115(11):1313-20. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteI , RustinGJ , et al.Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. Journal of Clinical Oncology2016;Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. United States. 34(Supplement 15):5501. LedermannJA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Journal of Clinical Ocology. Vol. 29. 2011. MatulonisUA , HarterP , GourleyC , FriedlanderM , VergoteIB , RustinGJ , et al.Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-5. 2014. ">Study 19 (Ledermann 2012)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo after chemotherapy (maintenance therapy)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.7 (NR)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.9 (NR)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Recurrent, platinum‐resistant EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Medians not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>EOC:</b> epithelial ovarian cancer; <b>OLA:</b> olaparib; <b>NR:</b> not reported </p> <p>(1) a subgroup with BRCA mutation;</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Median Overall Survival time (months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007929-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Median Progression‐Free Survival time (months)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>PARP inhibitor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (95%CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Newly‐diagnosed EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo (maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>269</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.5 (19.3 to 26.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3 (15.1 to 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy only</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2 (14.1 to 17.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3 (15.1 to 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants with <i>BRCA</i> mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 1*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 (11.1, 18.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.7 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7<br/>(31.8, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0 (17.8, 29.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.1 (17.0, 25.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.0 (17.8, 29.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAOLA‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with BEV versus BEV alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.7 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>and as maintenance versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VELIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>(placebo in maintenance) versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(2) PARP inhibitor monotherapy compared with chemotherapy in recurrent EOC</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 3<b>* </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4 (10.9, 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.6, 11.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with CED versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICEBERG 3 (Kaye 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA 200 mg) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5 (5.5, 10.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (3.7, 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICEBERG 3 (Kaye 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA 400 mg) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8 (5.4, 9.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(3) PARP inhibitor compared with placebo after chemotherapy in recurrent EOC(maintenance therapy)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.7 (11.0, 19.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (5.1, 5.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study 19 (Ledermann 2012)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 2<b>^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1 (16.3, 25.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.2, 5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy </p> <p>followed by PARP inhibitor as maintenance </p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (9.7, 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6 (9.1, 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with BRCA mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 3<b>* </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4 (10.9, 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.6, 11.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT02446600<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with CED versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.8<br/>(19.2, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (4.9, 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOLO 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.3 (16.5, 27.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.0, 5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached <br/>(9.6, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.3, 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARIEL3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (RUC) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9<br/>(16.2, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (5.1, 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NOVA<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(4) PARP inhibitor in recurrent ovarian cancer (various comparisons)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015<b>*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy </p> <p>followed by PARP inhibitor as maintenance </p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (9.7, 15.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6 (9.1, 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV </p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9 (8.5, 16.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (3.8, 6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with BRCA mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kummar 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (VEL) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oza 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) with chemotherapy</p> <p>versus chemotherapy alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reached <br/>(9.6, not reached) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.3, 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV</p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4 (6.2, 22.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (3.9, 13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Subgroup: participants with HRD mutation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVANOVA2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (NIR) with BEV</p> <p>versus PARP inhibitor (NIR) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9 (8.5, 22.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (3.9, 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>(5) PARP inhibitor compared with chemotherapy in recurrent platinum‐resistant ovarian cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLIO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PARP inhibitor (OLA) versus chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>BEV:</b> bevacizumab; <b>CED:</b> cediranib; <b>NIR:,</b> niraparib; <b>NR:</b> not reported; <b>OLA:</b> olaparib; <b>PARP: </b> poly adenosine diphosphate‐ribose polymerase; <b>PLB:</b> placebo;<b>RUC:</b>  rucaparib;<b>VEL:</b> veliparib. </p> <p>*studies that recruited only participants with BRCA mutation;<br/>^97% of participants in the SOLO2 study had a BRCA mutation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Median Progression‐Free Survival time (months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/full#CD007929-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.49, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.16, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.59, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Progression‐free survival by HRD status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.45, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Participants with HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.19, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Participants without HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.83, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Quality of Life ‐ European Organization for Research and Treatment of Cancer Questionnaire QLQ‐C30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.07, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.28, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Progression‐free survival by HRD status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Participants with HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.43, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Participants without HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Newly diagnosed EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Overall survival by HRD status  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Participants with HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.27, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Participants without HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.19, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Progression‐free survival by HRD status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Participants with HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.31, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Participants without HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.49, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.65, 4.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Newly diagnosed EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 with a lower dose of PARP inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.62, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 with a higher dose of PARP inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.42, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.07, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.56, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.28, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.20, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.39, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Progression‐free survival by HRD status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Participants with HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.27, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Participants without HRD mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.36, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Quality of Life ‐ European Quality of Life 5‐dimensions questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Quality of Life ‐ Trial Outcome Index score of Functional Assessmentof Cancer Therapy—Ovarian Cancer questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐2.16, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.41 [5.37, 7.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS) by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.66 [6.19, 9.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.78, 4.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.52 [5.69, 7.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Quality of Life ‐ Time without symptoms of treatment toxicity (TWiST) by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.62 [7.37, 9.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.85, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [1.85, 3.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi with chemotherapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Progression‐free survival by BRCA status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Participants with BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.08, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Participants without BRCA mutation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum‐sensitive recurrent EOC: PARPi with chemotherapy and as maintenance therapy compared with chemotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007929-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Objective response rate (no response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2  Any severe adverse event (grade 3 or higher) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum‐resistant recurrent EOC: PARPi monotherapy compared with chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007929.pub4/references#CD007929-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007929.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007929-note-0039">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007929-note-0033">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007929-note-0036">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007929-note-0030">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007929-note-0027">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007929-note-0024">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD007929-note-0021">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007929-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007929\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007929\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007929\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007929\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007929\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007929.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007929.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007929.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007929.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007929.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725950868"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007929.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725950873"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007929.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e87bd6bb69371',t:'MTc0MDcyNTk1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 